Relationship Between Patient-Health Coach Interactions and Changes in Markers of Glucose Homeostasis by Nagy, Jason P.
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2018 
Relationship Between Patient-Health Coach Interactions and 
Changes in Markers of Glucose Homeostasis 
Jason P. Nagy 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Endocrinology, Diabetes, and Metabolism Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/5686 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
   
 
 
 
 
 
 
 
 
 
 
 
©Jason P. Nagy                              2018 
All Rights Reserved 
 
 
 
   
 
 
 
 
 
Relationship Between Patient-Health Coach Interactions and Changes in Markers of Glucose 
Homeostasis 
 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
 
 
 
 
 
 
 
by 
 
Jason P. Nagy, MS, MT(ASCP)
CM 
Master of Science in Clinical Laboratory Science, Virginia Commonwealth University, 2007 
Bachelor of Science in Clinical Laboratory Science, Virginia Commonwealth University, 2007 
 
 
 
 
 
 
Advisor: William J. Korzun, Ph.D., DABCC, MT(ASCP)
CM 
Associate Professor 
Department of Clinical Laboratory Sciences 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
December, 2018 
 
ii 
 
 
 
 
 
 
Acknowledgements 
 
I must first thank my committee members Dr. Teresa S. Nadder, Dr. Melissa Jamerson, 
Dr. John H. Contois, Dr. Thomas Dayspring and especially my committee advisor, Dr. William 
J. Korzun. Without your support and guidance, I would never have reached this point in my 
career.  
 I must also thank the members of the 2013 cohort, the 5 of 13, Pat Armour, Marianne 
Cosgrove, Allison Kaczmarek, and Mercedes Weir. I could not have asked for a better collection 
of individuals to make us the best group possible. Thank you all for sharing in this unforgettable 
experience.  
 A special thanks to the  members of the Pd.D. program in the College of Health 
Professions, the amazing faculty, and all the individuals who support the department. Your 
countless efforts to provide the best lectures, a structured workload, and a supportive learning 
environment kept me focused and on track. This is something I could never have accomplished 
without the work of so many wonderful and talented people.  
 I would like to thank those who supported my through this journey, but could not be with 
us today. My father-in-law Dennis, who taught me that sometime just you need to find a quiet 
place on the water to ponder. Only then will you find the answers to your question and see the 
path you must choose. My Brother Donald, who encouraged me to push on, to keep my eye on 
the prize, and reminded me that the sacrifices of today will lead to the rewards of tomorrow.  My 
iii 
 
 
 
mother Nadine, who has been an inspiration throughout my entire life. I have tried to live life as 
she did, always trying to lend a helping hand to make the world a better place.  
 Last but not least, I must thank my friends family. My father William, and stepmother 
Barbara. You raised me to be the man I am today, for that I am forever grateful. My brother 
Tony, thank you for showing me the ropes in life. You are proof that you can accomplish 
anything if you set your mind to it. My mother in-law, Lilo, was a pillar of support for us during 
this time. Sean and Shilo, your encouragement was greatly appreciated. My amazing circle of 
friends and family too numerous to count, thank you for all that you have done. My amazing 
wife, Shannon, you endured all the sacrifices with me. You understood what this meant for us, 
and remained by side. Thank you so much for your love, patience, and support.  I definitely 
could not have done this without you. I love you! Finally, I must thank our beautiful daughter, 
Evelyn, who inspired my creativity and kept me grounded.  
 
 
  
 
 
 
 
 
 
 
 
iv 
 
 
 
 
 
 
Table of Contents 
 
 
List of Tables ................................................................................................................................. ix 
List of Figures .............................................................................................................................. xiv 
List of Abbreviations .................................................................................................................... xv 
Abstract ....................................................................................................................................... xvii 
Chapter 1: Introduction ................................................................................................................... 1 
Overview ..................................................................................................................................... 1 
Background ................................................................................................................................. 2 
Research Problem ........................................................................................................................ 4 
Purpose of the Study and Research Question ............................................................................. 5 
Specific Aims .............................................................................................................................. 5 
Significance of the Study ............................................................................................................ 6 
Summary of Data Sources and Analysis ..................................................................................... 7 
Chapter Summary ........................................................................................................................ 7 
Chapter 2: Literature Review .......................................................................................................... 9 
Introduction ................................................................................................................................. 9 
Overview ..................................................................................................................................... 9 
Glucose Homeostasis ................................................................................................................ 10 
v 
 
 
 
Diabetes ..................................................................................................................................... 12 
Type 1 Diabetes ......................................................................................................................... 13 
Type 2 Diabetes ......................................................................................................................... 15 
Gestational Diabetes .................................................................................................................. 18 
Diabetes Due to Other Causes ................................................................................................... 20 
Treatments for Diabetes ............................................................................................................ 20 
Glucose ...................................................................................................................................... 24 
Hemoglobin A1c ....................................................................................................................... 25 
1,5-anhydroglucitol ................................................................................................................... 26 
Insulin ........................................................................................................................................ 28 
C-Peptide ................................................................................................................................... 29 
Proinsulin .................................................................................................................................. 30 
Health Coaches .......................................................................................................................... 32 
Chapter Summary ...................................................................................................................... 39 
Chapter 3: Methodology ............................................................................................................... 40 
Overview ................................................................................................................................... 40 
Problem Statement .................................................................................................................... 40 
Research Design ........................................................................................................................ 43 
Sampling Strategy ..................................................................................................................... 43 
Population and Sample .............................................................................................................. 43 
Handling of Protected Health Information ................................................................................ 44 
Marker Testing Methods ........................................................................................................... 48 
Glucose. ............................................................................................................................ 48 
vi 
 
 
 
HbA1c. .............................................................................................................................. 48 
1,5-AG. ............................................................................................................................. 49 
Insulin. .............................................................................................................................. 49 
C-peptide. .......................................................................................................................... 49 
Proinsulin. ......................................................................................................................... 50 
BMI. .................................................................................................................................. 51 
Research Setting ........................................................................................................................ 51 
Data Collection .......................................................................................................................... 52 
Validity and Reliability ............................................................................................................. 54 
Sample Size and Statistical Power ............................................................................................ 56 
Data Cleaning ............................................................................................................................ 57 
Data Analysis ............................................................................................................................ 61 
Data Interpretation..................................................................................................................... 63 
Chapter Summary ...................................................................................................................... 65 
Chapter 4: Results ......................................................................................................................... 66 
Introduction ............................................................................................................................... 66 
Specific Aim 1 ........................................................................................................................... 66 
Subject selection and results of analysis of the change in blood glucose concentration. . 68 
Subject selection and results of analysis of the change in 1,5-AG  concentration. .......... 72 
Subject selection and results of analysis of the change in insulin  concentration. ............ 74 
Subject selection and results of analysis of the change in C-peptide  concentration. ....... 76 
Subject selection and results of analysis of the change in proinsulin  concentration. ...... 78 
Subject selection and results of analysis of the change in BMI. ....................................... 80 
vii 
 
 
 
Specific Aim 2 ........................................................................................................................... 82 
Subject selection and results of analysis of the change in glucose health score. .............. 83 
Subject selection and results of analysis of the change in HbA1c health score. .............. 85 
Subject selection and results of analysis of the change in BMI health score. .................. 87 
Specific Aim 3 ........................................................................................................................... 89 
Subject selection and results of analysis of the change in glucose concentration  by 
number of CHC interactions. ............................................................................................ 90 
Subject selection and results of analysis of the change in %HbA1c by number of           
CHC interactions. .............................................................................................................. 94 
Subject selection and results of analysis of the change in 1,5-AG by number of            
CHC interactions. .............................................................................................................. 96 
Subject selection and results of analysis of the change in insulin concentration by     
number of CHC interactions. ............................................................................................ 99 
Subject selection and results of analysis of the change in C-peptide concentration               
by number of CHC interactions. ..................................................................................... 102 
Subject selection and results of analysis of the change in proinsulin concentration             
by number of CHC interactions. ..................................................................................... 105 
Subject selection and results of analysis of the change in BMI by number of                  
CHC interactions. ............................................................................................................ 108 
Post-Hoc Analysis of Sample Size Requirements .................................................................. 111 
Chapter 5: Discussion ................................................................................................................. 113 
Discussion of the Study ........................................................................................................... 113 
viii 
 
 
 
Specific Aim 2 ......................................................................................................................... 117 
Specific Aim 3 ......................................................................................................................... 119 
Conclusions ............................................................................................................................. 120 
Limitations .............................................................................................................................. 120 
Recommendations for Future Studies ..................................................................................... 121 
References ................................................................................................................................... 122 
Vita .............................................................................................................................................. 140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
 
 
 
 
 
List of Tables 
 
 
Table 1: Type 1 Diabetes Diagnosis by Stage .............................................................................. 14 
Table 2: Criteria for GDM Diagnosis ........................................................................................... 19 
Table 3: Health Score Variable Table ........................................................................................... 45 
Table 4: Units of Measure ............................................................................................................. 44 
Table 5: Study Independent and Dependent Variables ................................................................. 46 
Table 6: Study Covariates ............................................................................................................. 47 
Table 7: Patient Classification by BMI ......................................................................................... 51 
Table 8: Subject Data Elements Extracted from Harvest LIS and Health Coach IMS ................. 53 
Table 9: Deidentified Study Dataset ............................................................................................. 54 
Table 10: Non-CHC Random Selection ....................................................................................... 58 
Table 11: Non-CHC Random Selection ANOVA ........................................................................ 59 
Table 12: AMR and CRR ............................................................................................................. 61 
Table 13: Disease Marker Health scores ...................................................................................... 63 
Table 14: Mean Changes in Markers of Glucose Homeostasis in Subjects with and without      
CHC Interactions, and their Statistical Significance .................................................... 67 
Table 15: The Significance of CHC Interactions After Adjusting for Covariates on the   
Difference Between the Change in Biomarkers ........................................................... 68 
x 
 
 
 
Table 16: Demographics and Change in Glucose Concentrations for Subjects With and     
Without CHC Interactions ........................................................................................... 69 
Table 17: Significance of Covariates and CHC Interactions on the Mean Change in             
Glucose Concentration ................................................................................................. 70 
Table 18: Demographics and Change in %HbA1c for Subjects With and Without CHC 
Interactions ................................................................................................................... 71 
Table 19: Significance of Covariates and CHC Interactions on the Mean Change in            
%HbA1c ....................................................................................................................... 72 
Table 20: Demographics and Change in 1,55-AG Concentrations for Subjects With and    
Without CHC Interactions ........................................................................................... 73 
Table 21: Significance of Covariates and CHC Interactions on the Mean Change in 1,5-AG 
Concentration ............................................................................................................... 73 
Table 22: Demographics and Change in Insulin Concentrations for Subjects With and          
Without CHC Interactions ........................................................................................... 75 
Table 23: Significance of Covariates and CHC Interactions on the Mean Change in Insulin 
Concentration ............................................................................................................... 75 
Table 24: Demographics and Change in C-peptide Concentrations for Subjects With and    
Without CHC Interactions ........................................................................................... 77 
Table 25: Significance of Covariates and CHC Interactions on the Mean Change in                      
C-peptide Concentration .............................................................................................. 77 
Table 26: Demographics and Change in Proinsulin Concentrations for Subjects With and 
Without CHC Interactions ........................................................................................... 79 
xi 
 
 
 
Table 27: Significance of Covariates and CHC Interactions on the Mean Change in          
Proinsulin Concentration .............................................................................................. 80 
Table 28: Demographics and Change in BMI for Subjects With and Without CHC           
Interactions ................................................................................................................... 81 
Table 29: Significance of Covariates and CHC Interactions on the Mean Change in BMI ......... 81 
Table 30: Mean Changes in Glucose, %HbA1c, and BMI Health Scores in Subjects with           
and without CHC Interactions, and their Statistical Significance ................................ 82 
Table 31: The Significance of CHC Interactions After Adjusting for Covariates on the    
Difference Between the Change in Glucose, HbA1c, and BMI .................................. 83 
Table 32: Demographics and Change in Glucose Health Score for Subjects With and            
Without CHC Interactions ........................................................................................... 83 
Table 33: Significance of Covariates and CHC Interactions on the Mean Change in Glucose 
Health Score ................................................................................................................. 84 
Table 34: Classification of Subjects by Glucose Health Score ..................................................... 85 
Table 35: Demographics and Change in HbA1c Health Score for Subjects With and           
Without CHC Interactions ........................................................................................... 85 
Table 36: Significance of Covariates and CHC Interactions on the Mean Change in HbA1c 
Health Score ................................................................................................................. 86 
Table 37: Classification of Subjects by %HgbA1c Health Score ................................................. 86 
Table 38: Demographics and Change in BMI Health Score for Subjects With and                  
Without CHC Interactions ........................................................................................... 87 
Table 39: Significance of Covariates and CHC Interactions on the Mean Change in BMI          
Health Score ................................................................................................................. 88 
xii 
 
 
 
Table 40: Classification of Subjects by BMI Health Score .......................................................... 88 
Table 41: The Significance of the Number of CHC Interactions on the Change in                 
Markers of Glucose Homeostasis................................................................................. 90 
Table 42: Demographics and Change in Glucose Concentration for Subjects by Number               
of CHC Interactions ..................................................................................................... 91 
Table 43: The Effects of Covariates and the Number of CHC interactions on the              
Significance of Mean Change in Glucose .................................................................... 92 
Table 44: Bonferroni Multiple Comparison for Glucose and Number of CHC Interactions ....... 93 
Table 45: Demographics and Change in %HbA1c for Subjects by CHC Number of           
Interactions ................................................................................................................... 94 
Table 46: The Effects of Covariates and the Number of CHC interactions on the               
Significance of Mean Change in %HbA1c .................................................................. 95 
Table 47: Bonferroni Multiple Comparison for HbA1c and Number of CHC Interactions ......... 96 
Table 48: Demographics and Change in 1,5-AG Concentration for Subjects by Number         of 
CHC Interactions .......................................................................................................... 97 
Table 49: The Effects of Covariates and the Number of CHC interactions on the            
Significance of Mean Change in 1,5-AG ..................................................................... 98 
Table 50: Bonferroni Multiple Comparison for 1,5-AG and Number of CHC Interactions ........ 99 
Table 51: Demographics and Change in Insulin Concentration for Subjects by                        
Number of CHC Interactions ..................................................................................... 100 
Table 52: The Effects of Covariates and the Number of CHC interactions on the             
Significance of Mean Change in Insulin .................................................................... 101 
Table 53: Bonferroni Multiple Comparison for Insulin and Number of CHC Interactions ....... 102 
xiii 
 
 
 
Table 54: Demographics and Change in C-peptide Concentration for Subjects by                   
Number of CHC Interactions ..................................................................................... 103 
Table 55: The Effects of Covariates and the Number of CHC interactions on the            
Significance of Mean Change in C-peptide ............................................................... 104 
Table 56: Bonferroni Multiple Comparison for C-peptide and Number of CHC                
Interactions ................................................................................................................. 105 
Table 57: Demographics and Change in Proinsulin Concentration for Subjects by               
Number of CHC Interactions ..................................................................................... 106 
Table 58: The Effects of Covariates and the Number of CHC interactions on the           
Significance of Mean Change in Proinsulin .............................................................. 106 
Table 59: Bonferroni Multiple Comparison for Proinsulin and Number of CHC                 
Interactions ................................................................................................................. 108 
Table 60: Demographics and Change in BMI for Subjects by Number of CHC                         
Interactions ................................................................................................................. 109 
Table 61: The Effects of Covariates and the Number of CHC interactions on the                    
Significance of Mean Change in BMI ....................................................................... 109 
Table 62: Bonferroni Multiple Comparison for BMI and Number of CHC Interactions ........... 111 
Table 63: Post-Hoc Sample Size Determination ........................................................................ 112 
Table 64: Relationship Between Within-Subject Biological Variation and the Observed             
Mean Change in Markers of Glucose Homeostasis for Subjects  with                       
CHC Interactions ........................................................................................................ 116 
Table 65: Analytical Variation Observed with Reagent Change During the                                       
Study Timeframe ........................................................................................................ 117 
xiv 
 
 
 
 
  
 
List of Figures 
 
 
Figure 1: Diabetes Progression Timeline ...................................................................................... 16 
Figure 2: Glucose and 1,5- anhydroglucitol molecules ................................................................ 27 
Figure 3 Mean Change in Glucose by Number of CHC Interactions ........................................... 93 
Figure 4 Mean Change in HbA1c by Number of CHC Interactions............................................. 95 
Figure 5 Mean Change in 1,5-AG by Number of CHC Interactions ............................................ 98 
Figure 6 Mean Change in Insulin by Number of CHC Interactions ........................................... 101 
Figure 7 Mean Change in C-peptide by Number of CHC Interactions ...................................... 104 
Figure 8 Mean Change in Proinsulin by Number of CHC Interactions ...................................... 107 
Figure 9 Mean Change in BMI by Number of CHC Interaction ................................................ 110 
 
 
 
 
 
 
 
 
 
xv 
 
 
 
 
 
List of Abbreviations  
 
 
1,5-AG 1,5- Anhydroglucitol 
AACC  American Association of Clinical Chemistry  
ADA  American Diabetes Association 
AMR  Analytical measurement range 
ANCOVA Analysis of Covariance 
AV   Analytical variability 
BMI  Body mass index 
BV  Biological variability 
CAP  College of American Pathologists 
CAD  Coronary artery disease 
CHC  Clinical Health Consultant 
CHWP  Connected Health and Wellness Platform 
CLIA88 Clinical Laboratory Improvement Act of 1988 
CRR  Clinical reportable range 
CV   Covariate 
DKA  Diabetic ketoacidosis 
DPMP  Diabetes Prevention and Management Panel 
EDTA  Ethylenediaminetetraacetic acid 
ER  Endoplasmic reticulum 
FPG   Fasting plasma glucose  
GDM  Gestational diabetes mellitus 
GLM  General Linear Module 
GLUT2 Glucose transporter 2 
G-6-P  Glucose-6-phosphate 
G6PD  Glucose-6-phosphate dehydrogenase 
HbA1c  Hemoglobin A1c 
HgbA  Hemoglobin A 
HIIE  High intensity intermittent exercise 
HK  Hexokinase 
HPLC  High pressure liquid chromatography 
HLA  Human leukocyte antigen 
IAA  Insulin antigen antibody 
IFG  Impaired fasting glucose 
IGT  Impaired glucose tolerance 
IMS  Information management system 
xvi 
 
 
 
IT  Information technology 
kDa  kilodalton 
LDL   Low density lipoprotein 
LIS  Laboratory information system 
MD  Mahalanobis distance 
MI  Motivational interviewing 
MODY Maturity onset of diabetes of the young 
NAD+  Nicotinamide adenine dinucleotide (oxidized) 
NADH  nicotinamide adenine dinucleotide (reduced) 
NDDG  National Diabetes Data Group 
NIDDM Non-insulin dependent diabetes mellitus 
nm  Nanometers 
OGTT  Oral glucose tolerance test 
PI  Principle investigator 
PID  Patient identification number 
PI3K  Phosphatidylinositol 3-kinase 
PPGi  Post-prandial glycemic index 
PROD  Pyranose oxidase 
QC  Quality control 
rBWL  Reduced intensity behavioral weight loss 
SAS  Statistical Analysis Software 
SD  Standard deviation 
SI  System International 
SID  Sample identification number 
sdLDL  Small dense lipoprotein 
SST  Serum separator tube 
T2D  Type II diabetes  
T1D  Type 1 diabetes 
TTM  Transtheoretical model 
US  United States 
 
 
 
 
 
 
 
 
xvii 
 
 
 
 
 
Abstract 
 
 
RELATIONSHIP BETWEEN PATINET-HEALTH COACH INTERACTIONS AND 
CHANGES IN MARKERS OF GLUCOSE HOMEMSTASIS 
 
By Jason P. Nagy, MS, MT(ASCP)
CM 
A dissertation submitted in partial fulfilment of the requirements for the degree of doctor of 
Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2018 
Advisor: Advisor: William J. Korzun, Ph.D., DABCC, MT(ASCP)
CM 
Associate Professor, 
Department of Clinical Laboratory Science 
 
 
 
 
Diabetes and insulin resistance are on the rise in the United States. Early detection and 
deployment of therapies has allowed for the reversal of pancreatic beta cell damage. 
Unfortunately, not all providers can offer the support to facilitating the required life style 
modifications. The introduction of clinical health consultants (CHC) as supplemental care has 
improved patient health for a variety of chronic diseases. Missing in the literature are studies 
investigating the correlation between the number of CHC interactions and improvement in 
biomarkers.  
The study utilized a non-experimental, retrospective study design to evaluate the 
relationship between the use between the use of CHCs and the number of CHC interactions, and 
xviii 
 
 
 
the mean changes in glucose, hemoglobin A1c, insulin, proinsulin, C-peptide, and 1,5-
anhydroglucitol, over a one-year period for patients presented with the opportunity to participate 
in CHC interactions. The subjects’ follow-up results were compared to their initial results for 
each group using the ANCOVA and one-way t-test.  
A statistically significant difference was detected between the mean change in BMI and 
the use of CHCs (p <0.001). In addition, a statistically significant relationship was identified 
between the number of CHC interactions and the magnitude of change in BMI (p< 0.001).  No 
statistically significant differences were detected for the other study biomarkers.  Initial 
biomarker values and random error explained a majority of the differences found between the 
CHC and non-CHC groups. The use of CHC interactions had a minimum effect on the statistical 
models used to compare the CHC and non-CHC groups.  
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Chapter 1: Introduction 
 
 
Overview 
 The study investigated the relationship between the number of clinical health consultant 
(CHC) interactions and changes in biomarkers used to evaluate glucose homeostasis related to 
diabetes, insulin resistance and beta cell dysfunction. The retrospective study utilized previously 
collected data, including glucose, hemoglobin A1c (HbA1c), 1,5-anhydroglucitol (1,5-AG), 
insulin, C-peptide, proinsulin, and BMI results, as well as the number of patient-CHC 
interactions. The results of this study contributed to the knowledge of the potential efficacy of 
CHCs in improving the management and outcomes of patients with diabetes, insulin resistance or 
beta cell dysfunction.   
 Chapter 1 states the study’s purpose, hypotheses, and a summary of health coaching and 
data sources with background information on the health risks related to diabetes, and some of its 
potential precursors, insulin resistance and beta cell dysfunction. Chapter 2 provides an overview 
of diabetes and a literature review of biomarkers related to glucose homeostasis, diabetes, insulin 
resistance, and beta cell dysfunction, disease treatment, and the CHC profession. Chapter 3 
details the methods used in the study, including sample selection, biomarker testing, and 
statistical analysis. Chapter 4 presents the results of statistical analysis and subject demographics. 
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Chapter 5 offers a discussion of the results, study limitations, and recommendations for future 
studies.  
Background 
Diabetes is a disorder of glucose metabolism that affects 30.3 million people in the 
United States (US), or 9.4% of the American population. Of those, 7.2 million or 23.1% are 
reportedly undiagnosed (Centers for Disease Control and Prevention, 2014; Centers for Disease 
Control and Prevention, 2017). Diabetes increases the risk of heart disease and stroke, as well as 
many other microvascular and macrovascular comorbidities. Improperly managed diabetes can 
result in kidney disease, blindness, and amputations. There are four classifications of diabetes: 
Type 1 diabetes (T1D) is caused by the autoimmune or other toxic destruction of pancreatic beta 
cells. Type 2 diabetes (T2D) is due to a progressive loss of beta cell insulin secretion that follows 
the development of insulin resistance. Gestational diabetes mellitus (GDM) develops during the 
second or third trimester of pregnancy, with no diagnosis of diabetes prior to pregnancy. 
Secondary diabetes is caused by monogenic defects resulting in beta cell dysfunction, including 
neonatal and maturity-onset diabetes (Riddle, 2018).  Additional causes of secondary diabetes 
include disorders of the pituitary, thyroid, or adrenal glands, diseases of the exocrine pancreas, or 
drug and chemical related diabetes (Riddle, 2018).  Estimates show that of all the individuals 
with diabetes, 90-95% have T2D. (Centers for Disease Control and Prevention, 2017). Type 2 
diabetes, unlike T1D, is potentially a preventable disease. The development of T2D is not an 
acute process, but rather a slowly progressive condition that results in beta cell dysfunction.  
Several conditions are associated with the risk of developing T2D including obesity, reduced 
exercise, smoking, high blood pressure, and high cholesterol (Centers for Disease Control and 
Prevention, 2017).  
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Peripheral blood glucose levels are determined by exogenous glucose from the 
breakdown of consumed food, and endogenous glucose produced by the liver. Hepatic 
conversion of glycogen to glucose, known as glycogenolysis, and glucose production from 
amino acids known as gluconeogenesis, occur during times of decreased glucose ingestion such 
as sleep and between meals. To compensate for increases in plasma glucose concentrations, in 
insulin resistant states, the pancreatic beta cells secrete more insulin, in an effort to enable 
peripheral tissues to take up glucose. Over time, the beta cells become exhausted and lose their 
ability to produce sufficient insulin. Early detection of this process allows for lifestyle 
modifications that can potentially delay or reverse the progression to T2D. Diabetes was ranked 
as the seventh leading cause of death in 2015, due to complications such as cardiovascular 
disease, stroke, end-stage renal disease, and diabetic ketoacidosis. Early detection and 
intervention has the potential to reduce diabetes related morbidity and mortality (Centers for 
Disease Control and Prevention, 2017).   
The lifestyle modifications required of patients to prevent and/or treat T2D can be 
controversial, challenging, and sometimes overwhelming to the patient.  The American Diabetes 
Association (ADA) recommends that individuals with diabetes should participate in diabetes 
self-management education and support (DSMES), medical nutrition therapy (MNT), physical 
activity, smoking cessation counseling, and psychosocial care (American Diabetes Association, 
2018).  The introduction of self-management programs has shown to have a positive effect on 
weight loss and lifestyle modification. 
CHCs can help facilitate the process of lifestyle modification and treatment compliance 
that is required for positive patient outcomes. The development of treatment goals through 
discussion between the patient and a CHC is an initial step of therapy. CHC involvement 
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provides support for patients secondary to the care received from their providers. The CHC-
patient interaction can increase motivation to comply with recommended therapies through 
behavior change therapies, identifying underlying factors that may influence an individual’s 
motivation, as well as plan nutritional and exercise options. The main objective of a CHC 
program is not to treat but to educate the patient and help create the changes needed to overcome 
their condition.  
Research Problem  
 Many patients find it difficult to change their lifestyle based on health care provider 
recommendations, despite the understanding that it is needed to improve their overall health. 
Perceived treatment efficacy, physician trust, worsening of diabetes symptoms, medication cost, 
complexity of medication dosage and the side effects of medications are factors that lead to 
patient noncompliance (Polonsky & Henry, 2016). These barriers to patient compliance suggest 
that doctor-patient interaction is not sufficient for implementing lifestyle changes. Ambivalence 
related to motivation and lifestyle changes may also present as barriers (Kehler et al., 2008). 
Studies demonstrate that CHC interactions may facilitate and improve adherence to these 
lifestyle changes and correlate CHC interactions with changes in markers such as BMI and 
HbA1c (Leahey & Wing, 2013; Pettitt, 2013; Wayne & Ritvo, 2014; Wolever et al., 2010). The 
mentioned studies only compare a control group to a treatment group with a set number of CHC 
interactions. Missing are studies relating the number of CHC interactions to the magnitude of 
change in specific biomarkers are lacking. Furthermore, there is no literature on the effect of 
CHC interactions on markers of insulin resistance and beta cell dysfunction such as insulin, C-
peptide, and proinsulin, or the more recent glycemic marker, 1,5-AG.   
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Purpose of the Study and Research Question 
The purpose of this study was to retrospectively examine the relationship between 
patients engaging in CHC interactions and changes in glucose, %HbA1c, 1,5-AG, insulin, C-
peptide, proinsulin, and BMI to determine the effectiveness of CHC interactions on potential 
change in patient health. The study examined patient results and CHC utilization to determine if 
a correlation between the number of CHC-patient interactions and changes in biomarkers over 
time exists. The study attempted to answer the research question, is there a relationship between 
the changes in patients’ biomarkers of glucose homeostasis and beta cell health and their 
interactions with CHCs? 
Specific Aims  
The study had three Specific Aims: 
Specific Aim 1: Determine if there are statistically significant differences between 
patients who do or do not participate in CHC interactions in their changes in 1) blood 
glucose concentration, 2) %HbA1c, 3) blood 1,5-anhydroglucitol concentration (1,5-AG), 
4) blood insulin concentration, 5) blood C-peptide concentration, 6) blood proinsulin 
concentration, and 7) body mass index (BMI). 
This was addressed by comparing the difference between initial biomarker results and follow-up 
results 10-14 months from initial testing, for two groups, 1) those who participated in CHC 
interactions, and 2) those who did not. Changes in biomarker values were calculated for each 
marker in both the CHC and non-CHC groups and compared statistically. 
Specific Aim 2: Determine if statistically significant differences exist in the change in 
diabetes and BMI health scores between subjects who did and those who did not interact 
with CHCs for glucose and HabA1c. 
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Arbitrary health scores were assigned to initial and follow-up testing results. Health scores were 
based upon ADA recommended cutoffs for normal, prediabetic, and diabetic values for glucose 
and HbA1c, and BMI guidelines for normal, overweight, and obese individuals. The change in 
health score was calculated between initial and follow-up testing 10-14 months from initial 
testing for two groups, 1) those who participated in CHC interactions, and 2) those who did not. 
Group health score differences were then statistically compared. 
Specific Aim 3:  Determine the relationship between the number of CHC interactions and  
magnitude of the change in 1) blood glucose concentrations, 2) % HbA1c, 3) blood 1,5-
anhydroglucitol (1,5-AG) concentrations, 4) blood insulin concentrations, 5) blood C-
peptide concentrations, 6) blood proinsulin concentrations and 7) body mass index 
(BMI).   
This was determined by the use of a general linear model to compare the magnitude of change in 
each biomarker between subjects with different numbers of CHC interactions. Change in 
biomarker values were compared to varying numbers of CHC interactions. Post-hoc Bonferroni 
tests of multiple comparisons evaluated the mean change between groups. 
Significance of the Study 
 CHC interactions have shown to be effective in the management and treatment of 
diabetes and other related conditions. Studies investigating the effect of CHC interactions have 
only utilized the markers of weight loss and HbA1c (Leahey & Wing, 2013; Pettitt, 2013; Wayne 
& Ritvo, 2014; Wolever et al., 2010). There is no literature on CHC interactions and potential 
change in insulin, C-peptide, proinsulin, and 1,5-AG, nor on the connection between the number 
of CHC interactions and the magnitude of the biomarker change. The results of this study 
increase the knowledge on the relationship between the number of CHC-patient interactions and 
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improvements in biomarkers for diabetes and insulin resistance. This knowledge could help 
guide the creation and planning of CHC-mediated therapies to maximize their effectiveness and 
efficiency for attaining patient treatment goals. Study findings could also serve as a foundation 
for future studies on how to reduce health care costs and improve patient care utilizing CHCs.  
Summary of Data Sources and Analysis 
Data for this study was gathered from two databases. The laboratory information system 
(LIS) at a laboratory in Richmond, VA contained archived patient results for the biomarkers of 
interest, starting in April 2012. A query of the LIS provided biomarker results, along with subject 
demographics such as age, gender, and body mass index.  
The CHC information management system (IMS) database at the same laboratory housed 
the dates of patient-CHC interactions.  An initial query of the LIS identified patients that met the 
study inclusion criteria. Then, a query of the IMS accessed information on CHC interactions for 
the subjects identified from the LIS query.  
Data from both the LIS and the IMS were merged into a single Microsoft Excel file.  The 
Principle Investigator imported the data set into Statistical Package for the Social Sciences 
(SPSS) for data analysis. The study utilized a one-way analysis of covariance (ANCOVA) and 
linear regression. This approach allowed for the determination of within subject differences in 
biomarkers, as well as the relationship between CHC-patient interactions, the study independent 
variable (IV) and the changes in the markers, the study dependent variables (DVs), while 
adjusting for the patient demographics sex, age, and BMI, the study covariables (CV).   
Chapter Summary  
 Chapter 1 provided background on diabetes, the challenges of lifestyle modification, and 
how CHCs can help facilitate the change required to improve patient health. Multiple studies 
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demonstrate the ability of CHCs to change BMI and %HgbA1c but none address the effects of 
CHCs on other makers used to monitor glucose homeostasis and beta cell health. Chapter 2 
offers an overview of the pathophysiology of diabetes, biomarkers of glucose homeostasis, and 
the potential impact of CHCs on health care outcomes, along with the gaps in literature that this 
study hopes to fill. Chapter 3 provides the proposed study’s methodology, including the target 
population, sampling strategy, data collection methods and analysis, and potential limitations. 
Chapter 4 presents the study findings, while Chapter 5 discusses the study results and describes 
the study limitations, and recommendation for future studies.  
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Chapter 2: Literature Review  
 
 
Introduction 
Chapter 1 introduced the proposed study including the study purpose, aims, and research 
questions. Chapter 2 provides an overview of the pathophysiology of diabetes, biomarkers of 
glucose homeostasis, treatments for diabetes, and the clinical health coach professions. First, an 
overview of glucose homeostasis and diabetes is presented. Next, information detailing the 
markers used in the study is discussed. Finally, information describing CHCs and relevant 
studies demonstrating their effect on improving patient health is presented.       
Overview 
A key to controlling diabetes, and potentially reversing the progression towards T2D, is 
the identification of biomarkers of the prediabetic state. Monitoring biomarkers closely linked to 
diabetes, insulin resistance, and beta cell function allows for the evaluation of diabetes risk and 
control.  Measuring glucose, 1,5- anhydroglucitol (1,5-AG), and hemoglobin A1c (%HbA1c) 
provide a snapshot of glucose concentration in the peripheral blood at the time of venipuncture, 
as well as an estimate of the average glucose concentration over the past two weeks to 3 months. 
Abnormal levels of C-peptide, insulin, and proinsulin in the blood alerts providers to the 
presence of beta cell dysfunction or death. If detected early, deployment of therapies can 
potentially reverse the damage sustained to pancreatic beta cells.  
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Adherence to the lifestyle changes required to manage or prevent diabetes is not easy. It 
is estimated that a majority of adult diabetics fail to follow physician prescribed treatments for 
their disease (Funnell, 2006; Gonzalez, Shreck, Psaros, & Safren, 2014; Willard-Grace et al., 
2013). CHC interactions, when coupled with provider therapies, have shown to have a positive 
effect on health outcomes (Appel et al., 2011; Battista et al., 2012; Eakin, Lawler, Vandelanotte, 
& Owen, 2007).  A common belief in health coaching is that the patient has the ability to adopt 
healthy behaviors if given the proper guidance. The professional health coach is an educator, one 
whose goal is to provide information and support that elicit change in patient behavior and 
physical health.  
Glucose Homeostasis 
Plasma glucose homeostasis is the result of the dynamic balance between glucose intake 
and hepatic synthesis, and the demand for and uptake of glucose by organs and cells including 
the brain, gut, liver, kidneys, pancreas, adipocytes and myocytes. The liver and brain take up 
glucose directly, not requiring an insulin dependent glucose transporter. The kidneys help 
regulate glucose by allowing glucose to be excreted into the urine if the glucose renal threshold 
of 180 mg/dL is exceeded.  Beta cells, the site of insulin production, are found in a region of the 
pancreas called the Islets of Langerhans. Two major types of cells in the Islets of Langerhans, the 
alpha and the beta cells, are specific to glucose homeostasis. Alpha cells produce glucagon, a 
hormone that stimulates the production of glucose from glycogen, amino acids, glycerol, and 
lactate in the liver. Beta cells produce insulin, the hormone responsible for the regulation of 
glucose transportation from the peripheral blood into the cell.  
Insulin production begins with the synthesis of a parent peptide, preproinsulin. (Chan, 
Keim, & Steiner, 1976). Preproinsulin, a protein comprised of approximately 100 amino acids, 
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has a short half-life of approximately one minute before it is enzymatically cleaved (Patzelt et 
al., 1978). Within the rough endoplasmic reticulum (ER) of the beta cells, the 23 amino acids at 
the N-terminal of  preproinsulin are removed and two disulfide bonds are formed, resulting in the 
formation of proinsulin (Steiner, Cunningham, Spigelman, & Aten, 1967).  Proinsulin is then 
transported to the Golgi apparatus where it is packaged into storage granules along with 
prohormone convertases 1 and 2, and carboxypeptidase H. This conversion is proportionate with 
glucose concentration and dependent on the availability of convertase enzymes PC2 and 
PC1/PC3 (Nagamatsu, Bolaffi, & Grodsky, 1987). Within the Golgi apparatus, the cleavage of 
the 31 amino acid C-peptide from proinsulin forms the hormone insulin. C-peptide and insulin 
remain within secretory granules in the beta cells until an increase in blood glucose levels 
triggers the release of insulin into the blood.  
  Glucose stimulation of insulin secretion by the beta cells requires a cascade of events. 
First, the glucose transporter 2 (GLUT2) found on the membrane of beta cells transports glucose 
from peripheral blood into the beta cell. Glucose then undergoes glycolysis within the beta cell, 
generating an increase in ATP.  The increase in ATP causes the ligand-gate potassium channel to 
close, resulting in an increase in intracellular potassium level and membrane depolarization. 
Membrane depolarization allows extracellular calcium to enter the beta cell via voltage-gated 
Ca2+ channels, with increasing calcium concentrations signaling the insulin-containing vesicles 
to release insulin and C-peptide. Insulin secretion is biphasic, with the first phase of insulin 
secretion occurring 2-3 minutes after glucose levels rise and lasting for around 10 minutes. The 
second phase of insulin release occurs after the initial, with glucose levels still elevated, and 
continues until glucose homeostasis is achieved. Individuals with T2D are shown to have 
impaired insulin secretion in the first phase (Cerasi, 1992). Secreted insulin circulates in the 
  
12 
 
blood and binds to insulin receptors on the surface of cells such as adipocytes and muscle cells, 
stimulating the translocation of the glucose transporter GLUT4 from intracellular storage 
vesicles to the cell membrane (Saltiel & Kahn, 2001).  
The alpha and beta cells of the pancreas work in tandem to maintain glucose homeostasis. 
In addition to facilitating the glucose uptake by peripheral cells, a high ratio of insulin/glucagon 
also promotes the storage of glucose as glycogen in the liver and muscle cells. Conversely, when 
plasma glucose concentrations fall as in a fasting state, the alpha cells release glucagon, signaling 
the liver to convert glycogen to glucose and to promote gluconeogenesis. The inability of the 
body to regulate glucose levels in the peripheral blood, caused by lack of insulin, or insulin 
resistance, is characteristic of diabetes.  
Diabetes 
Diabetes is a disorder of glucose metabolism that affects 30.3 million people in the 
United States (US), or 9.4% of the American population. Of those, 7.2 million or 23.1% are 
reportedly undiagnosed (Centers for Disease Control and Prevention, 2014; Centers for Disease 
Control and Prevention, 2017). There are four classifications of diabetes: Type 1 diabetes (T1D) 
is caused by the autoimmune destruction of pancreatic beta cells. Type 2 diabetes (T2D) is a 
progressive loss of beta cell insulin secretion that is highly correlated with insulin resistance. 
Gestational diabetes mellitus (GDM) is a diagnosis of diabetes during the second or third 
trimester of pregnancy with no diagnosis of diabetes prior to pregnancy. Secondary diabetes is 
due to causes including neonatal and maturity-onset diabetes, disease of exocrine pancreas, 
disorders of the pituitary, thyroid, or adrenal glands, pancreatic insufficiency, and drug and 
chemical related diabetes (Riddle, 2018) . One of the diagnostic clinical signs of diabetes is the 
inability to regulate plasma glucose concentration. Over time, the metabolic abnormalities of 
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diabetes can lead to numerous potential microvascular complications such as diabetic 
nephropathy and failure, neuropathy, retinopathy, macrovascular complications, and 
atherosclerotic vascular disease (coronary, peripheral, cerebrovascular). Uncontrolled diabetes 
can also result in a sudden onset of ketoacidosis and hyperosmolar coma, as well as eventual 
kidney failure, blindness, and amputations (Forbes & Cooper, 2013).  
Type 1 Diabetes 
Type I diabetes is characterized by an autoimmune destruction of pancreatic beta cells, 
the cells responsible for secreting the hormone insulin. Genetic mutations, specific to class II 
human leukocyte antigen (HLA) alleles encoding HLA DRB1*03:01-DQA1*05:01-
DQB1*02:01 abbreviated DR3 and HLA DRB1*04:01/02/04/05/08-DQA1*03:01-
DQB1*03:02/04 (or DQB1*02; abbreviated DR4 on chromosome 6p21.31, are highly correlated 
with T1D. The HLA regions I and II are responsible for the production of antigens that bind 
antigenic peptides involved with T-helper cell presentation. Specifically to T1D, T- cell 
presentation of autoantigens typically leads to the production of autoantibodies to proteins found 
in the beta cells. It was noted that mutations resulting in HLA DR3/DR4 heterozygotes are more 
closely linked to T1D than homozygotes of either haplotype (Nobel & Valdes, 2011). The 
antibodies typically found in the plasma of Type 1 diabetics are insulin antigen antibody (IAA), 
and anti-glutamic acid decarboxylase (anti-GAD) (Balakhadze, Giorgadze, & Lomidze, 2016).   
Type 1 diabetes usually occurs before the age of 15, but may not be diagnosed until later in life. 
In addition to their age at the time of diagnosis, patients with adult onset of T1D can be 
distinguished from adolescent T1D by higher body mass index (BMI) and C-peptide values 
(Törn et al., 2000).  
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There are several stages of T1D (Table 1), with clinical symptoms usually seen at the 
later stages (Skylar et al., 2017), (Insel et al., 2015). In stage 1, autoantibodies are present, with 
the absence of any clinical signs of diabetes and normal glucose metabolism. During stage 2, 
patients begin to have impaired fasting glucose. Fasting plasma glucose (FPG) levels may rise 
above the normal cutoff of 99 mg/dL but still below the 126 mg/dL clinical cutoff for diabetes; 
or the 2-hour post-prandial sample in an  oral glucose tolerance test (OGTT) may be between 
140-199 mg/dL. Percent HbA1c values may rise above the normal cutoff of 5.6%, but below the 
diabetic cutoff of 6.5%. Patients in Stage 3 display clinical signs of diabetes, polyuria/polydipsia, 
with one-third having diabetic-ketoacidosis. Stage 3 is also confirmed with FPG and % HbA1c 
values consistent with a diagnosis of diabetes: FPG ≥ 126 mg/dL, a two-hour OGTT ≥ 200 
mg/dL, or %HbA1c ≥ 6.5. 
Table 1: Type 1 Diabetes Diagnosis by Stage 
Stage of Type 1 Diabetes Diagnostic Criteria 
1  Positive for multiple autoantibodies 
 No impaired glucose tolerance test 
 No impaired fasting glucose 
2  Positive for multiple autoantibodies 
 Dysglycemia:  
o FPG 100–125 mg/dL (5.6–6.9 mmol/L) 
o 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L) 
o A1C 5.7–6.4% (39–47 mmol/mol) or ≥ 10% 
increase in A1C 
3  Clinical symptoms 
o polyuria/polydipsia, and one-third with diabetic 
ketoacidosis (DKA) 
 Hyperglycemia 
 Diabetes by standard criteria 
Adopted from (Skylar et al., 2017), (Insel et al., 2015), (Cefalu, 2017), (Dabelea et al., 2014) 
Controlling T1D involves coordinated management of diet, exercise, and insulin 
injections (Riddle, 2018). Therapies designed to normalize glucose metabolism in type 1 
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diabetics have secondary benefits of reducing cardiovascular events. The link between glycemic 
control and macrovascular disorders is well-established (Klein, 1995; Shamoon et al., 1993).  
Type 2 Diabetes  
Unlike T1D, T2D is not due to a cellular immune reaction to the beta cells in the 
pancreas. Rather, the development to T2D begins with accumulation of fat on muscle, liver, and 
pancreatic tissue, resulting in inflammation, insulin resistance, and then eventual beta cell 
dysfunction (Riddle, 2018; Skyler et al., 2017).  Inflammation can lead to a disruption of the 
ability of insulin to activate receptors on the cells in insulin dependent tissues such as muscles. 
This phenomenon, termed “insulin resistance,” leads to diminished activity in insulin-mediated 
pathways, such as the uptake of glucose (Sinaiko & Caprio, 2012). Cusi et al. concluded that the 
ability of insulin to stimulate the phosphatidylinositol 3-kinase (PI 3-kinase) pathway, the 
enzyme responsible for the transduction of insulin binding to its receptor and the recruitment of 
glucose transport proteins to the surface of cells, was reduced in obese patients and almost 
undetectable in patients with T2D (Cusi et al., 2000). The reduction of glucose transport into the 
cells results in increased plasma glucose concentrations.  
Individuals with insulin resistance can have glucose concentrations and % HbA1c that are 
still below the diabetic diagnostic threshold.  Protracted hyperglycemia due to insulin resistance 
signals pancreatic beta cells to secrete more insulin, leading to increases in the beta cell products 
proinsulin, insulin, and C-peptide in the blood. The state of insulin resistance with mild 
hyperglycemia may be present for many years before beta cell damage is clinically apparent. 
When the beta cells can no longer produce enough insulin to maintain FPG and %HbA1c within 
normal levels, the diagnostic threshold of prediabetes are crossed. The American Diabetes 
Association (ADA) and the International Expert Committee on the Diagnosis and Classification 
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of Diabetes Mellitus have recognized this group of individuals whose glucose levels do not meet 
criteria for diabetes as “prediabetic” (The Expert Committee on the Diagnosis and Classification 
of Diabetes Mellitus, 2003). Prediabetes is not considered its own disease state; patients with 
prediabetes are at an increased risk for developing T2D and cardiovascular complications 
(Armstrong, 2017). 
At this point, beta cell function continues to deteriorate without lifestyle adjustments. 
When patients in a prediabetic state are identified, interventions such as lifestyle changes can 
delay or even prevent progression to T2D.  When 80% of beta cell function is lost, circulating 
levels of insulin, proinsulin, and C-peptide start to decrease, eventually leading to levels of 
hyperglycemia and %HgbA1c that are consistent with T2D (DeFronzo & Abdul-Ghani, 2011). If 
interventions fail to preserve the remaining beta cells, the patient will require exogenous sources 
of insulin, similar to Type 1 diabetics (Weir & Bonner-Weir, 2004).   
Figure 1 illustrates the chronological relationships between various parameters of the 
derangement of glucose homeostasis along the progression to T2D.   
 
 
Figure 1: Diabetes Progression Timeline 
Duplicated with permission, (Ramlo-Halsted & Edelman, 1999) 
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Weir, et al have proposed 5 stages in the progression to T2D:  
 Stage 1, Compensation. The first stage is characterized by the ability to maintain 
normal blood glucose concentrations but only because of an increase of insulin 
production. Compensation is thought to entail an increase in beta cell mass to 
accommodate the increase in insulin. Monitoring blood glucose concentrations or 
%HgbA1c would not indicate the presence of insulin resistance or potential 
progression towards T2D. 
 Stage 2, Stable adaptation. Beta cells can no longer maintain normal glucose 
levels in the peripheral blood, and patients demonstrate sustained elevated post-
prandial glucose, and fasting blood glucose levels up to 130 mg/dL, along with 
impaired glucose stimulation of insulin secretion. Patients may avoid progression 
to Stage 3 for many years, with lifestyle changes such as diet and exercise 
(Knowler et.al., 2002).  
 Stage 3, Unstable Early Decompensation. Functional beta cells have declined to a 
level where there is inadequate response to elevated glucose concentrations, and 
glucose levels rise to as high as 350 mg/dL in a short period of time. 
 Stage 4, Stable Decompensation. Beta cell size and mass that is half of that in 
normal individuals. Most patients with T2D can remain in Stage 4 for the rest of 
their lives, with a sufficient amount of insulin production to prevent diabetic 
ketoacidosis.  
 Stage 5, Severe Decompensation. The loss of beta cells is so severe that patients 
become susceptible to ketoacidosis and are totally dependent on insulin for 
survival. Glucose levels are typically >350 mg/dL (Weir & Bonner-Weir, 2004).  
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According to the ADA, a diagnosis of diabetes is made if one of any of the following 
conditions is demonstrated on more than one occasion: [1] HbA1c is ≥ 6.5%, [2] fasting glucose 
is  ≥  126 mg/dL, [3] the two-hour specimen from an oral glucose tolerance test (OGTT) is  ≥ 
200 mg/dL or  [4] the patient has a random blood glucose concentration > 200 mg/dL along with 
the clinical symptoms of diabetes (Cefalu, 2017). Patients without  clinical signs of diabetes and 
whose lab results do not meet the criteria for diabetes may be classified as prediabetic, according 
to the ADA, if they demonstrate fasting blood glucose concentrations between 100 mg/dL and 
125 mg/dL, %HbA1c concentrations between 5.7 and 6.4%, or a two-hour post-prandial blood 
specimen from an OGTT between 140 mg/dL and 199 mg/dL (Cefalu, 2017).  In 2015, it was 
estimated that in the US, 37% of adults over 18 and 48.3% of all adults aged 65 and above are 
prediabetic (Centers for Disease Control and Prevention, 2017). It is recommended that 
individuals who are asymptomatic have their blood glucose and %HgbA1c measured if they 
have a BMI greater than 25 kg/m
2
 or have other risk factors for diabetes such as reduced 
exercise, a family history of diabetes, or a less than healthy lifestyle (American Diabetes 
Association, 2013).  Increases in age and BMI are highly correlated with the occurrence of T2D 
(American Diabetes Association, 2013);(Centers for Disease Control and Prevention, 2017). 
Gestational Diabetes  
 Gestational diabetes is the diagnosis of diabetes in the second or third trimester of 
pregnancy, in the absence of T1D or T2D prior to conception. Gestational diabetes is associated 
with an increased risk of perinatal complications and maternal T2D after delivery (Riddle, 2018). 
The exact pathophysiology of GDM is unknown; however, obesity and increased BMI are highly 
correlated with the development of GDM (Ehrenberg, Dierker, Milluzzi, & Mercer, 2002; 
Hedderson, Williams, Holt, Weiss, & Ferrara, 2008). Testing for GDM usually occurs at 24-28 
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weeks gestation in women with no prior diagnosis of diabetes. If a woman is diagnosed with 
GDM, she is tested again at 4-12 weeks postpartum for persistent diabetes. Testing can be done 
two ways, a one-time dose of 75g glucose OGTT or a two-step 50g OGTT screen followed by a 
100g OGTT for positive screen results. The one-time 75g OGTT cutoffs for diagnosis of GDM 
are a fasting glucose ≥ 92 mg/dL, 1 hour glucose ≥ 180 mg/dL, or a 2 hour glucose ≥153 mg/dL. 
According to the ADA, glucose measurements of ≥ 130 mg/dL, 135 mg/dL, or 140 mg/dL at 1 
hour following a 50g load are all acceptable positive cutoffs, with the 140 mg/dL cutoff being 
the most specific (70-88%) and the 130 mg/dL cutoff being the most sensitive (69-89%) (Riddle, 
2018). The cutoff used is dependent on the physician’s preference. Patients would then receive a 
100 g OGTT at their next visit. There are two criteria for 100g OGTT cutoffs, the Carpenter-
Coustan and the National Diabetes Data Group (NDDG). According to Carpenter-Coustan, the 
diagnosis of diabetes is made if at least two of the following are met: Fasting glucose ≥ 95 
mg/dL, a 1 h glucose ≥180 mg/dL, a 2 h glucose ≥ 155 mg/dL, a 3 h glucose ≥ 140 mg/dL. 
According to the NDDG, a diagnosis of diabetes is made if fasting glucose is ≥ 105 mg/dL, 1 
hour glucose ≥190 mg/dL, 2 hour glucose ≥ 165 mg/dL, or 3 hour glucose ≥ 145 mg/dL 
following the 100 g load. Table 2 illustrates the two different methods for diagnosis GDM. 
Table 2: Criteria for GDM Diagnosis  
One Step strategy 75-g OGTT 
Two-Step Testing 
50-GOGTT ≥ 130 mg/dL (7.5 mmol/L) positive 
100- OGTT Cut-off 
Carpenter-Coustan NDDG 
Fasting 
92 mg/dL  
(5.1 mmol/L) 
95 mg/dL  
(5.3 mmol/L) 
105 mg/dL  
(5.8 mmol/L) 
1 h 
180 mg/dL  
(10 mmol/L) 
180 mg/dL  
(10.0 mmol/L) 
190 mg/dL  
(10.6 mmol/L) 
2 h 
153 mg/dL  
(8.5 mmol/L) 
155 mg/dL  
(8.6 mmol/L) 
165 mg/dL 
 (9.2 mmol/L) 
3 h N/A 
140 mg/dL  
(7.8 mmol/L) 
145 mg/dL  
(8.0 mmol/L) 
Classification and Diagnosis of Diabetes (Riddle, 2018) 
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Treatment for gestational diabetes could include a lifestyle changes such as a modified diet and 
exercise schedule, along with glucose monitoring and/or insulin injections to assist reaching 
glycemic targets of fasting glucose < 95 mg/dL (Riddle, 2018).  
Diabetes Due to Other Causes 
 Causes for secondary diabetes include single gene mutations causing neonatal diabetes, a 
diagnosis of diabetes within the first six months of life, and maturity-onset diabetes of the young 
(MODY), a condition typically characterized by impaired insulin secretion and hyperglycemia 
before the age of 25. Specifically, MODY is the result of defective insulin production in 
response to increases in plasma glucose concentration (Fajans & Bell, 2011). In both neonatal 
and MODY, the cause of genetic mutation can be spontaneous, or the result of autosomal or 
recessive gene inheritance.  Due to their unusual circumstance, these types of diabetes usually 
require the involvement of a diabetes specialist to determine the best treatment routine. Disease 
of exocrine pancreas such as cystic fibrosis and pancreatitis are also causes of secondary 
diabetes. Additionally, disorders in the pituitary, thyroid, or adrenal glands, pancreatic 
insufficiency, and drug or chemical interactions can cause secondary diabetes (Riddle, 2018).   
Treatments for Diabetes  
Lifestyle choices such as smoking, lack of exercise, diets high in carbohydrates and low 
in fiber can contribute to the development towards T2D.  If detected early, lifestyle modifications 
such as regular exercise, lower energy intake, better food choices, smoking cessation, and 
medication can diminish or halt disease progression and improve cells’ sensitivity to insulin 
(American Diabetes Association, 2018; National Diabetes Information Clearinghouse, 2014).  
Furthermore, Godsland et al. concluded that loss of beta cell function is highly correlated with 
increases in age and BMI (Godsland, Jeffs, & Johnston, 2004). Unfortunately, reversal of overt 
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T2D is much more difficult. By the time diagnostic glycemic thresholds of hyperglycemia have 
been crossed, severe beta cell damage has already occurred. It is recommended to develop and 
maintain a healthy lifestyle early, before beta cell damage becomes irreversible. A 2005 study 
reported that individuals who underwent intensive lifestyle modifications significantly improved 
insulin sensitivity and beta cell preservation over the course of one year (The Diabetes 
Prevention Program Research Group, 2005). Diabetes self-management, such as self-monitoring 
of blood glucose levels and diet selection, combined with education, and support, are correlated 
with increases in diabetes knowledge and self-care (Haas et al., 2012). 
 Once a patient is identified as being at risk for progression to T2D, education and 
support are important components, along with lifestyle changes, of a plan to reverse the process. 
However, patients often lack the ability to stick to a treatment plan. Gonzales pointed out that 
less than half of adult diabetics maintain an HbA1c level below recommended glycemic goal, 
mostly due to non-adherence to medication (Gonzalez, Shreck, Psaros, & Safren, 2014). 
Furthermore, less than 10% of individuals follow physician guidelines to stop smoking or lose 
weight (Haynes, 2001). Specifically, less than 17% of patients with T2D reportedly follow 
providers’ prescribed regimens for diet, exercise, medication taking, glucose testing, and 
appointment keeping (Funnell, 2006; Skovlund & Peyrot, 2005).  Data suggests that dependence 
solely on physicians’ directives is not sufficient to successfully manage T2D. Barriers to 
compliance include: patient’s perceived treatment efficacy, worsening of diabetes symptoms and 
side effects of medication, treatment complexity and convenience, cost of treatment, concerns 
related to negative effects of the medication being prescribed, and /or physician trust (Polonsky 
& Henry, 2016). In their 2001 study, Claxton et al. concluded that adherence to diabetes 
medication is inversely related to the number of daily doses. They found that the percent 
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adherence dropped from 79% with a single dose per day to 51% for medications requiring four 
doses per day (Claxton, Cremer, & Pierce, 2001).  In 2009, Mann et al investigated the 
correlation of disease and medication beliefs and drug regimen adherence. Their survey of poorly 
adherent subjects concluded that some barriers to adherences include beliefs that [1] medication 
is needed only at times of hyperglycemia (56%, p=0.006),  [2]  is not needed when their glucose 
is normal (53%, p=0.02), [3] when the side effects would likely be severe (42% of poorly 
adherent subjects, p=0.001), and [4] that the medications instructions made them too difficult to 
take (74% of poorly adherence subjects, p=0.001) (Mann, Ponieman, Leventhal, & Halm, 2009).   
Examples of some currently available medications include those to help control glucose 
levels by promoting insulin secretion (sulfonylureas and meglitinides), by reducing hepatic 
glucose production (biguanids), by reducing the reabsorption of glucose by kidney (SGLT2 
inhibitors), or by reducing the absorption of glucose in the intestines (a-Glucosidase Inhibitors). 
Medications may not be needed for all patients. Lifestyle modifications, such as a low-calorie, 
low-fat recommended diets, and moderate intensity exercise for at least 150 minutes per week, 
have the potential to improve glucose control in patients with T2D (American Diabetes 
Association, 2018).  Nondiabetic patients who adhere to these recommendations saw greater than 
50% reduction in the occurrence of T2D, compared to only 31% of those only taking metformin, 
an oral drug used to help control plasma glucose levels by reducing hepatic glucose production, 
for 2.8 years (National Institute of Health, 2002).  In addition to diet, a structured and monitored 
moderate exercise program alone may lead to improvement of glucose metabolism (Liao et al., 
2015). Torjensen et al. investigated the effect of three interventions, diet alone, diet and exercise, 
and exercise alone on the reduction of insulin resistance. At the end of one year, they found that 
the all interventions group showed a decrease in fasting glucose; but the diet and exercise 
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intervention group showed the greatest (0.3 mmol/L reduction compared to the control group 
(0.0 mmol/l reduction) (p < 0.0010) (Torjesen et al., 1997). 
CHC interventions, especially the promotion of increased physical activity, may have an 
impact on the improvement of 1,5-AG levels in patients.  Honda et al. demonstrated that a post 
prandial exercise routine consisting of stair climbs (two sets) for three minutes, increased 
peripheral blood 1,5-AG concentrations (Honda et al., 2017). Measuring plasma 1,5-AG 
concentrations may serve as a marker for the success of CHC intervention to change lifestyle 
behaviors that lead to improved glycemic control.  
Lifestyle modifications used to improve glucose homeostasis may also reduce insulin 
resistance, as evidenced by lower insulin levels. In their inpatient study, Boden et al. concluded a 
low carbohydrate diet reduced insulin as well as glucose concentrations in the plasma of patients 
with T2D (Boden, 2008). Trap et al. demonstrated that high intensity intermittent exercise (HIIE) 
significantly reduced fasting plasma insulin concentrations in women compared to the control 
and steady state exercise groups (p < 0.05) ( Trapp, Chisholm, , Freund,  & Boutcher, 2008). 
Rice also demonstrated that a combination of reduced caloric intake and exercise has a greater 
effect on reducing insulin levels as opposed to diet alone (p< 0.05) (Rice, Janssen, Hudson, & 
Ross, 1999).  
Treatment of patients with diet, exercise, and medication has been shown to reduce 
proinsulin levels. Medication, such as pioglitazone, a thiazolidinedione class drug, increases 
insulin sensitivity by increasing glucose transporters 1 and 4, improving glucose uptake by cells, 
and reducing circulating glucose, thus lowering the demand of insulin secretion (Smith, 2001). 
Kubo found that treatment of patients with T2D with pioglitazone led to a significant decrease in 
proinsulin levels from a mean of 24.7 pmol/L to a mean of 14.0 pmol/L (p <0.01) (Kubo, 2002).  
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Torjesen et al. compared the effects of three interventions on insulin sensitivity. Subjects were 
randomly assigned to a control group, or one of three treatment groups: diet only, exercise only, 
or diet and exercise combined intervention. After one year, subjects in all three different 
treatment groups showed significantly lower proinsulin levels compared to subjects in the control 
group (Torjesen et al., 1997). In addition, the subjects in all three treatment groups showed 
significantly lower plasma C-peptide concentrations compared to those in the control group (p 
value of < 0.0011 for all three intervention groups) (Torjesen et al., 1997).  
Glucose 
 Glucose is a monosaccharide that is utilized by every cell in the body to drive the 
phosphorylation of ADP to ATP. Plasma glucose may originate from the digestion of complex 
carbohydrates in food, the breakdown of glycogen in the liver, and gluconeogenesis, the 
production of glucose from non-carbohydrate substances by the liver and kidney (Krebs, 1964). 
Additionally, in times of prolonged starvation, liver and kidney glucose production is equal in 
proportion (Owen et al., 1969).   
The body normally maintains circulating blood glucose levels between 70 - 99 mg/dL 
when in a fasting state.  In patients with diabetes or prediabetes, prolonged exposure to higher 
than normal levels of glucose in the peripheral blood have been linked to both microvascular and 
macrovascular complications. These can include nephropathy, neuropathy, retinopathy, 
cardiovascular disease and peripheral arterial disease. In their 2005 study of normal male 
patients, Tirsho et al. concluded higher fasting plasma glucose levels within the normal glycemic 
range are at an increased risk for T2D (Tirosh et al., 2005).  
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Hemoglobin A1c 
Hemoglobin, the principal cytoplasmic protein of red blood cells (RBC), is a tetramer 
consisting of four globin chains, each one having a heme group bound to the polypeptide 
structure. Normal adult hemoglobin A (HgbA) consists of two alpha chains and two beta chains. 
Within each heme group, one ferrous iron binds to four nitrogen atoms within the heme 
structure. The ferrous iron binds reversibly with oxygen.  In a non-enzymatic reaction, glucose 
can form a Schiff base with the N-terminal valine of the beta chains at a rate directly 
proportional to the concentration of glucose in the blood (Brownlee, 1995). The product of this 
glycation reaction can undergo an Amadori rearrangement to form a stable covalent 1-amino-1-
deoxy-2-ketose derivative of hemoglobin A, also known as HbA1c.  
Once hemoglobin is glycated, it remains glycated for the life of the erythrocyte in which 
it is contained. Since the rate of HbA1c production is directly proportional to the peripheral 
blood glucose concentration, the higher the average concentration of glucose in the blood, the 
higher the percent of HgbA that is glycated at any point in time.  The average lifespan of normal 
RBCs is 120 days. Therefore, the percent of HbA1c in a blood specimen reflects the integrated 
average of blood glucose concentrations over the previous 3 months. As with FPG, the risk of 
diabetes related microvascular and macrovascular complications in patients with T2D is 
positively associated with %HbA1c levels >6.0% (Stratton et al., 2000).  Furthermore, the risk of 
myocardial damage increases as patients move from normal to a prediabetic state, to a diagnosis 
of diabetes (Selvin et al. 2014). Other hemoglobins, such as hemoglobin A2, hemoglobin S, and 
hemoglobin E can also be glycated; but since their half-life is not the same as HbA1c, the 
reference range for % HbA1c cannot currently be used to assess glycemic control in patients 
with these variant hemoglobins. The %HbA1c at any point in time has been shown to be a better 
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indicator of average blood glucose concentrations over time than periodically measured blood 
glucose concentrations; therefore, a better indicator of the risk for the long-term complications of 
persistently elevated plasma glucose concentrations (International expert committee report on the 
role of the A1C assay in the diagnosis of diabetes, 2009). Treatments aimed at lowering glucose 
in turn affect %HbA1c over time. As average blood glucose concentrations decrease, the 
%HbA1c decreases proportionately.   
There are limitations if only %HbA1c is used to monitor patients for the risks of 
complications of diabetes and/or response to diabetes therapy. Variations in RBC lifespan can 
influence the cumulative glycation of HgbA, and can alter the %HbA1c (R.M. Cohen et al., 
2008).  This could give %HbA1c values that do not quantitatively reflect average blood glucose 
concentration. The %HbA1c could be falsely elevated in patients with iron deficiency anemia 
and asplenia due to the longer lifespan of these RBCs (Christy, Manjrekar, Babu, Hegde, & 
Rukmini, 2014);(Radin, 2014). Falsely decreased levels may be seen with conditions resulting 
from increased RBC turnover such as acute or chronic blood loss, splenomegaly, and red cell 
transfusion (Radin, 2014).  
1,5-anhydroglucitol 
Another method of monitoring elevated or postprandial blood glucose concentration is to 
measure 1,5-anhydroglucitol (1,5-AG) concentrations in blood. 1,5-AG (Figure 2) is a dietary 
monosaccharide that closely resembles the molecular structure of glucose  
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Figure 2: Glucose and 1,5- anhydroglucitol molecules 
 
Concentrations of 1,5-AG in blood can provide an indication of hyperglycemia and 
postprandial glycemia. Normally, 1,5-AG is removed from the blood by glomerular filtration, 
and reabsorbed by the renal tubules in the kidney. Most 1,5-AG is returned to the blood via renal 
tubular reabsorption, with very little excreted in the urine, thus maintaining a constant level in 
the blood. In patients with normal glucose homeostasis, the concentration of 1,5-AG in blood 
remains stable over a 24-hour period, with minimal variation due to short-term dietary changes 
(Yamanouchi et al., 1987). In states of hyperglycemia, glucose competes with 1,5-AG for renal 
tubular reabsorption. Due to the similarity in structure, once plasma glucose concentrations 
exceed the renal threshold for reabsorption of approximately 180 mg/dL, 1,5-AG is also excreted 
in the urine with a concomitant decrease in plasma 1,5-AG concentrations.  
Plasma 1,5-AG concentration is inversely correlated with both FPG concentration and 
short-term average blood glucose concentrations. In their 1996 study of 56 subjects with newly 
diagnosed non-insulin dependent diabetes mellitus (NIDDM), Yamanouchi et al. reported slight 
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changes in glycaemia can be detected within two weeks using serum 1,5-AG as a marker, sooner 
than with %HbA1c or serum fructosamine concentration. Subject’s 1,5-AG levels dropped from 
7.4 µg/mL to 4.8 µg/mL (p=0.673), while A1c values showed no significant change (P= 0.001) 
(Yamanouchi et al., 1996). Dungan et al (2006). were able to demonstrate, using a continuous 
glucose monitoring system, that plasma 1,5-AG concentrations can be used as indicators of 
glucose change after a meal in patients in either a prediabetic state or with overt diabetes 
(Dungan et al., 2006). Akanuma et al. reported plasma 1,5-AG concentrations in newly 
diagnosed diabetic patients to be 1.9 ± 1.8 µg/mL, compared to 13.4 ± 28.3 µg/mL in healthy 
subjects (Akanuma, Morita, Fukuzawa, Yamanouchi, & Akanuma, 1988). In addition, 
decreasing plasma 1,5-AG concentrations have been correlated with the risk of developing T2D. 
In their 2012 study, Juraschek et al, evaluated serum 1,5-AG and the incidence of diabetes over a 
three-year period. They concluded that higher baseline quartiles of 1,5-AG were associated with 
a lower incidence of diabetes (Juraschek, Steffes, Miller, & Selvin, 2012).    
Insulin 
 Insulin, a 6 kilodalton (kDa) peptide hormone consisting of 51 amino acids, is the 
primary regulator of glucose uptake by peripheral cells. It is composed of one α-chain and one β-
chain connected by two disulfide bonds.  Insulin is secreted by the beta cells, located in the Islets 
of Langerhans of the pancreas, in response to elevated plasma glucose concentrations. The 
binding of insulin to insulin receptors on the surface of insulin-dependent cells stimulates the 
translocation of the glucose transporter GLUT4 from intracellular storage vesicles to the cell 
membrane, facilitating the uptake of glucose. Increases in plasma insulin concentration, in 
concert with decreases in plasma glucagon concentrations, also inhibit hepatic gluconeogenesis. 
(Saltiel & Kahn, 2001).  
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Normal fasting serum insulin concentrations range from 3-9 µU/mL or 20.8 – 62.5 
pmol/L. In cases of frequent hyperglycemia, prolonged exposure of the body’s cells to insulin 
can lead to a desensitization of the cellular receptors to insulin, leading to a state of “insulin 
resistance.” The decreased ability of cells to take up glucose from peripheral blood exacerbates 
the hyperglycemia. Beta cells initially compensate by producing additional insulin, with 
hyperinsulinemia an indication of insulin resistance. Over time, insulin levels continue to rise in 
response to extended elevated plasma glucose concentrations. The increased demand for insulin 
results in beta cell stress, with prolonged beta cell stress eventually lead to beta cell death. As 
beta cell death occurs, the pancreas loses the ability to produce insulin, indicated by 
hyperglycemia with hypoinsulinemia. 
C-Peptide 
C-peptide is the 31- amino acid peptide released from proinsulin by prohormone 
convertases 1 and 2 during the formation of insulin in the storage vesicles of the pancreatic beta 
cells. Insulin and C-peptide are secreted into the portal vein in equimolar concentrations, but the 
concentration of C-peptide in peripheral blood is greater than that of insulin. This is due to C-
peptide not undergoing first-pass metabolism in the liver as insulin does. As a result, the half-life 
of C-peptide is around 30 minutes, six times that of insulin (Polonsky et al., 1986). The majority 
of C-peptide is metabolized and excreted by the kidney (Zavaroni et al., 1987). 
C-peptide may have a physiological effect on cell recognition of glucose and may 
facilitate some transmembrane movement of glucose into cells. Renal tubule cells possess 
numerous C-peptide binding sites. C-Peptide is involved in numerous cell signaling pathways, as 
well as protecting kidney cells from tumor necrosis alpha, a contributing factor in diabetic 
nephropathy (Hills & Brunskill, 2009). In addition, C-peptide has several downstream effects 
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upon binding to cell surface components, including raising intracellular calcium levels, 
increasing PI-3-kinase activity, and stimulation of the Na+/K+ ATPase, the protein complex 
responsible for using energy generated from the hydrolysis of ATP to facilitate the counter 
transport of NA
+
 and K
+ 
across plasma membranes (Hills & Brunskill, 2008). In their 2012 
study, Patel et al. correlated fasting serum C-peptide levels with cardiovascular risk. They 
concluded that nondiabetic patients in the highest quartile (72%) had a significantly higher 
incidence of cardiovascular death, compared to those in the lowest quartile (60 %) (Patel, 
Taveira, Choudhary, Whitlatch, & Wu, 2012). In addition, Heding and Rasmussen concluded in 
their study that mean C-peptide levels of 0.37 nmol/L or 1.11 ng/dL were indicative of normal 
subjects, and mean C-peptide of 0.86 nmol/L or 2.6 ng/mL were correlated with maturity onset 
of diabetes (Heding & Rasmussen, 1975).   
Plasma C-peptide concentrations may be used to evaluate beta cell function. In their 
systematic review, Jones concluded that C-peptide is useful in evaluating insulin secretion and 
diabetes management (Jones & Hattersley, 2013).  C-peptide allows for the evaluation of beta 
cell function in patients taking exogenous insulin. Serum insulin concentrations include both 
endogenous and exogenous insulin, whereas C-peptide concentrations reflect only the 
endogenous activity of the beta cells (Clark, 1999). Plasma C-peptide concentrations also aid in 
the differentiation between T1D and T2D, with higher values associated with insulin secretion 
and the progression to T2D (Service, Rizza, Zimmerman, & Dyck, 1997).   
Proinsulin 
Proinsulin is formed from the polypeptide preproinsulin. Within the endoplasmic 
reticulum of the beta cells, the 23 amino acid-residue signal peptide of preproinsulin is removed 
to form proinsulin. The primary structure of proinsulin consists of the sequence of amino acids 
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that eventually become the alpha and beta chains of insulin, along with the C-peptide fragment. 
Most of the proinsulin is converted to insulin and C-peptide in the storage vesicles of the beta 
cells, and only a small amount of proinsulin is released in to the peripheral blood. However, 
plasma concentrations of proinsulin are usually higher than insulin. Proinsulin has a much longer 
half-life, around 17 minutes, compared to insulin, with a half-life of around 5 minutes (Starr & 
Rubenstein, 1974). In addition, proinsulin has a much lower hepatic extraction than insulin 
(Horwitz, Starr, Mako, Blackard, & Rubenstein, 1975).  
In states of insulin resistance, there is an increased demand for insulin. Proinsulin levels 
may rise in the peripheral blood due to impaired formation of C-peptide and insulin. This is due 
to the increased compensatory synthesis of preproinsulin and the decreased availability of beta 
cell carboxypeptidase H, the enzyme needed to cleave the amino acids from the C-terminal of 
proinsulin to form insulin and C-peptide (Pfützner, Pfützner, Larbig, & Forst, 2004). Research 
has shown that fasting plasma proinsulin concentrations can predict the conversion from 
impaired glucose tolerance (IGT) to T2D along with the severity of hyperglycemia. (Nijpels, 
Popp-Snijders, Kostense, Bouter, & Heine, 1996). Elevated plasma proinsulin concentrations can 
be found in states of glucose intolerance, even in the absence of elevated plasma C-peptide or 
insulin concentrations (Krentz, Clark, Cox, & Nattrass, 1993).  Vangipurapu et al. reported a 
correlation between increased plasma proinsulin concentrations and the worsening of 
hyperglycemia and conversion to T2D (Vangipurapu et al., 2015). Saad et al. reported that the 
degree of proinsulin elevation was directly related to the severity of hyperglycemia (Saad et al., 
1990). This was subsequently confirmed by Røder et al (Røder, Porte, Schwartz, & Kahn, 1998). 
Furthermore, elevated proinsulin levels have been shown to be a risk factor for premature 
coronary artery disease (CAD) (Katz, Ratner, Cohen, Eisenhower, & Verme, 1996).  In addition, 
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Pfutzner et al. concluded that fasting proinsulin levels above 10 pmol/L were associated with 
insulin resistance (Pfützner et al., 2004).  
The previous sections described the various markers of the progression to diabetes. 
Although there is evidence that patients can achieve improvements in biomarkers of glucose 
homeostasis through lifestyle modification, these changes are not easily accomplished.  The next 
section describes the various treatments for diabetes and prediabetes, the CHC profession, and 
the potential impact of CHCs on biomarker results.  
Health Coaches 
Health or wellness coaches have become popular as part of the movement towards 
preventative health. Three types of health coaches exist: peer, mentor, and professional (Leahey 
& Wing, 2013). Peer coaches are individuals with the same condition as the patient, while 
mentors have overcome the affliction of interest. Both peers and mentors can help others achieve 
similar success by sharing experiences of what worked for them at different times of their 
disease/condition. The third type is a professional health or wellness coach. Professional health 
coaches, described as clinical health consultants (CHC) in this study, receive formal training by 
means of procedure review, training checklist completion, and attendance of required training 
seminars. CHCs are also often certified in facilitating support by organizations such as the 
National Society of Health Coaches, the American Council on Exercise, or the Wellness School 
of Coaching. The role of a CHC is not to treat the patient, but rather to supplement the work of 
physicians with information and support (Leahey & Wing, 2013). The CHC is an educator whose 
overall goal is eliciting change in a patient’s behavior and physical health.  
 A search of the available literature demonstrates that patient-health/wellness coach 
interactions reduce weight and %HbA1c concentration in diabetic patients, and have a major 
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impact on improving health behaviors (Liddy, Johnston, Nash, Ward, & Irving, 2014). Various 
programs involving repetitive education and support outlets influence positive health outcomes 
(Haas et al., 2012; Liddy et al., 2014), (Leahey & Wing, 2013), (Wayne & Ritvo, 2014). 
Professional education, especially when delivered frequently and over a long period, may yield 
more of the desired patient outcomes for those with T2D (Loveman, Frampton, & Clegg, 2008). 
In a 2007 study, Ko monitored the %HbA1c of subjects who participated in 30 hours of diabetes 
education for five days, followed by a three-hour reinforcement educational session during 
annual follow-up sessions over a course of four years. They found that the study group had lower 
mean %HbA1c values (7.9%), compared to their control group, those who only received an 
initial education of four hours with no annual reinforcement during follow-up visits, ( 8.7%), (P< 
0.05) (Ko et al., 2007). 
A common belief among all coaching approaches is that the patient has the ability to 
adopt healthy behaviors if given the proper guidance. The CHC interactions are geared toward 
changing the behavior of the patient to foster changes in their health.  Achievement of this goal 
for T2D, or patients in a prediabetes state, is dependent on the patient changing their lifestyle to 
include getting regular exercise, eating healthier foods, smoking cessation, or changing other 
negative behaviors that are unique to a specific patient.  
Grounded in coaching psychology, CHCs foster and promote the behavior change 
processes that help produce desired health outcomes (Pettitt, 2013; Wayne & Ritvo, 2014).  One 
key element in reaching the desired change is the patient’s self-efficacy, or belief in their 
capability to reach their goal.  Promoting self-efficacy in patients is a major strategy in health 
coaching to help patients develop the confidence needed to initiate change (Bandura, 1977). In 
addition, it is important that health coaches develop positive experiences with their patients, as 
  
34 
 
negative attitudes can have a major effect on a patient’s self-efficacy (Gonzalez et al., 2014). A 
therapy designed to enhance self-efficacy increases patient involvement and activities that can 
improve both their overall well-being and health outcomes (Wu et al., 2011). 
Clinical health coaches often utilize the framework of the Transtheoretical Model (TTM), 
a model that identifies stages of behavior change. Use of the TTM can help determine the 
patient’s current position on change, as well as their readiness to make the behavior change. 
Transtheoretical Model based interventions focused on physical activity, nutrition and behavior 
change have shown reductions in weight, percent calories from fat and overall calorie intake, and 
increases in exercise (Johnson et al., 2008; Riebe et al., 2003). The TTM consists of five stages 
of change: precontemplation, contemplation, preparation, action, and maintenance. In the 
precontemplation stage, persons are not intending to change in the near future. These individuals 
may not be aware of their poor diet choice or the harmful effects of smoking and lack of 
exercise. In the contemplation stage, persons are more aware of the pros and cons of change, and 
have intentions of changing within 6 months. Persons in the preparation phase are ready to 
change, usually within the next month. They have a plan of action and made accommodations to 
move to the next phase. They may have researched exercise routines and/or gym options, or 
researched healthy eating options. The action phase marks the first significant effort to change 
their behavior.  In the action phase, lifestyle modifications, such as quitting smoking, refraining 
from buying high sugar/high fat foods, and beginning an exercise regimen, are started. Those in 
the maintenance phase are trying to prevent a relapse back to the undesired behavior. These 
individuals continue to eat healthy, exercise regularly, and avoid poor health choices. Movement 
from phase-to-phase is different for each individual; however, those participating in a TTM are 
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more likely to move to action and maintenance stages for self-monitoring of blood glucose and 
healthy eating (H. Jones et al., 2003).  
Adopting the TTM, CHCs often use motivational interviewing (MI) in coaching sessions. 
Motivational interviewing is a coaching approach centered on the patient’s readiness to change, 
and is defined as “client centered, directive method for enhancing intrinsic motivation to change 
by exploring and resolving ambivalence” (Miller, 2002).  Motivational interviewing assists the 
CHC to determine how the CHC interaction session should be carried out (Marley, Carbonneau, 
Lockner, Kibbe, & Trowbridge, 2011). Motivational interviewing has the potential to improve 
patient self-efficacy, patient activation (the patient’s empowerment to work with their provider to 
manage their health), and perceived health status (Linden, Butterworth, & Prochaska, 2010). In 
addition to MI, CHCs are trained to provide empathy during their interaction with the patient. 
Empathy is cognitive understanding of what the patient is feeling or going through and being 
able to project this in a way that can foster assistance for the other individual (Hojat, Louis, 
Maio, & Gonnella, 2016; Hojat, 2007). Empathy can create a bond and strengthen trust between 
the patient and CHC (Hojat, Louis, Maio, & Gonnella, 2013). The use of MI during CHC 
interactions can further foster empathy from the CHCs. When used during health coaching 
sessions, a combination of MI and patient education session has shown to reduce BMI and waist 
circumference, and increase physical activity compared to those receiving education alone (p< 
0.001) (Barrett, Begg, O’Halloran, & Kingsley, 2018). Furthermore, in their 2007 study, Brug et 
al. demonstrated that the use of MI to elicit empathy in patient centered coaching sessions results 
in lower saturated fat intake compared to patients seen by non-MI based dietitians (Brug et al., 
2007).  
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 Health coaches have been used to improve the general health of patients as well as in the 
treatment of patients with chronic conditions such as hypertension and diabetes. In a recent 
study, Leahey and Wing investigated the impact of three different types of health coaches on 
subjects in a weight loss program over six months.  Subjects were all enrolled in a reduced 
intensity behavioral weight loss treatment, with caloric intakes limited to 1200-1500 kcal daily. 
They were expected to increase activity to 40 minutes each day for 5 days per week. This 
program consisted of weekly meetings for the first six weeks, biweekly meetings (once every 
two weeks) for the next six weeks, and then monthly meetings for the last three months of the 
six-month program. Eligible participants were randomized into one of the three types of health 
coaches: professional (n=14), peer (n=16), or mentor (n= 12). The study results demonstrated 
that participants across all of the groups showed reduction in body weight; however, those who 
received the professional health coach intervention had the greatest percentage of weight loss 
(Leahey & Wing, 2013).   
 Apple et al. investigated the effects of different types of health coach interactions on 
weight loss and the ability of participants to meet the goal of either 5% and/or 10% weight 
reduction.  Four hundred and fifteen obese patients were randomly assigned to one of three 
groups: 1) a control group with self-directed weight loss management, 2) a remote intervention 
group receiving weight loss support over the telephone, a study website, and email, and 3) an in-
person intervention group receiving both group and individual weight loss management support. 
After 24 months, both intervention groups showed significant weight loss vs. the control group 
(p<0.001). There was no significant difference in weight loss or participant ability to meet 
weight loss goals between the remote or in-person intervention groups (Appel et al., 2011). The 
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study also provided evidence that CHC interactions can be impactful using technology, and that 
face-to-face communication may not be necessary to influence patient behavior change.     
 Battista et al. investigated the effects of a 12-month dietitian-coached program on T1D 
and T2D patients. In their study, participants were assigned to either a control group with only 
endocrinologist guidance (n=50), or a treatment group receiving quarterly on-site diabetes self-
management education with annual endocrinologist follow-up (n=51). They reported that 
repetitive dietitian guidance significantly reduced %HbA1c levels (0.6% reduction, p=0.04) vs 
the control group (Battista et al., 2012).  
Mobile technologies could help facilitate coaching by introducing a new method of 
communication to aid in client/health coach interactions. The use of smartphones would allow 
faster responses to client questions and encourage a consistent stream of communication between 
the health coach and the client. In 2014, Wayne and Ritvo demonstrated that health coach 
interaction conducted via smartphone technology could aid in the management of clients with 
T2D. The goal of their study was to test a newly developed smartphone-assisted intervention to 
improve behavioral management of T2D in an ethnically diverse, lower socioeconomic 
population within an urban community health setting. A new smartphone application, the 
Connected Health and Wellness Platform (CHWP) Health Coach App, was tested in a 24-week 
intervention with reduction of %HbA1c levels as the primary outcome of interest. For the 19 
individuals entered into their study, the overall mean reduction in HbA1c level was 0.28%. In 12 
subjects who started the program with %HgbA1c values > 7%, the mean reduction was 0.43% (p 
< 0.05) (Wayne & Ritvo, 2014).  
Research into CHC interaction and improvement of health outcomes shows patient 
benefit with CHC utilization. However, there is no published research on the effect of CHC 
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interactions on early markers of insulin resistance and beta cell dysfunction, or research 
concerning the number of interactions required to achieve these benefits. In a systematic review 
of literature on health/wellness coaching and effects on various aspects of health, Wolever found 
that of the 284 health/wellness coach studies identified, 148 did not specify the total number of 
coaching sessions used (Wolever et al., 2013). Of the remaining 136, the authors did not 
investigate the effects of varying numbers of sessions. In addition, only 185 of the 284 total 
studies were empirical with systematic data collection.  In the relevant articles reviewed, study 
participants in the intervention group underwent structured initial coaching sessions, with several 
studies investigating the effects of long-term coaching over several years. Variations in the 
timeframe of coaching interventions were noticed in several studies in their review; however, 
research specifically the effects of the number of coaching sessions on change in health 
outcomes was not reported.   
In their 2008 study, Bray et al. investigated the effects of a diabetes life coach on recently 
diagnosed T1D and T2D patient health. Study participants were assigned a life coach for 
guidance on exercise and diet lifestyle modification. Participants were deemed engaged, 
participating in face-to-face and telephone interventions, or non-engaged. Life coach-patient 
interactions were at least biannually, with the opportunity for unlimited access if necessary. They 
found that individuals who were engaged were 50% more likely to meet ADA guidelines of 
%HbA1c levels < 7.0%, with interventions improving adherence to diet and exercise routines, 
and medication regimens ( p <0.001). The number of visits was not recorded, but could have 
been a potential co-variate in their analysis (Bray, Turpin, Jungkind, & Heuser, 2008). 
 In their systematic review of the effect of telephone interventions on exercise and dietary 
behavior change, Eakin et al. noted that factors associated with a positive outcome included 
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programs that lasted between 6-12 months and those with 12 or more interactions during their 
study (Eakin et al., 2007).  Research describing the effects of differences in the number of CHC 
interactions and changes in biomarkers of glucose homeostasis could provide evidence that 
scheduling additional CHC interactions could improve the health outcomes of patients with or at 
risk of developing diabetes. Therefore, additional research on the effectiveness of CHCs has the 
potential to influence patients to pursue treatment routes that include CHC engagement. 
Furthermore, the lack of research on the effects of CHC interactions on other markers of glucose 
homeostasis such as 1,5-AG and markers of beta cell health such as proinsulin, insulin, and C-
peptide represents a gap in the knowledge of CHC capabilities. This study investigated if there is 
a relationship between CHC interactions and changes in biomarkers of glucose homeostasis. 
Finally, the study explored if the number of CHC interactions is related to those changes.  
Chapter Summary 
 Chapter 2 reviewed disorders of glucose homeostasis, biomarkers of this process and of 
diabetes and prediabetes, and reviewed the CHC profession. Chapter 2 summarized the impact of 
CHC interactions on changes in personal behavior and lifestyle modifications. The review of 
available literature demonstrates the ability of CHC interaction to improve patient health and its 
importance to health care. Literature on CHC interactions and changes in diabetes-related 
markers is not limited. However, research on the effect of the number of CHC interactions on the 
levels of specific biomarkers is lacking. Furthermore, knowledge of CHC interactions and their 
effect on additional markers of glucose homeostasis and beta cell health is absent.  
 
 
 
  
40 
 
 
 
 
Chapter 3: Methodology 
 
 
Overview 
Chapter 3 discusses details of the research design, subject database creation, subject 
selection, the research setting, and study variables. The databases used to gather patient results 
and CHC interaction are described, including data extraction, assessment of validity, and 
database management. Statistical analyses used to evaluate each Specific Aim are discussed.  
Problem Statement 
Many patients find it difficult to change their lifestyle based on health care provider 
recommendations, despite the understanding that it is needed to improve their overall health. 
Less than 20 % of adult diabetics comply with provider prescribed medications and lifestyle 
modifications (Funnell, 2006; Gonzalez et al., 2014; Willard-Grace et al., 2013). This suggests 
that doctor-patient interaction is not sufficient in implementing lifestyle changes. Some studies 
demonstrate that CHC interactions may help facilitate and improve adherence to these lifestyle 
changes, improving BMI and % HbA1c, a marker of glucose homeostasis (Haas et al., 2012; 
Leahey & Wing, 2013; Liddy et al., 2014; Wayne & Ritvo, 2014) . However, there are no 
published studies relating the number of CHC interactions to the magnitude of change in specific 
markers. There is also no published research on how CHC interactions affect changes in other 
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markers of glucose hemostasis such as 1,5-AG, or markers of beta cell function such as  
proinsulin, insulin, and C-peptide. 
 Research Question, Specific Aims, and Hypotheses 
The research question for this study is: is there a relationship between the changes in 
patients’ biomarkers of glucose homeostasis and beta cell function and utilization of CHCs? 
Specific Aim 1: Determine if there are statistically significant differences between 
patients who do or do not participate in CHC interactions in their changes in 1) blood 
glucose concentration, 2) %HbA1c, 3) blood 1,5-anhydroglucitol concentration (1,5-AG), 
4) blood insulin concentration, 5) blood C-peptide concentration, 6) blood proinsulin 
concentration, and 7) body mass index (BMI). 
To accomplish this aim, the following hypothesis was tested: 
There is no significant difference in the changes in blood glucose, %HbA1c, 1,5-AG, 
insulin, C-peptide, proinsulin or BMI between patients who interacted with CHCs and 
those who did not.  
This was tested by comparing the difference between initial and follow-up biomarker results, 10-
14 months from initial testing, for two groups, 1) those who participated in CHC interactions, 
and 2) those who did not. Changes in biomarker values were calculated for each marker in both 
the CHC and non-CHC groups and compared statistically. 
Specific Aim 2: Determine if statistically significant differences exist in the change in 
glucose, HabA1c, and  BMI health scores between subjects who did and those who did 
not interact with CHCs. 
To accomplish this aim, the following hypotheses will be tested: 
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There is no significant difference in the change in health scores for glucose, %HabA1c, 
and BMI for patients who had CHC interactions and those who did not.  
Aim 2 was accomplished by first assigning a “health score” to the initial and follow-up 
biomarker results. Health score were based upon ADA recommended cutoffs for normal, 
prediabetic, and diabetic values for glucose and HbA1c, and BMI guidelines for normal, 
overweight, and obese individuals. Normal values for glucose and %HbA1c and a normal BMI 
were given a score of 0. Individuals in a pre-diabetic state based on glucose and %HbA1c results, 
and those with BMIs in the overweight category were assigned a score of 1. Those in the diabetic 
and obese classifications were assigned a value of 2. Changes in health score were evaluated by 
subtracting the follow-up score from the initial score and compared between the treatment and 
control group.  
Specific Aim 3 Determine the relationship between the number of CHC interactions and the 
magnitude of the change in 1) blood glucose concentrations, 2) % HbA1c, 3) blood 1,5-
anhydroglucitol (1,5-AG) concentrations, 4)blood  insulin concentrations, 5) blood C-peptide 
concentrations, 6) blood proinsulin concentrations and 7) body mass index (BMI). 
 To accomplish this aim, the following hypotheses will be tested: 
There is no relationship between the number of CHC interactions and the change in blood 
glucose concentration, %HbA1c, 1,5-AG, insulin, C-peptide, proinsulin, or BMI.  
Specific Aim 3 will be accomplished by linear regression of the magnitude of change in patient’s 
marker results versus the number of CHC interactions. Additionally, a one-way t-test was used to 
compare the mean change of those subjects who utilized CHC interactions. 
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Research Design 
 The current study utilized a retrospective non-experimental study design to investigate 
the relationship between changes in patients’ biomarker results and CHC interactions (Polit, 
2008). The retrospective design allows for the collection of data across varying ages, sex, and 
patient BMI over a span of four years, which would not be practical if a true experimental design 
were utilized.  Repeated measures were used to identify the changes in marker results from the 
subjects’ initial blood draw to their follow-up blood draw 12+2 months after their initial draw.  
Sampling Strategy 
 Preliminary research identified over 200,000 patients that had initial test results and at 
least one set of results 10 to14 months later. The study sample included all of the patients who 
did not meet the exclusion criteria: 
 Patients under the age of 18 years old. 
 Patients over the age of 89 years old 
 Patients missing age, sex, and BMI demographics 
Population and Sample 
 The target population was all persons seen by a health care provider that had laboratory 
testing performed at the Richmond, VA based laboratories, Health Diagnostics Laboratory and 
True Health. This population included patients from across the continental United States. The 
sample for the study consisted of patients with follow-up testing 12+2 months after initial testing 
between April 2, 2012 and July 15, 2016.  A data use agreement between Virginia 
Commonwealth University (VCU) and True Health was signed, allowing research collaboration. 
In addition, an approved VCU IRB (IRB HM20013795) qualified for exemption according to 45 
CFR 46.101(b), Category 4 prior to data collection. In 2012, the laboratory began offering 
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providers a menu of tests specific to diabetes, glucose homeostasis, and pancreatic health. This 
offered providers a tool to screen patients for their risk of developing diabetes and to help 
monitor patients already diagnosed with diabetes or insulin resistance.  
Handling of Protected Health Information 
 For this study, only deidentified patient information was provided to the principle 
investigator (PI). The information technology (IT) team removed patient identifiers such as 
name, date of service, medical record number, and sample ID, and assigned a study number to 
each subject, prior to allowing the PI access to the data. Only the subjects’ biomarker test results, 
age, gender, and BMI were included in the final Excel worksheet used for the data analysis. A 
data use agreement between True Health and VCU along with VCU IRB approval (IRB 
HM20013795) ensure patients are protected and permission granted to use deidentified patient 
data.  
Variables 
Disease marker results were from previously tested subject samples. The same dependent 
variables were utilized for both Specific Aim 1 and 3: changes in the results for glucose, 
%HbA1c, 1,5-AG, proinsulin, insulin, and C-peptide, and BMI over a 10-14-month period. The 
units of measurement for all dependent variables are given in Table 3. 
Table 3: Units of Measure 
Test Units of Measurement of Change 
Glucose mg/dL 
Hemoglobin A1c % 
1,5-Anhydroglucitol µg/mL 
Insulin μU/mL 
C-Peptide ng/mL 
Proinsulin pmol/L 
BMI Weight (Kg)/(height (m))
2
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Specific Aim 1 has one independent variable, CHC interactions or no CHC interactions. 
The independent variable for Specific Aim 3 was the number of CHC interactions over the 10-14 
month interval for those subject in the study.  Specific Aim 2 had the same subjects as Specific 
Aim 1 for glucose, HbA1c, and BMI. The IV was also the same, but the DVs were the changes 
in health score for glucose, HbA1c, and BMI. Specific Aim 2 health scores are described in 
Table 4.  
Table 4: Health Score Variable Table 
 
Test 
Initial Testing 
Health score 
Follow-up Testing 
Health score 
Mean Change in 
Health score 
Glucose Health score 
(Category) 
Health score 
(Category) 
Absolute 
health score change 
Hemoglobin A1c Health score 
(Category) 
Health score 
(Category) 
Absolute 
health score change 
BMI Health score 
(Category) 
Health score 
(Category) 
Absolute 
health score change 
 
Patient demographics of age, sex, initial BMI, and initial marker values were used as 
covariates (CV) in the statistical analysis for all three Aims. The CHCs used in this study were 
registered dietitians, exercise specialist, or registered nurses. These CHCs may have prior 
certifications in health or wellness coaching; however, no certifications in were required for 
employment. All CHCs did complete an initial training, including the completion several online 
based training specific to behavior change, as well as annual competency assessments. The study 
variables described above are listed in Table 5. 
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Table 5: Study Independent and Dependent Variables 
Variable Level of 
Measurement 
Definition of Variable By Aim, IV, DV, 
or CV 
CHC (Y/N) Dichotomous Exposure to CHC. 
Transferred to 0 and 1 for 
statistical analysis. 1 
defines CHC visits, 0 
defines no CHC visits 
Aim 1-IV 
Aim 2-IV 
 
Number of CHC 
interactions 
Interval If utilized CHC, the 
number of interactions 
during study timeframe 
Aim 3-IV 
Change in glucose  Ratio Difference between initial 
and follow-up glucose 
Aim 1-DV 
Aim 3-DV 
Change in % 
hemoglobin A1c 
Ratio Difference between initial 
and follow-up %HgbA1c 
Aim 1-DV 
Aim 3-DV 
Change in 1,5-
Anhydroglucitol  
Ratio Difference between initial 
and follow-up 1,5- 
anhydroglucitol 
Aim 1-DV 
Aim 3-DV 
Change in insulin  Ratio Difference between initial 
and follow-up 
Aim 1-DV 
Aim 3-DV 
Change in C-
peptide 
Ratio Difference between initial 
and follow-up proinsulin 
Aim 1-DV 
Aim 3-DV 
Change in 
proinsulin  
Ratio Difference between initial 
and follow-up C-peptide 
Aim 1-DV 
Aim 3-DV 
Change in BMI Ratio Difference between initial 
and follow-up BMI 
Aim 1-DV 
Aim 3-DV 
Change in glucose  
health score  
Ratio Difference between initial 
and follow-up Glucose 
health score 
Aim 2-DV 
 
Change in HbA1c  
health score 
Ratio Difference between initial 
and follow-up HbA1c 
health score 
Aim 2-DV 
 
Change in in BMI 
health score 
Ratio Difference between initial 
and follow-up BMI health 
score 
Aim 2-DV 
 
CV= covariate, DV = dependent variable, IV = independent variable 
 .  
As previously mentioned, the patient demographics of age, sex, and initial BMI were 
collected and used as covariables in the statistical analysis of the data.  Increases of age as well 
as BMI have been highly correlated with incidences of diabetes. (American Diabetes 
Association, 2013); (Centers for Disease Control and Prevention, 2017). Using these as 
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covariates helped identify the effects of age, sex, and BMI on potential change in biomarker 
values. For evaluating change in BMI, only the subject’s age and sex were included as covariates 
since changes in BMI is the dependent variable. To evaluate the possible propensity for a subject 
to participate in CHC interactions, the relationship between initial biomarker value and changes 
in biomarker values was investigated using ANCOVA. The study CVs are listed in Table 6. 
Table 6: Study Covariates 
Variable Level of 
Measurement 
Definition of Variable By Aim, IV, DV, 
or CV 
Subject ID Nominal Assigned study number  
Sex Dichotomous Transformed to 0 and 1 
for statistical analysis. 1 
defines male, 0 defines 
female 
Aim 1-CV 
Aim 2-CV 
Aim 3-CV 
Age at initial testing Interval Time in years Aim 1-CV 
Aim 2-CV 
Aim 3-CV 
Initial BMI  Ratio BMI at initial blood Draw 
is used as part of the DV, 
change in BMI. BMI 
could be a CV for all 
biomarkers.  
Aim 1-CV/DV 
Aim 2-CV/DV 
Aim 3-CV/DV 
Initial glucose Ratio Used as a CV  Aim 1-CV 
Aim 2-CV 
Aim 3-CV 
Initial HbA1c Ratio Used as a CV  Aim 1-CV 
Aim 2-CV 
Aim 3-CV 
Initial 1,5-AG Ratio Used as a CV  Aim 1-CV 
Aim 3-CV 
Initial insulin Ratio Used as a CV  Aim 1-CV 
Aim 3-CV 
Initial C-peptide Ratio Used as a CV  Aim 1-CV 
Aim 3-CV 
Initial proinsulin Ratio Used as a CV  Aim 1-CV 
Aim 3-CV 
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Marker Testing Methods 
Glucose. Glucose was measured using the Beckman Coulter 5800 automated chemistry 
analyzer. This analyzer utilizes the hexokinase method for glucose measurement (Stein, 1965). 
The Beckman Coulter 5800 has an analytical measurable range (AMR) between 10-800 mg/dL 
and a Clinical reportable range (CRR) between 10-2400 mg/dL with auto dilution.  To evaluate 
assay performance, daily quality control (QC) results were averaged amongst all instruments 
used for patient testing over the lifetime of a single lot. Based upon quality control data for four 
instruments from January 1, 2018 and June 20, 2018, the coefficient of variation for this assay 
was 1.08% at a concentration of 59.57 mg/dL, and 1.74% at a concentration of 362.85 mg/dL. 
The most recent calibrator lot verification, performed in November 2017, indicated a 0% bias 
between the previous lot and the new lot.  
HbA1c.  Prior to March 2015, the Richmond based laboratory utilized the BIO-RAD 
VARIANT II Turbo for measuring %HgbA1c. This method utilizes ion exchange high-pressure 
liquid chromatography (HPLC) (Jones 1979).  In 2014, the laboratory changed to the Premier 
Hb9210™ HgbA1c Analyzer, manufactured by Trinity Biotech, for %HgbA1c measurement, 
which utilizes boronate affinity HPLC (Fairbanks & Zimmerman 1983); (Millia 1981). The 
method comparison between the two showed a slight positive bias in the Trinity assay (Y), 
Y=1.0553x-0.1088, R
2
 = 0.9873. 
The daily QC results were averaged amongst all instruments over the lifetime of a single 
lot to evaluate assay performance.  The Trinity Premier quality control data for seven 
instruments used of patient testing from October 2, 2017 to June 20, 2018 the coefficient of 
variation for this assay was 1.23% at a concentration of 6.04% HgbA1c, and 1.61% at a 
concentration of 9.70% HgbA1c. The most recent calibrator lot verification, performed in May 
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2018, indicated a 1 % bias between the previous lot and the new lot. The BioRad Turbo Variant 
II quality control data for six instruments from December 11, 2013 to March 22, 2014, had a 
coefficient of variation of 2.36% at a concentration of 5.36% HgbA1c, and 1.61% at a 
concentration of 9.70% HgbA1c.  
1,5-AG.  Serum 1,5-AG was measured on the Beckman Coulter AU 5800 platform, with 
a two-step enzymatic assay and reagents produced by Glycomark (Yamanouchi 1996). Assay 
AMR is 1.0-100 µg/mL.  The daily QC results were averaged amongst all instruments used for 
patient testing over the lifetime of a single lot. The coefficient of variation for this assay was 
3.9% at a concentration of 5.47 µg/mL, and 2.56% at a concentration of 14.51 µg/mL for a single 
lot of QC used on seven instruments between December 19, 2017 to April 2, 2018. The most 
recent calibrator lot verification, performed in July 2017, indicated a -2% bias between the 
previous lot and the new lot. 
Insulin.  Insulin was measured on the Roche EMOD
TM
 electro-chemiluminescence 
testing platform. The EMOD
TM 
 Elecsys insulin assay utilizes the sandwich immunoassay 
principle utilizing monoclonal antibodies specific for insulin (Sapin et al., 2001). The AMR is 1-
1000 µU/mL.  Daily QC results were averaged amongst all instruments over the lifetime of a 
single lot. Based upon quality control data for six instruments totaling 12 measuring cells 
between April 25, 2018 and June 20, 2018, the coefficient of variation for this assay was 2.51% 
at a concentration of 25.39 µU/mL, and 2.29% at a concentration of 77.08 µU/mL. The most 
recent calibrator lot verification, performed in August 2017, indicated a -2% bias between the 
previous lot and the new lot. 
C-peptide.  C-peptide was measured on the Roche EMOD
TM
 electro-chemiluminescence 
testing platform. The Roche EMOD 
TM
 assay utilizes the sandwich principle, and uses two 
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monoclonal antibodies specific for C-peptide (Kao, Talyor, & Heser 1992). The AMR is 0.3 – 40 
ng/mL.  The daily QC results were averaged amongst all instruments over the lifetime of a single 
lot. The coefficient of variation for this assay was 2.02% at a concentration of 1.94 ng/mL, and 
2.46% at a concentration of 9.65 ng/mL for four instruments, totaling eight measuring cells for a 
single lot of QC between February 20, 2018 and June 20, 2018. The overall mean bias for two 
calibrator lot verifications, performed in 2018, was 0.0%. 
Proinsulin.  Proinsulin was measured on the Dynex DSX
TM
 testing platform, utilizing an 
ELISA kit from Mercodia
TM
. The proinsulin assay is a solid phase assay based on the sandwich 
immunoassay principle, employing two monoclonal antibodies against separate antigenic 
determinants on the proinsulin molecule (Kjems et al, 1993). The AMR is 2-150 pmol/mL, with 
a CRR of 2-1500 with auto dilution. To evaluate assay performance, daily QC results were 
averaged amongst all plate runs over the lifetime of a single lot. Based upon quality control data 
between May 1, 2018 and June 20, 2018, the coefficient of variation for this assay was 3.92% at 
a concentration of 9.11pmoL/L, and 6.13% at a concentration of 31.23 pmoL/L. The most recent 
lot verification, performed in November 2017, indicated a -2 % bias between the previous lot and 
the new lot.  
From April 2012 to July 2016, all of the assays used to measure the biomarkers included 
in this study underwent changes in reagent and calibration lots that could have potentially led to 
differences in biomarker results from the initial measurement to the follow-up measurement. The 
Richmond based laboratory utilized the following protocol to minimize shifts in patient results 
due to lot changes:  
 For reagent lot changes, 10 patients that ranged from the low-end to the high-end 
of the assay AMR, along with QC, were run using the current lot of reagent, and 
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again using the new lot of reagent. A percent bias of less than 10% was required 
for the new lot to be accepted.  
 For calibrator lot changes, 10 patients that ranged from the low-end to the high-
end of the assay AMR, along with QC, were run using the current calibration 
curve , and again using the new calibration curve. A percent bias of less than 10% 
was required for the new lot to be accepted.  
BMI. Body mass index is calculated as the patient’s mass divided by the square of their 
height in meters =  
𝑀𝑎𝑠𝑠 (𝑘𝑔)
(𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚))2
 . Height and weight, if available, were collected at the time of 
blood draw. Body mass index can be categorized as underweight, normal, overweight, and obese, 
with obesity subdivided into three classes. The BMI classifications for the current study are 
displayed in Table 7. For the purpose of this study, health scores were assigned solely according 
to the categories of normal, overweight, and obese.  
Table 7: Patient Classification by BMI 
BMI category BMI (kg/m
2
)
 Study Classification 
Underweight < 18.5 NA 
Normal 18.5 – 24.9 Normal 
Overweight 25.0 – 29.9 Overweight 
Obesity Class 1 30.0 – 34.9 Obese 
Obesity class 2 35.0 – 39.9 Obese 
Extreme Obesity Class 3  ≥ 40 Obese 
Adopted from (Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in 
adults : The evidence report 1998) 
 
Research Setting 
 Laboratory testing was completed at either Health Diagnostics Laboratory or True Health 
Diagnostics, in Richmond, Virginia. The patient population was dispersed throughout the 
continental United States.  Most, but not all specimens, were collected at a physician’s office or 
at other draw sites by a phlebotomist. All samples were sent to Richmond, Virginia for testing 
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and usually arrived within 24 hours of the venipuncture. All samples were shipped with ice packs 
to ensure the optimal temperatures were maintained during sample transportation, with 
temperature verification if samples were suspected of being out of optimal refrigeration 
temperature range of 2-8°C. The laboratory Pre-Analytics Department received and accessioned 
all serum separator tubes (SST) and whole blood Ethylenediaminetetraacetic acid (EDTA) tubes. 
Samples received unspun or outside the optimum temperature range were flagged and affected 
tests were not tested.   
 Patient-CHC interactions were conducted in in a variety of locations. For face-to-face 
interactions, the CHC met with the patient either at a physician’s office or a wellness location, an 
office provided to CHCs and other health practitioners.  Patient-CHC interactions could have 
also occurred over the phone. In either setting, the CHCs were instructed to follow the same 
CHC visit protocol in accordance with their training. In addition, CHC interactions could vary in 
length of time or topics discussed based on patient conditions. There was no data recorded on the 
length of the visit or topics discussed during the CHC interaction.  
 Data collection and analysis took place at True Health Diagnostics. Senior IT analysts 
wrote the code that allowed a search of the LIS and IMS databases, and assisted with sorting and 
refining data once extracted.  
Data Collection 
Data collection was a two-step process. First, a query of the LIS identified potential study 
subjects. The IT team at the laboratory identified patients who had an initial blood draw after 
April 1, 2012, and that had a follow-up blood draw 10 to 14 months after their initial blood draw, 
up to July 15, 2016. Once potential study subjects were selected from the LIS query, a search of 
the CHC information management system (IMS) for the same subjects provided the number and 
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date of the subjects’ CHC interactions, if any. The format of each of the data elements that were 
extracted from each of the two databases are listed in Table 8.  
Table 8: Subject Data Elements Extracted from Harvest LIS and Health Coach IMS 
 
Data Element Format 
Patient identification number XXXXXXX 
Sample ID at initial draw YYMMDDXXXXX 
Date of initial draw MM/DD/YYYY 
Age at initial draw Digit-Continuous 
BMI at initial draw Digit-Continuous 
Sample ID at follow up draw YYMMDDXXXXX 
Date of follow up draw MM/DD/YYYY 
Age at follow up draw Digit-Continuous 
BMI at follow up draw Digit-Continuous 
CHC interactions During Study 0 for no CHC or 1for CHC 
Sex M/F 
Fasting Status at initial draw 
0 for non-fasting, 1 for fasting, or 
2 for not indicated 
Fasting Time at initial draw Digit-Continuous 
Fasting status at follow up draw 
0 for non-fasting, 1 for fasting, or 
2 for not indicated 
Fasting time at follow up draw Digit-Continuous 
Glucose at initial draw Digit-Continuous 
%HgbA1c at initial draw Digit-Continuous 
Insulin at initial draw Digit-Continuous 
Proinsulin at initial draw Digit-Continuous 
C-peptide at initial draw Digit-Continuous 
1,5-anhydroglucitol at Initial Draw Digit-Continuous 
Glucose at follow up draw Digit-Continuous 
%HgbA1c at follow up draw Digit-Continuous 
Insulin at follow up draw Digit-Continuous 
Proinsulin at follow up draw Digit-Continuous 
C-peptide at follow up draw Digit-Continuous 
1,5-anhydroglucitol at follow up draw Digit-Continuous 
 
The data from the LIS and IMS were merged into a single Microsoft Excel file. After 
verification of the data, the IT team provided the PI with a deidentified file. The final 
deidentified study components are listed in Table 9. 
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Table 9: Deidentified Study Dataset 
Data Element Format 
Subject Number Digit 
Age at Initial Draw Digit 
Age at Follow-up Draw Digit 
Sex M/F 
Fasting at Initial  0, 1, or 2                
Fasting Time at Initial Draw Digit 
Fasting at Follow-up Draw 0, 1, or 2                
Fasting Time at Follow-up Draw Digit 
Number of CHC Visits During the Study 
Timeframe 0 or 1 
Number of CHC interactions During Study Digit-Continuous 
BMI at Initial Draw Digit-Continuous 
BMI at Follow-up Draw Digit-Continuous 
Insulin at Initial Draw Digit-Continuous 
Insulin at follow up draw Digit-Continuous 
Glucose at Initial Draw Digit-Continuous 
Glucose at follow up draw Digit-Continuous 
Hemoglobin A1c at Initial up draw Digit-Continuous 
Hemoglobin A1c at follow up draw Digit-Continuous 
C-peptide at Initial up draw Digit-Continuous 
C-peptide at follow up draw Digit-Continuous 
Proinsulin at Initial up draw Digit-Continuous 
Proinsulin at Follow-up draw Digit-Continuous 
1,5-AG at Initial up draw Digit-Continuous 
1,5-AG at follow up draw Digit-Continuous 
 
Validity and Reliability 
Specimen integrity, accuracy of specimen testing and verification of data collection, were 
essential to ensure the results of the current study were valid and reportable. Improperly 
collected, transported, or stored sample could have varying effects on the quality of results 
generated from laboratory instrumentation. Preanalytical component of laboratory quality control 
included a check of specimen integrity and proper labeling prior to testing. Blood specimen 
integrity, i.e. proper tube labeling, shipping temperature of 2-8°C (specimens were acceptable if 
shipped with a cold pack and/or temperature was verified by infrared thermometer if temperature 
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was questioned), signs of hemolysis, clotted or specimens partially spun samples, was checked 
upon arrival to the laboratory that performed the analysis. The Pre-Analytics team reviewed all 
specimens for proper shipping conditions. The date and time of collection was also recorded by 
the Pre-Analytics team, but not included in the study dataset.   
To ensure accuracy of specimen testing, the laboratory adheres to analytical quality 
control measures. Daily, weekly, monthly, and annual maintenance was performed and 
documented for all instruments and equipment used in the preanalytical and analytical phases of 
testing, according to manufacturer’s guidelines and standards set forth by the College of 
American Pathologists (CAP). Calibration and QC of all testing methods were performed in 
accordance with manufacturers’ guidelines or laboratory operating procedure, whichever was 
more stringent. New lots of reagent and calibrator were verified according to the laboratory’s 
standard operating procedures, which require that 10 patient specimens that span the AMR along 
with quality controls for the analyte were measured with both the current and new lot of reagents 
or calibrator. The % bias slope between the two lots must be less than ±10% to be acceptable.  
Quality control measures were also taken in the post analytical phase of data collection. 
The use of two databases allowed for the collection and merging of data while reducing the 
potential of human error associated with transcription. Results were automatically transferred 
from the LIS and MS to the Excel file without human manipulation. The IT team checked 100 
random subjects from the combined Excel database file and compared their name, initial and 
follow-up biomarker testing results, and demographics to those in the LIS and IMS to ensure 
they match. Once the data set was established, The IT team de-identified the subjects by 
replacing patient name and sample number with a new unique study number that was unrelated 
to the laboratory patient identification system.  
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 Polit and Beck (2008) define internal validity as the ability of the study to measure a true 
effect rather than another external factor (Polit, 2008). This study was subject to threats of 
internal validity concerning the laboratory testing and CHC interactions. Threats to internal 
validity concerning the laboratory instrumentation were reduced by limiting testing platform 
variation by following the analytical standards described above required by the laboratory and 
accrediting agencies. Concerning CHC interactions, threats to internal validity were reduced by 
ensuring CHCs followed a structured protocol for behavior change during interactions. Before 
CHCs were allowed to interact with clients, all CHCs were required to participate in company 
mandated training courses. The goal of their training was to standardize the approach of the 
consultation while adapting the best counseling method dependent on the patient’s readiness and 
ability to change the behavior of interest. However, CHC interactions may vary from one patient 
to another, as well as from health coach to health coach.   
Sample Size and Statistical Power 
Sample size requirements were dependent on effect size, power, significance, and the 
number of predictors. A post-hoc sample size calculation was performed with a confidence of 
80% against Type II errors and a confidence of 95% against Type I errors.  Effects size, the 
difference between two groups, aids in the statistical explanation of the effectiveness of a 
particular intervention.  
The study utilized Cohen’s d to generate estimates of effect size for all biomarkers and 
BMI.  Cohen’s d=
𝐺𝑟𝑜𝑢𝑝 1 𝑚𝑒𝑎𝑛−𝐺𝑟𝑜𝑢𝑝 2 𝑚𝑒𝑎𝑛
𝐺𝑟𝑜𝑢𝑝𝑠 𝑐𝑜𝑚𝑚𝑜𝑛 𝑆𝐷
 . A Cohen’s of 0.2 is considered a small effect size, a 
Cohen’s d of 0.5 is considered a medium effects size, and a Cohen’s d of 0.8 is considered a 
large effect size (J. Cohen, 1988). To assess effect size of CHC interactions and change in the 
study biomarkers and BMI, the effects size was calculated post hoc using means and SDs 
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gathered during data collection and calculated from SPSS frequency data analysis. Soper’s 
online calculator for apriori estimates for a multiple regression analysis was used to determine 
sample size requirements, using a power 0.8, probability level of 0.05, the effects size for each 
DV, and up to five predictors dependent on individual model CVs where significant (Soper, 
2018).  
Data Cleaning 
Data from both the laboratory LIS and the CHC IMS were merged into a single Microsoft 
Excel file. The Excel data set was examined for accuracy by the IT team. One hundred random 
subjects from the unaltered data set were checked against the LIS and IMS for biomarker, 
demographics, and CHC interaction data.  The following were removed from the Excel 
spreadsheet prior to loading into SPSS: 
 Patients that did not have both an initial and follow-up result for the disease marker 
being analyzed 
 Non-fasting initial and final draw results for glucose, proinsulin, insulin, or C-
peptide.  
After the data set was reviewed in Excel, the data set was imported into SPSS v24 for data 
analysis (IBM Corp. 2016). 
Randomization was required for the selection of the control groups (non-CHC groups) to 
test the hypotheses for Specific Aims 1and 2. Subjects from the non-CHC group were randomly 
selected to match the approximate number of subjects in the CHC group for each biomarker, 
with the exception of 1,5-AG. For 1,5-AG, the number of subjects in the CHC group (n = 142) 
was > 10% of the non-CHC group (n = 25). Therefore, randomization was not required. The 
number of subjects in the CHC group was divided into the number of subjects in the non-CHC 
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group to calculate the percent of subjects needed to for random selection. Once the percentage 
was calculated, SPSS was used to randomly select the corresponding number of subjects from 
the non-CHC group. The number of subjects used to test each hypothesis is shown in Table 10. 
Table 10: Non-CHC Random Selection 
Test 
CHC 
and 
non-
CHC 
Sample 
CHC 
Subjects 
Non- 
CHC 
Subjects 
% of non-
CHC 
Subjects 
Selected for 
Analysis 
Calculated 
non-CHC 
Sample 
Final 
Sample 
Size for 
Analysis 
Glucose 15,803 969 14,834 6.5 975 1944 
Hemoglobin 
A1c 
37,594 1,357 36,597 3.7 1328 2685 
1,5-AG 142 25 117 21.4 NA NA 
Insulin 15,375 1031 14,344 7.1 922 2023 
C-Peptide 3739 407 3332 12.2 425 832 
Proinsulin 2303 277 2026 13.7 257 534 
BMI 88747 4029 84718 4.8 4043 7854 
 
To ensure the randomly selected sample was not statistically different from the total non-
CHC population, ANOVA was performed on the age, sex, BMI, the initial value for each marker 
to answer the question, was whether there was a difference in each of the variables between the 
group randomly sampled from the non-CHC data set and the complete non-CHC data set?  The 
results from the ANOVA, as shown in Table 11, demonstrate that there was no statistically 
significant difference in age, sex, initial BMI or initial marker result between the entire non-CHC 
sample and the subjects randomly selected for inclusion in the statistical analysis.  
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Table 11: Non-CHC Random Selection ANOVA 
Test 
Age 
p value 
Sex 
p value 
Initial BMI 
p value 
Initial 
Marker 
p value 
Glucose 0.306 0.142 0.464 0.084 
Hemoglobin 
A1c 
0.378 0.444 
 
0.563 
 
0.160 
1,5-AG NA NA NA NA 
Insulin 0.365 0.194 0.956 0.361 
C-Peptide 0.651 0.372 0.916 0.982 
Proinsulin 0.717 0.858 0.870 0.366 
BMI 0.370 0.795 0.613 0.711 
 
Missing data was not a threat to statistical validity as all missing biomarker data were 
eliminated prior to loading the data set into SPSS. Descriptive statistics such as, means and 
maximum and minimum values, for age, sex, initial BMI, and mean change in biomarker along 
with their frequency distributions generated were generated in SPSS prior to data analysis. 
Univariate outliers, or outliers within a single variable, were identified by analyzing 
descriptive statistics and standardized z scores. The standardized score, or z score is the number 
of standard deviations (SD)  a particular value is from the mean of all values (Tabachnick & 
Fidell, 2007). To reduce the effect of BMI univariate outliers on the statistical analyses, all initial 
BMI values were converted to a standardized z score to identify potential outliers.  Eligible 
subjects from all six biomarker groups were entered into a single SPSS file. Descriptive analysis 
performed in SPSS was able to generate a z score of each initial BMI to confirm with 99.9% 
confidence that the cases in the BMI dataset are part of the population represented by the study 
samples (Tabachnick & Fidell, 2007).  Normalization of all subjects’ initial BMI was calculated 
in SPSS to generate a standardized z score. BMI outliers were defined as a BMI z score of < -3.3 
or > 3.3. Subjects with an initial BMI >52.26 were eliminated as having a z score > 3.3. None of 
the initial BMI values had a BMI z score of < -3.3. However, The Diagnostic and Statistical 
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Manual of Mental Health Disorders (DSM-5), derived from World Health Organization 
categories for thinness in adults, classifies BMI between 24 and 17 as mild anorexia, BMI 
between 16.0-16.99 as moderate anorexia, BMI between 15.0-15.99 as sever anorexia, and BMI 
< 15 as extreme anorexia (American Psychiatric Association, 2013). Subjects with BMIs <15 
were eliminated as extreme values.  
To identify univariate outliers, or extreme values for a single variable, the change in each 
marker, with the exception of HbA1c, and BMI were converted to standardized z score in SPSS. 
Markers with z scores < -3.3 and > 3.3 were eliminated as univariate outliers. For %HbA1c, 
Tukey’s extreme values were used to eliminate univariate outliers related to difference in initial 
and final HbA1c values. Tukey’s extreme values were chosen as opposed to z score distribution 
due to the large number of cases that would have been eliminated if z score distributions were 
used (Tukey, 1977). A change in %HbA1c > 9% was determined to be an outlier if z score 
distributions were used, this was not such an abnormal value.  In a 2015 study of %HbA1c 
values and the risk of chronic obstructive pulmonary disease in patients with T2D, Li et al. 
classified patients with HbA1c values > 10% as high, with 9,390 of their 45,753 subjects in that 
category (Li et al, 2015).  
Multivariate outliers, or a combination of extreme values, were identified by 
Mahalanobis distance test (Mahalanobis, 1936). This test generates a score for each subject 
based upon the combination of values of all variables and compares the score to the centroid for 
all other subjects. The cutoff for MD with 6 degrees of freedom is 22.46 and 20.52 for 5 degrees 
of freedom (Pearson and Hartly, 1958). Cases with MD greater than the cutoff were eliminated. 
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 Biomarker minimum and maximum values were compared to the clinical reportable 
range (CRR) for their respective methods in the excel file prior to loading into SPSS.  Values 
outside their CRR (Table 12) were identified and deleted.  
Table 12: AMR and CRR 
Test AMR Dilution CRR 
Glucose mg/dL 10-800 X3 10-2400 
Hemoglobin A1c % 3.8-18.5 NA 3.8-18.5 
1,5-Anhydroglucitol 1.0-110 NA 1.0-110 
Insulin uU/mL 1-1000 NA 1-1000 
C-Peptide 0.3-40.0 NA 0.3-40.0 
Proinsulin 2.0-150 X10 2-1500 
 
Data Analysis 
The goal of Specific Aim 1 was to determine if there are differences in the changes in 
markers between patients who interacted with a CHC and those who did not. The change for 
each marker for each case was calculated. The mean change for each marker for all subjects in 
each group was then calculated, along with the variance in marker change within each group. 
The change for each marker was compared between the two groups.  Patient demographics of 
age, sex, and initial BMI were used as covariates in the analysis of change in marker results and 
included in the final statistical model if significant. For evaluating the relationship between CHC 
interactions and changes in BMI, patient demographics of sex and age were used as covariates. 
To evaluate the possibility that the propensity for a subject to seek CHC interactions might 
influence the change in marker results, the relationship between initial biomarker values and the 
change in biomarker values was investigated. A structural model was developed using the 
general linear model (GLM) procedure in SPSS.  For each marker change, CHC interaction and 
all CVs were proposed as predictors.  The GLM entered each variable using stepwise regression 
and returned one or more models that were statistically significant (p<0.05) on their own and 
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statistically significantly different from the prior (reduced) model. Estimates of the magnitude of 
the correlation and statistical significance (P<0.05) of marker differences and exposure to CHC 
interactions were provided for each model returned by GLM. For those markers in which a 
significant relationship was found, initial biomarker values were used as covariates in the final 
analysis. For each model returned by GLM, an ANOVA table provided sums of squares, an F 
statistic, degrees of freedom for the model, a p value and an eta squared statistic.  The final 
model for each analysis included CHC interaction and any CVs that were statistically significant 
(p<0.05).  Standardized beta weights for each significant predictor in each model, and a t test for 
each beta and zero-order correlations determined the effect size for each of the biomarkers or 
how much variance is shared with the independent variable. The final model output stated if the 
means between the two groups were statistically significantly different, as well as if the use of 
CHC explained a statistically significant amount of that difference.  A p value less than 0.05 
indicated a statistically significant difference between groups, as well as a relationship between 
CHC interaction and change in biomarker and BMI values.   
The goal of Specific Aim 2 was to evaluate the change in glucose, %HgbA1c, and  BMI 
health scores. For this specific aim, the general construct of diabetic health was measured by 
transformation of initial and final glucose, %HgbA1c, and BMI results into health scores.  The 
criteria for the assignment of health scores is listed in Table 13. Interaction with a CHC or no 
interaction with a CHC was the IV. The change in health score was a separate DV.  Interaction or 
no interaction with a CHC was the IV, and initial marker values, if significant, along with age, 
sex, initial BMI, and effects of the CHC interaction, were inserted step-wise as covariates into a 
linear regression to attain estimates of the interactions.  A p value less than 0.05 indicated a 
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statistically significant difference between groups, as well as a relationship between CHC 
interaction and change in biomarker and BMI health scores. 
Table 13: Disease Marker Health scores 
 Health Score 
Test 0 1 2 
Glucose (mg/dL) ≤ 99 100-125 >125 
Hemoglobin A1c (%) ≤ 5.6 5.7-6.4 ≥ 6.5 
BMI 18.5-24.9 25.0-29.9 > 29.9 
 
For Specific Aim 3, the SPSS GLM procedure was again used to perform an ANCOVA 
to provide relevant statistical evidence relating the number of CHC interactions to change in 
mean marker values, using the number of CHC visits as the IV.  As for Specific Aim 1, marker 
differences were used as the DVs, each analyzed separately.  Covariates were initial marker 
values, age, sex, and initial BMI.  Patients who did not interact with a CHC were not included in 
this analysis.  Linear regression was used to attain estimates of the relationship between the 
number of CHC interactions and the changes in biomarker results.  As with Aim 1, p values less 
than 0.05 indicates a significant relationship between the number of CHC visits and marker 
differences. A one way paired t-test was conducted to investigate the mean marker change 
between the number of CHC interactions defined as one, two, three, and four or more visits. A 
Bonferroni post hoc test was used to assess the significance of mean differences between these 
groups (Dunn, 1961). The resulting statistics provided evidence relevant to a proportional 
relationship between the number of CHC interactions and the magnitude of the changes in 
marker results. 
Data Interpretation 
For all three Specific Aims, a stepwise regression model was created to provide evidence 
relevant to each research question for each marker difference or health score difference. The 
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results were presented as a series of numbered models, one for the addition of each predictor, 
regardless of whether the predictor was considered a CV or the IV.  The first model identified the 
predictor that explained the greatest proportion of the variance in the DV.  The next model 
identified the predictor that explained the greatest proportion of the remaining variance in the 
DV.  This process was repeated until the addition of the next predictor resulted in a model that 
was no longer statistically significant.  This process generated from one to four models that 
revealed the statistically significant CVs, and the IV.  For each marker, a model summary table 
was constructed with the R, R
2
, R
2
 change, F-score change, and the significance of the change in 
F-score.  The R
2
 represents the proportion of the variance in the DV that is explained by the CV 
or IV. The change in R
2 
represents the change in variance explained with the addition of each 
CV, if applicable. The change in F-statistic and accompanying p value indicate the significance 
of each CV when added to the model, as well as the significance of the addition of the IV in the 
final model.  
For Aims 1and 2, an initial t-test determined if there was a statistically significant 
difference in the unadjusted means between the CHC and non-CHC groups. The ANCOVA 
generated for Specific Aims 1 and 2 determine if there were statistically significant differences in 
the mean changes in the DV between those who had CHC interactions and those who did not. 
The significance of the final model would also determine if the addition of the IV to the model 
explained a statistically significant amount of that difference.   
 For Specific Aim 3, the F-score change and accompanying p values only indicate the 
effect of the addition of each CV on the change in BMI or marker value and the number of CHC 
interactions. Since the number of CHC interactions is not a categorical level of measurement, an 
ANCOVA was not utilized to provide a statement of significance concerning the difference 
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between the IV groups.  However, ANCOVA was used to describe statistically significant 
relationships between marker difference and number of CHC visits.  Subjects were grouped 
based on the number of CHC interactions they had.  There was a group with one visit, another 
with two visits, one with three visits, and if needed, a group for four or more visits. Groups were 
created for each marker to ensure that each group was as equal in size as possible to preserve 
homogeneity of variance between the groups.  Differences in mean BMI and marker differences 
between groups was determined by a one-way ANOVA and pairwise comparisons.  In these 
situations, a summary table for the ANOVA and a table of paired comparisons, with a 
Bonferroni adjustment was presented.  
Chapter Summary 
 Chapter 3 discussed information on the study methodology. Information was provided 
concerning the population and sampling strategies employed, as well as details concerning how 
the data was acquired from two data courses and merged. Steps required for data cleaning were 
discussed, along with how the data was analyzed for each Specific Aim. Finally, Chapter 3 
concluded with an explanation of how the data was examined and interpreted for statistical 
significant findings.  
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Chapter 4: Results 
 
 
Introduction 
 Chapter 4 describes the subject demographics generated for all dependent variables 
across all three Aims. In addition, sample selection for each biomarker is presented, along with 
sample exclusion criteria and resulting sample sizes. Next, Chapter 4 provides statistical 
evidence related to all three aims; diabetes related disease markers related to CHC interaction, 
diabetes related disease markers related to health scores, and diabetes related disease markers 
related to CHC frequency.   
Specific Aim 1 
The purpose of Aim 1 was to determine if there are statistically significant differences 
between subjects who do or do not participate in CHC interactions in their changes in blood 
glucose concentration, %HbA1c, blood 1,5-AG, blood insulin concentration, blood C-peptide 
concentration, blood proinsulin concentration, and BMI. Before statistical analysis was 
performed, the data set was cleaned and reviewed for univariate and multivariate outliers. The 
results of this process are presented for each marker, following the summary tables for the 
changes before and after adjustment for covariates.  
The changes in markers were determined by subtracting the subjects’ follow-up marker 
values from their initial marker values. A negative change indicates an improvement in glucose 
homeostasis, with the exception of 1,5-AG. For 1,5-AG, a positive change in marker value 
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indicates an improvement. Table 14 displays the mean changes in markers before adjustment for 
covariates. The group of subjects who interacted with CHCs showed significantly greater 
improvements in insulin, proinsulin, and BMI than the group with no CHC interactions. Both 
groups showed worsening of %HgbA1c and 1,5-AG.  However, the differences between the 
groups was not statistically significant.  
Table 14: Mean Changes in Markers of Glucose Homeostasis in Subjects with and without CHC 
Interactions, and their Statistical Significance 
Test CHC
a Non-
CHC
b F df p value 
Glucose 
(mg/dL) 
-0.57 0.08 
 1.195 
1 
0.275 
 
HbA1c 
(%) 
0.10 0.11 
 0.790 
1 
0.374 
 
Insulin 
(μU/mL) 
-0.78 -0.11 
 7.369 
1 
0.007 
 
C-Peptide 
(ng/mL) 
-0.11 -0.03 
 1.838 
1 
0.176 
 
Proinsulin 
(pmol/L) 
-1.17 0.23 
 4.163 
1 
0.042 
 
1,5-AG 
(µg/mL) 
-0.37 -1.29 
 1.300 
1 
0.256 
 
BMI -0.49 -0.20 
 33.878 
1 
<0.001 
 
a.)subjects who interacted with CHCs. b.)subjects who did not interact with CHCs 
To investigate the role of potential covariates on the mean change in the marker results, 
linear regression was used to evaluate the change in model significance with stepwise additions 
of the CVs age, sex, initial BMI, and initial marker value, and the IV, the use of CHCs. The 
results of this analysis, summarized in Table 15, revealed that the initial result for each marker 
was a significant covariate with CHC-patient interactions for the change in that marker. Other 
covariates influenced some, but not all markers. After adjusting for the covariates, only the 
change in BMI was significantly different between subjects with CHC interactions and those 
without CHC interactions.  
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Table 15: The Significance of CHC Interactions After Adjusting for Covariates on the Difference 
Between the Change in Biomarkers  
Test 
Mean 
Marker 
Change 
CHC 
Mean 
Marker 
Change 
Non-CHC 
Significant 
Covariates 
Significance of 
CHC 
Interactions 
(p value) 
Glucose 
(mg/dL) 
-0.57 0.08 
Initial glucose, Age, 
sex 
0.546 
HbA1c 
(%) 
0.10 0.11 Initial HbA1c 0.768 
1,5-AG 
(µg/mL) 
-0.37 -1.29 Initial 1,5-AG 0.379 
Insulin 
(μU/mL) 
-0.78 -0.11 
Initial insulin, BMI, 
sex 
0.112 
C-Peptide 
(ng/mL) 
-0.11 -0.03 
Initial C-peptide, 
BMI, Age 
0.453 
Proinsulin 
(pmol/L) 
-1.17 0.23 
Initial proinsulin, 
sex, age, BMI 
0.104 
BMI -0.49 -0.20 Initial BMI < 0.001 
 
Subject selection and results of analysis of the change in blood glucose 
concentration.  The initial number of available subjects was 171,614. Subjects that did 
not fast for at least 8 hours were excluded from the analysis of the change in glucose 
concentration. Subjects that did not have both an initial and a follow-up measurement of glucose 
concentration were also excluded. After these exclusions, 16,150 subjects remained with 992 
having CHC interactions and 15,158 without CHC interactions.  From this sample of subjects, 
one was removed for having a BMI < 15, and 100 were removed for having a BMI > 52.26. Z 
scores were generated to identify univariate outliers, yielding 124 subjects with changes in 
glucose concentration corresponding to z scores <-3.3, and 122 with a z score > 3.3. These 
subjects were eliminated prior to random selection of subjects without CHC interaction. Prior to 
randomization, 15,803 subjects remained with 969 having had CHC interactions and 14,834 
without CHC interactions. After randomization, 1944 total subjects remained. To eliminate 
multivariate outliers, a Mahalanobis Distance  (MD) was generated using study number as the 
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DV, and age, sex, initial BMI, CHC yes or no, initial insulin, and difference in BMI as the IVs. 
The cutoff for Chi Square table with 6 degrees of freedom is 22.46, indicating that a MD > 22.46 
would be considered an outlier (Pearson and Hartly, 1958). Based upon the MD generated, 49 
subjects showed multicollinearity with MD > 22.46.  These were removed from the dataset for 
prior to the statistical .  Table 16 describes the subject demographics for the glucose biomarker 
sample.  
Table 16: Demographics and Change in Glucose Concentrations for Subjects With and Without 
CHC Interactions 
CHC 
Interactions   
Initial 
Age 
Sex Initial BMI 
Initial  
Glucose 
(mg/dL) 
Change in 
Glucose 
(mg/dL) 
Yes        
n= 962 Mean 56.0 33% M 30.0 99.2 -0.57 
 SD 13.4 67% F 6.6 22.8 12.77 
No        
n=964 Mean 54.5 45% M 28.8 98.1 0.08 
 SD 14.2 55% F 6.0 24.2 13.31 
Total       
n =1926 Mean 55.2 39% M 29.4 98.8 -0.24 
 SD 13.8 61% F 6.3 23.5 13.04 
 
Statistical analysis using a t-test in SPSS revealed there was no statistically significant 
difference in the mean change in glucose concentration between subjects that utilized CHC 
interactions and those who do not with 95% confidence (p = 0.275).   
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown in Table17. The final model includes initial glucose concentration, age, and sex as 
significant CVs and the IV. Initial glucose concentration accounted for 11.1 % of the variance in 
the model, while, age and sex accounted for 0.8 and 0.5 % respectively. After adjusting for initial 
glucose, age and sex, linear regression confirmed no statistically significant difference in the 
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mean change in glucose concentration between those who did (- 0.57 mg/dL), and those who did 
not (0.08 mg/dL), participate in CHC interactions, (p=0.546).  
Table 17: Significance of Covariates and CHC Interactions on the Mean Change in Glucose 
Concentration 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 Initial Glucose .334 .111 .111 241.063 < 0.001 
2 
Initial Glucose, 
Age 
.346 .119 .008 17.797 < 0.001 
3 
Initial Glucose, 
Age, Sex 
.353 .125 .005 11.660 0.001 
4 
Initial Glucose 
Age 
 Sex 
 CHC Y/N 
.354 .125 .000 .365 0.546 
 
Subject selection and results of analysis of the change in %HbA1c.  The initial 
number of available subjects was 38,320. Fifty-four subjects had results below the AMR for 
either their initial or follow-up result, and were excluded. After excluding subjects that did not 
have both initial and follow-up results, 38,266 subjects remained, with 1,368 having had CHC 
interactions and 36,898 without CHC interactions. There were 290 subjects with BMI > 52.26 
and 1 case with BMI < 15. These subjects were also excluded.  Next, extreme cases of changes 
in marker results were identified, using the extreme values in the SPSS explore function. Values 
that fell outside 3 times the interquartile range (IQR) were deemed extreme values (Tukey, 
1977). One subject was excluded due to a change in %HgbA1c > -9, and 13 subjects were 
excluded due to a change in %HgbA1c > 7.  
Prior to randomization, 37, 954 subjects remained, 1,357 with CHC interactions, and 
36,597 without CHC interactions. To eliminate multicollinearity outliers, a MD was generated 
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using study number as the DV and age, sex, initial BMI, CHC yes or no, initial %HbA1c, and 
difference in BMI as the IVs. The cutoff for chi square table with 6 degrees of freedom is 22.46, 
indicating that a MD > 22.46 would be considered an outlier (Pearson and Hartly, 1958). Based 
upon the MD generated, 85 cases were deemed multivariate outliers and were excluded prior to 
the statistical analysis. Table 18 describes the subject demographics for the HbA1c biomarker 
sample.   
Table 18: Demographics and Change in %HbA1c for Subjects With and Without CHC 
Interactions  
CHC 
Interactions   
Initial 
Age 
Sex Initial BMI 
Initial 
HbA1c 
(%) 
Change in 
HbA1c (%) 
Yes        
n= 1315 Mean 45.3 45% M 30.4 5.60 0.10 
 SD 14.4 55% F 6.8 0.67 0.40 
No        
n=1295 Mean 55.9 46% M 29.5 5.56 0.11 
 SD 14.0 54% F 6.4 0.69 0.39 
Total       
n =2610 Mean 
SD 
50.6 
15.1 
46% M 
54% F 
29.9 
6.6 
5.58 
5.68 
0.10 
0.40  
 
Statistical analysis using a t-test in SPSS revealed no statistically significant difference in 
the mean change in %HbA1c between those that utilized CHCs and those who did not (p = 
0.374). The mean change in %HbA1c was positive for both the CHC (0.10%) and non-CHC 
(0.11%) groups, indicating an increase in average blood glucose concentration over time. 
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown as Table 19. The only significant CV was the initial %HbA1c, which accounted for 15.4% 
of the variance. After adjusting for initial %HbA1c, linear regression confirmed 
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no statistically significant difference in the change in %HbA1c between those who did, and those 
who did not have CHC interactions (p=.768).   
Table 19: Significance of Covariates and CHC Interactions on the Mean Change in %HbA1c 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 
Initial 
%HbA1c 
.392 .154 .154 473.571 < 0.001 
2 
Initial 
%HbA1c  
.392 .154 .000 0.87 0.768 
CHC Y/N      
 
Subject selection and results of analysis of the change in 1,5-AG concentration.  The 
initial number of available subjects for 1,5-AG was 150. Five subjects had results below the 
AMR and were excluded.  Only 145 subjects remained with 25 having CHC interactions and 120 
without CHC interactions. One subject had a BMI > 55.26 and was excluded. Z scores were used 
to identify outliers for the change in 1,5-AG. Two subjects had z scores greater than 3.3, 
corresponding to a change in 1,5-AG greater than 18 µg/mL. Randomization of the subjects 
without CHC interactions was not performed since the number of subjects with CHC interactions 
was > 10% of the number of subjects without CHC interactions. No multivariate outliers were 
identified. Table 20 describes the subject demographics for the 1,5-AG biomarker sample.   
 
 
 
 
 
 
 
 
 
 
 
 
  
73 
 
Table 20: Demographics and Change in 1,55-AG Concentrations for Subjects With and Without 
CHC Interactions 
CHC 
Interactions   
Start age Sex Initial BMI  
Initial  
1,5-AG 
(µg/mL) 
Change in 
1,5-AG 
(µg/mL) 
Yes        
n= 25 Mean 51.5 36% M 28.4 15.80 -0.37 
 SD 15.0 64% F 5.6 9.01 3.67 
No        
n=117 Mean 50.3 33% M 28.2 17.05 -1.29 
 SD 15.23 67% F 6.9 6.81 3.64 
Total 
n =142 
      
Mean 
SD 
50.6 
15.15 
34% M 
66% F 
28.3 
6.7 
16.83 
7.23 
-1.13 
3.7 
 
Statistical analysis using a t-test in SPSS revealed no statistically significant difference in 
the mean change in 1,5-AG between those with CHC interactions and those without CHC 
interactions ( p=0.256). 
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV. The model summary table is 
shown as Table 21. The only significant CV was the initial 1,5-AG, which accounted for 19.2% 
of the variance. After adjusting for initial 1,5-AG, linear regression confirmed 
no statistically significant difference mean change in 1,5-AG between those who did, and those 
who did not have CHC interactions (p=0.379). 
Table 21: Significance of Covariates and CHC Interactions on the Mean Change in 1,5-AG 
Concentration 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 Initial 1,5-AG .438 .192 .192 33.171 < 0.001 
2 
Initial 1,5-AG 
CHC Y/N 
.443 .196 .005 .779 0.379 
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Subject selection and results of analysis of the change in insulin concentration.  The 
initial number of available subjects for insulin was 123,401. Subjects that did not fast for at least 
8 hours were excluded from the analysis of the change in insulin concentration. Subjects that did 
not have both an initial and a follow-up measurement of insulin concentration were also 
excluded.  After exclusions, 15,629 subjects remained with, 1,031 having CHC interactions and 
14,344 without CHC interactions. From this sample, one was eliminated for having a BMI < 15 
and 105 for having a BMI < 52.26. Z scores were generated to identify univariate outliers, 
yielding 69 subjects with changes in insulin corresponding to z score >3.3 and 79 with a z score 
<-3.3. These subjects were eliminated prior to random selection of subjects without CHC 
interactions. Prior to randomization, 15,375 subjects remained, with 1031 having had CHC 
interactions, and 14,344 without CHC interactions. After randomization, 2023 subjects remained. 
To evaluate multivariate outliers, a MD was generated using study number as the DV and age, 
sex, initial BMI, CHC yes or no, initial insulin, and difference in BMI as the IVs. The cutoff for 
chi square table with 6 degrees of freedom is 22.46, indicating that a MD > 22.46 would be 
considered an outlier (Pearson and Hartly, 1958). Based upon the MD generated, 40 subjects 
showed to have multivariate outliers with MD > 22.46. These were removed and analysis ran. 
Table 22 describes the patient demographics for the insulin biomarker sample.   
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Table 22: Demographics and Change in Insulin Concentrations for Subjects With and Without 
CHC Interactions 
CHC  
Interactions  
Initial 
Age 
Sex Initial BMI  
Initial 
Insulin 
(μU/mL) 
Change in 
Insulin 
(μU/mL) 
Yes        
n= 973 Mean 55.6 34% M 30.0 11.9 -0.78 
 SD 13.8 66% F 6.4 7.5 5.65 
No        
n=1010 Mean 54.1 40% M 28.7 10.7 -0.11 
 SD 13.2 60% F 6.2 7.2 5.31 
Total       
n =1983 Mean 54.9 37% M 29.4 11.3 -0.45 
 SD 13.5 63% F 6.4 7.4 5.50 
 
Statistical analysis using a t-test in SPSS revealed a statistically significant difference in 
the mean change in inulin between those with CHC interactions and those without CHC 
interactions (p=0.007). 
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown as Table 23.  
Table 23: Significance of Covariates and CHC Interactions on the Mean Change in Insulin 
Concentration 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 Initial Insulin .401 .161 .161 380.081 < 0.001 
2 
Initial Insulin 
Initial BMI 
.426 .181 .020 48.825 < 0.001 
3 
Initial Insulin, 
Initial BMI 
Sex 
.431 .186 .005 11.369 0.001 
4 
Initial Insulin 
Initial BMI 
Sex 
CHC Y/N 
.432 .187 .001 2.523 0.112 
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The final model included initial insulin, initial BMI, and sex as CV and the IV, use of 
CHC.  Initial insulin accounted for 16.1% of the variance in the model, while initial BMI and sex 
accounted for 2% and 0.5% respectively. After adjusting for initial insulin, initial BMI and sex, 
linear regression confirmed no statistically significant difference was detected for the change in 
mean insulin between those who did ( -0.78 μU/mL), and those who did not (-0.11 μU/mL), 
participate in CHC interactions ( p = 0.112).  
Subject selection and results of analysis of the change in C-peptide concentration.  
The initial number of available subjects for C-peptide was 28,415. Subjects that did not fast for 
at least 8 hours were excluded from the analysis of chance in C-peptide concentration Subjects 
that did not have both an initial and a follow-up measurement of C-peptide concentration, and/or 
that had results outside the AMR, were also excluded. After these exclusions, 3,816 subjects 
remained with 414 having had CHC interactions and 3,402 that did not.  From this sample of 
subjects, one was eliminated for having a BMI < 15 and 76 were eliminated for having a BMI > 
52.26. Z scores were generated to identify univariate outliers, yielding 24 subjects with changes 
in C-peptide concentration corresponding to z score >3.3 and 26 with a z score <-3.3. Prior to 
random selection of the non-CHC groups, 3,739 subjects remained. After randomization, 832 
subjects remained.  The MD was generated using study number as the DV and age, sex, initial 
BMI, CHC yes or no, initial insulin, and difference in BMI as the IVs. The cutoff for chi square 
table with 6 degrees of freedom is 22.46, indicating that a MD > 22.46 would be considered an 
outlier (Pearson and Hartly, 1958). Based upon the MD generated, nine subjects were considered 
multivariate outliers with MD > 22.46. These were removed and analysis ran.  Table 24 
describes the patient demographics for the insulin biomarker sample. 
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Table 24: Demographics and Change in C-peptide Concentrations for Subjects With and Without 
CHC Interactions 
CHC 
Interactions   
Initial 
Age 
Sex Initial BMI  
Initial  
C-peptide 
(ng/mL) 
Change in 
C-peptide 
(ng/mL) 
Yes        
n= 401 Mean 56.1 32% M 30.2 3.02 -0.10 
 SD 14.0 68% F 6.2 1.34 0.83 
No        
n=422 Mean 52.5 41% M 29.2 2.76 -0.03 
 SD 14.6 59% F 6.5 1.26 0.73 
Total       
n =832 Mean 54.24 37% M 29.7 2.88 -0.07 
 SD 14.413 63% F 6.3 1.30 0.78 
 
Statistical analysis a t-test in using SPSS revealed no statistically significant difference in 
the mean change in C-peptide concentrations between subjects that utilized CHCs and those who 
did not (p = 0.176).  
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown as Table 25. 
Table 25: Significance of Covariates and CHC Interactions on the Mean Change in C-peptide 
Concentration 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 Initial C-peptide .351 .123 .123 115.356 < 0.001 
2 
Initial C-peptide  
Initial BMI 
.374 .140 .016 15.605 < 0.001 
3 
Initial C-peptide 
Initial BMI 
Start Age 
.380 .145 .005 4.839 0.028 
4 
Initial C-peptide 
Initial BMI 
Start Age 
CHC Y/N 
.381 .145 .001 .563 0.453 
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 The final model includes initial C-peptide concentration, initial BMI, and age as 
significant CVs, and the DV change in C-peptide. Initial C-peptide accounted for 12.3% of the 
variance in the model, while initial BMI and age accounted for 1.6% and 0.5% variance 
respectively. After adjusting for initial C-peptide, initial BMI, and age, linear regression 
confirmed no statistically significant difference was detected for the change in mean C-peptide 
between those who did (- 0.11 ng/mL), and those who did not (0.03 ng/mL), participate in CHC 
interactions (p = 0.453).   
Subject selection and results of analysis of the change in proinsulin concentration.  
The initial number of available subjects for proinsulin was 18,788. Subjects that did not fast for 
at least 8 hours were excluded from the analysis of change in proinsulin concentration. Subjects 
that did not have both an initial and follow-up measurement of proinsulin were also excluded. 
Additionally, 51 subjects had results below the AMR and were excluded. After these exclusions, 
2,356 subjects remained with 282 having CHC interactions and 2,074without CHC interactions. 
From this sample of subjects, 17 subjects were eliminated for BMI < 52.26. Z scores were 
generated to identify outliers yielding 18 subjects with change in proinsulin concentration 
corresponding to a z scores >3.3, and 18 with z scores < -3.3. These subjects were eliminated 
prior to random selection of subjects without CHC interactions. After randomizations, 523 
subjects remained.  To eliminate multivariate outliers, a MD was generated using study number 
as the DV and age, sex, initial BMI, the number of CHC Interactions, initial proinsulin, and 
difference in BMI as the IVs. The cutoff for chi square table with 6 degrees of freedom is 22.46, 
indicating that a MD > 22.46 would be considered an outlier (Pearson and Hartly, 1958).  Based 
upon the MD generated, 11 subjects were considered multivariate outliers with MD > 22.46. 
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These 11 subjects were removed and analysis ran. Table 26 describes the patient demographics 
for the proinsulin biomarker sample. 
Table 26: Demographics and Change in Proinsulin Concentrations for Subjects With and 
Without CHC Interactions 
CHC 
Interactions   
Initial 
Age 
Sex Initial BMI  
Initial 
Proinsulin 
(pmol/L) 
Change in 
Proinsulin 
(pmol/L) 
Yes        
n= 274 Mean 55.5 33% M 30.1 14.72 -1.17 
 SD 14.4 67% F 6.2 10.47 7.92 
No        
n=249 Mean 53.0 44% M 28.9 13.28 0.23 
 SD 14.8 56% F 6.2 9.42 7.71 
Total       
n =523 Mean 54.3 38%M 29.5 14.03 -0.50 
 SD 14.6 62% F 6.2 10.00 7.84 
 
Statistical analysis using a t-test in SPSS revealed a statistically significant difference in 
the mean change in proinsulin concentration between those that utilized CHC interactions and 
those who did not (p = 0.042).  
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown in Table 27. The final model includes, initial proinsulin, sex, age, and initial BMI as 
significant CVs, and the DV change in proinsulin.  Initial proinsulin concentration accounted for 
11.4% of the variance in the model, while sex, age and initial BMI accounted for 1.3, 0.9 and 
0.7% respectively. After adjusting for initial proinsulin, sex, age, and initial BMI, linear 
regression confirmed no statistically significant difference was detected for the change in 
proinsulin concentration between those who did (-1.17 pmol/L), and  those who did not (0.23 
pmol/L), participate in CHC interactions (p = 0.104).  
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Table 27: Significance of Covariates and CHC Interactions on the Mean Change in Proinsulin 
Concentration 
Model Model Components R R
2
 R
2 
Change F Change p value 
1 Initial Proinsulin .338 .114 .114 67.084 < 0.001 
2 
Initial Proinsulin 
Sex 
.357 .127 .013 7.983 0.005 
3 
Initial Proinsulin 
Sex 
Start Age 
.370 .137 .009 5.605 0.018 
4 
Initial Proinsulin 
Sex 
Start Age 
Initial BMI 
.379 .143 .007 4.042 0.045 
5 
Initial Proinsulin 
Sex 
Start Age 
Initial BMI 
CHC Y/N 
.385 .148 .004 2.654 0.104 
 
Subject selection and results of analysis of the change in BMI.  Subjects that did not 
have both an initial and follow-up BMI were excluded. After exclusion, 88,747 subjects 
remained for BMI analysis with 4,029 having CHC interactions and 84,718 without CHC 
interactions. For BMI, randomization occurred before univariate outlier investigation, generating 
8072 total subjects. From this sample, 77 subjects were removed for having a BMI > 52.26.  Z 
scores were generated to identify univariate outliers, yielding 74 subjects with a change in BMI 
corresponding to a z score < -3.3, and 67 with a z score > 3.3. These subjects were removed, 
leaving 7854 subjects for analysis.  
To eliminate multivariate outliers, MD was generated using study number as the DV and 
age, sex, initial BMI, CHC yes or no, and difference in BMI as the IVs. The cutoff for chi square 
table with 5 degrees of freedom is 20.52, indicating that a MD > 20.52 would be considered an 
outlier (Pearson and Hartly, 1958).  Based on the MD generated, 49 subjects were considered 
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multivariate outliers with MD > 20.52. These 49 subjects were removed and analysis ran. Table 
28 describes the patient demographics for the proinsulin biomarker sample.  
Table 28: Demographics and Change in BMI for Subjects With and Without CHC Interactions 
CHC 
Interactions   
Initial  
Age 
Sex Initial BMI  
Change in 
BMI  
Yes       
n= 3893 Mean 57.9 52% M 30.0 -0.49 
 SD 13.5 48% F 6.5 2.22 
No       
n=3912 Mean 56.7 44% M 29.2 -0.20 
 SD 14.0 56% F 6.2 2.16 
Total      
n = 7805 Mean 57.3 48% M 29.6 -0.34 
 SD 13.8 52% F 6.4 2.21 
 
Statistical analysis using a t-test in SPSS revealed a statistically significant difference in 
the mean change in BMI between those that utilized CHC interactions and those who did not (p 
< 0.001).   
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous VCs and the newly entered CV.  The model summary table is 
shown as Table 29.  
Table 29: Significance of Covariates and CHC Interactions on the Mean Change in BMI 
Model 
Model 
Components 
R R
2
 
R
2 
Change 
F Change p value 
1 Initial BMI .235
a
 .055 .055 456.735 < 0.001 
2 
Initial BMI 
CHC Y/N 
.241
b
 .058 .003 21.938 < 0.001 
 
The final model only included initial BMI as a significant CV, and the DV change in 
BMI. Initial BMI accounted for 5.5% of the variance explained. After adjusting for initial BMI, 
linear regression confirmed a statistically significant difference was detected for the change in 
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mean BMI between those who did (-0.49), and those who did not (- 0.20, participate in CHC 
interactions (p = < 0.001).  
Specific Aim 2 
The purpose of Specific Aim 2 was to determine if statistically significant differences 
exist in the change in glucose, %HgbA1c, and  BMI health scores between subjects who did and 
those who did not interact with CHCs. Before statistical analysis was performed, the data set was 
reviewed for univariate and multivariate outliers. The follow section presents the results of data 
cleaning and subject exclusion for each marker and BMI. 
For Specific Aim 2, regression was performed using the change in health score as the 
DV. The IV was the use or withholding of CHC interaction or no interaction, with BMI, sex, and 
age at the subjects’ initial visit as potential CVs. The change in health score was determined by 
subtracting the subjects’ marker health score at their follow-up blood draw from their marker 
health score at their initial blood draw. A negative change corresponds to an improvement in the 
health score for that particular marker, while a positive change corresponds to a worsening of the 
health score for that marker. The mean change in health score for %HbA1c, glucose, and BMI 
was calculated for both the CHC and non-CHC groups. Table 30 describes marker means for 
each group and the unadjusted t-test results of the comparison of change in health scores.  
Table 30: Mean Changes in Glucose, %HbA1c, and BMI Health Scores in Subjects with and 
without CHC Interactions, and their Statistical Significance  
Test CHC
a Non-
CHC
a F df p value 
Glucose 
 
-0.2 0.02 
3.562 
1 0.059 
HbA1c 
 
0.09 0.10 
0.081 
1 0.776 
BMI -0.07 -0.04 12.911 1 <0.001 
a.)subjects who interacted with CHCs. b.)subjects who did not interact with CHCs 
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Table 31 describes the ANCOVA linear regression which revealed the significant CVs 
for each marker, as well as the significance of the CHC and non-CHC groups differences.   
Table 31: The Significance of CHC Interactions After Adjusting for Covariates on the Difference 
Between the Change in Glucose, HbA1c, and BMI  
Test 
Mean Health 
Score Change  
CHC 
Mean 
 Health Score 
Change 
Non-CHC 
Significant CVs  
Significance of 
CHC 
Interactions  
(p value) 
Glucose -0.2 0.02 
Initial glucose, 
age, sex 
0.165 
HbA1c 0.09 0.10 Initial HbA1c 0.949 
BMI -0.07 -0.04 Initial BMI < 0.001 
 
Subject selection and results of analysis of the change in glucose health score.  For 
Specific Aim 2, the same 1944 subjects selected for the analysis of the changes in glucose 
concentration were examined for the changes in glucose health score. Twenty-five of these 
subjects exhibited a MD > 22.46, and were excluded from the analysis. The demographics of the 
subjects utilized for the analysis are presented in Table 32. 
Table 32: Demographics and Change in Glucose Health Score for Subjects With and Without 
CHC Interactions  
CHC 
Interactions  
Initial 
Age 
Sex 
Initial 
BMI 
Initial 
Glucose 
(mg/dL) 
Initial 
Health 
Score 
Change 
in Health 
Score 
Yes         
n=  958 Mean 56.1 33% M 30.1 97.9 0.40 -0.02 
 SD 13.4 67% F 6.6 17.5 0.62 0.54 
No         
n= 961 Mean 54.6 45% M 28.7 96.8 0.36 0.02 
 SD 14.2 55% F 5.9 18.0 0.60 0.52 
Total        
n = 1919 Mean 55.3 39% M 29.4 97.4 0.38 0.00 
 SD 13.8 61% F 6.3 17.8 0.61 0.53 
 
Statistical analysis using a t-test in SPSS revealed no statistically significant difference in 
the mean change in glucose health score for those that utilized CHC interactions and those who 
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did not (p = 0.059). Covariates were entered stepwise into a linear regression model, with each 
subsequent model including the previous CVs and the newly entered CV. This analysis revealed 
that initial glucose, age, and sex were significant CVs. Initial glucose accounted for 7.4% of the 
variance, while age and sex explained 0.6% and 0.4% of the variance respectively. Engaging or 
not engaging in CHC interactions only accounted for 0.1% of the variance. After adjusting for 
initial glucose, age, and sex, linear regression confirmed that there was no statistically significant 
difference in the change in mean glucose health score between those who did (-0.2), and those 
who did not (0.02) participate in CHC interactions (p = 0.165). The model summary is shown in 
Table 33. The final model includes all significant CVs and the DV.    
Table 33: Significance of Covariates and CHC Interactions on the Mean Change in Glucose 
Health Score 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 Initial Glucose .271 .074 .074 152.373 < 0.001 
2 
Initial Glucose 
Start Age 
.283 .080 .006 13.426 < 0.001 
3 
Initial Glucose 
Start Age 
Sex 
.290 .084 .004 8.229 0.004 
4 
Initial Glucose 
Start Age 
Sex 
CHC Y/N 
.291 .085 .001 1.927 0.165 
 
Based upon their assigned health score for glucose concentration, subjects were classified 
as normal, prediabetic, or diabetic. The distribution of these classifications between those who 
did or did not have CHC interactions in shown in Table 34. For the group with CHC interactions, 
the follow-up glucose health score showed a decrease in the number of subjects classified as 
diabetic by 17, an increase in the number classified as prediabetic by 11, and an increase in the 
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number classified as normal by six. For the group without CHC interactions, there was no 
change in the number of subjects classified as diabetic, and an increase of 21 classified as 
prediabetic.  
Table 34: Classification of Subjects by Glucose Health Score 
 Initial Classification  Follow-up Classification 
 
Normal Prediabetic Diabetic Normal Prediabetic Diabetic 
CHC 
Interactions 
644 246 68 650 257 51 
No CHC 
Interactions 
682 216 63 661 237 63 
Total 1326 462 131 1311 494 114 
 
Subject selection and results of analysis of the change in HbA1c health score.  For 
Specific Aim 2, the same 2685 subjects selected for the analysis of the changes in %HgbA1c 
were examined for the changes in %HgbA1c health score.  There were 45 subjects with a MD > 
22.46. These subjects were excluded from the analysis. The demographics of the subjects utilized 
for the analysis are presented in Table 35. 
Table 35: Demographics and Change in HbA1c Health Score for Subjects With and Without 
CHC Interactions 
CHC 
Interactions  
Initial 
Age 
Sex 
Initial 
BMI 
Initial 
HbA1c 
Initial 
Health 
Score 
Change 
in Health 
Score 
Yes         
n=  1330 Mean 45.3 45% M 30.4 5.6 0.43 0.09 
 SD 14.4 55% F 6.8 0.75 0.66 0.48 
No         
n= 1310 Mean 55.9 46% M 29.5 5.6 0.42 0.10 
 SD 14.0 54% F 6.3 0.75 0.66 0.47 
Total        
n = 2640 Mean 50.58 45% M 30.0 5.6 0.43 0.10 
 SD 15.1 55% F 6.6 0.75 0.66 0.47 
 
  
86 
 
Statistical analysis using a t-test in SPSS revealed no statistically significant difference in 
the mean change in %HbA1c health score for those that utilized CHC interactions and those who 
did not (p = 0.776). Covariates were entered stepwise into a linear regression model, with each 
subsequent model including the previous VCs and the newly entered CV. Only initial %HbA1c 
was a statistically significant CV in the best fit model, accounting for 1.8% of the variance. After 
adjusting for initial %HbA1c, linear regression confirmed no statistically significant difference in 
the change in mean %HbA1c health score between those who did (0.09), and those who did not 
(0.10) participate in CHC interactions (p = 0.949). The model summary is shown in Table 36. 
The final model includes all significant CVs and the DV. 
Table 36: Significance of Covariates and CHC Interactions on the Mean Change in HbA1c 
Health Score 
Model 
Model 
Components 
R R
2
 R
2 
 Change F Change p value 
1 Initial HbA1c .134 .018 .018 48.568 < 0.001 
2 
Initial HbA1c 
CHC Y/N 
.134 .018 .000 .004 0.949 
 
Based upon their assigned health score for %HgbA1c, subjects were classified as normal, 
prediabetic, or diabetic. The distribution of these classifications between those who did or did not 
have CHC interactions in shown in Table 37.  
Table 37: Classification of Subjects by %HgbA1c Health Score 
 Initial Classification Follow-up Classification 
 
Normal Prediabetic Diabetic Normal Prediabetic Diabetic 
CHC 
Interactions 
885 316 129 761 439 130 
No CHC 
Interactions 
884 303 123 778 385 147 
Total 1769 619 252 1539 824  277 
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For the group with CHC interactions, the follow-up glucose health score showed a 
decrease in the number of subjects classified as normal by 124, with an increase in the number 
classified as prediabetic by 123. For the group without CHC interactions, there was a decrease in 
the number of subjects classified as normal by 106, with increases of 82 classified as prediabetic 
and 24 classified as diabetic. 
Subject selection and results of analysis of the change in BMI health score.  For 
Specific Aim 2, the same 7854 subjects selected for the analysis of the changes in BMI were 
examined for the changes in BMI health score. There were 61 subjects with a MD > 20.52. These 
61 subjects were excluded prior to analysis. The demographics of the subjects utilized for the 
analysis are presented in Table 38. 
Table 38: Demographics and Change in BMI Health Score for Subjects With and Without CHC 
Interactions 
CHC 
Interactions  
Initial 
Age 
Sex 
Initial 
BMI 
Initial 
Classification 
Change in 
Classification 
Yes       
n=  3900 Mean 57.9 52% M 30.0 1.26 -0.07 
 SD 13.5 48% F 6.6 0.79 0.42 
No       
n= 3893 Mean 56.7 44% M 29.2 1.17 -0.04 
 SD 14.1 456% F 6.3 0.79 0.41 
Total       
n = 7793 Mean 57.3 48% M 29.6 1.21 -0.05 
 SD 13.8 52% F 6.4 0.80 0.42 
 
Statistical analysis using a t-test in SPSS revealed that there was a significant difference 
in the mean change in BMI health scores between subjects who had CHC interactions and those 
who did not (p < 0.001). Covariates were entered stepwise into a linear regression model, with 
each subsequent model including the previous CVs and the newly entered CV. Initial BMI was 
the only significant CV, accounting for 0.4% of the variance, while CHC interactions accounted 
for 0.6%. After adjusting for initial BMI, a statistically significant difference in the change in 
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mean BMI health scores remained, between those who did (-0.07), and those who did not (-0.04), 
participate in CHC interactions (p =0.001). The model summary table is shown as Table 39. The 
final model includes all significant CVs and the DV. 
Table 39: Significance of Covariates and CHC Interactions on the Mean Change in BMI Health 
Score 
Model 
Model 
Components 
R R
2
 R
2 
Change F Change p value 
1 Initial BMI .066 .004 .004 33.800 < 0.001 
2 
Initial BMI 
CHC Y/N 
.075 .006 .001 10.562 < 0.001 
 
Based upon their assigned health score for BMI, subjects were classified as normal, 
overweight, or obese. The distribution of these classifications between those who did or did not 
have CHC interactions in shown in Table 40. 
Table 40: Classification of Subjects by BMI Health Score 
 Initial Classification Follow-up Classification 
 
Normal Overweight Obese Normal Overweight Obese 
CHC 
Interactions 
840 1222 1838 945 1286 1669 
No CHC 
Interactions 
935 1345 1613 987 1383 1523 
Total      1775 2567 3451 1932  2669   3192 
 
 For the group with CHC interactions, the follow-up BMI health score showed a decrease 
in the number of subjects classified as obese by 169, with an increase in the number classified as 
normal by 105, and an increase in the number classified as overweight by 64. For the group 
without CHC interactions, there was a decrease in the number of subjects classified as obese by 
90, with increases of 52 classified as normal and 38 classified as diabetic. 
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Specific Aim 3 
The purpose of Aim 3 was to determine the relationship between the number of CHC 
interactions and magnitude of the change in blood glucose concentration, %HbA1c, blood 1,5-
AG, blood insulin concentration, blood C-peptide concentration, blood proinsulin concentration, 
and BMI. Subjects were grouped according to whether they had 1, 2, 3, or >4 CHC interactions. 
Before statistical analysis was performed, the data set was reviewed for univariate and 
multivariate outliers. The sections following Table 41 describe how subjects were eliminated, 
and the results of data cleaning for each marker and BMI. 
Linear regression was performed using the change in each marker as the DV, and the 
number of CHC interactions as the IV. A negative change in mean marker values would indicate 
an improvement in that particular marker, with the exception of 1,5-AG. As with Specific Aims 
1 and 2, initial BMI, sex, and age at the subject’s initial visit were used as potential CVs. Linier 
regression provided an ANCOVA table. However, since the number of CHC visits were an 
interval level of measurement, statements of significance of biomarker difference between those 
who and did not utilize CHCs could not be provided.  Linear regression could only determine the 
significance of the number of CHC interactions on the change in the DV. In addition to linear 
regression, the number of interactions were considered as a categorical variable and the 
significance of the differences in the changes in marker results between the number of CHC 
interactions was tested using ANOVA followed by a paired one way t-test.  Results are reported 
as Bonferroni post hoc mean comparisons to investigate the mean differences between the CHC 
interaction groups. Table 41 provides a summary of results and between-group differences. 
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Table 41: The Significance of the Number of CHC Interactions on the Change in Markers of 
Glucose Homeostasis 
Marker 
Best Model Including 
Significant CVs 
Significance of the 
Number of CHC 
Interactions  
(p value) 
Significance of 
Between Number of 
CHC Interaction 
Differences 
(p value) 
Glucose 
(mg/dL) 
Initial Glucose 
Start Age 
Sex 
Initial BMI 
# of CHC Interactions 
No 
p = 0.971 
No 
p > 0.05 
HbA1c 
(%) 
Initial %HbA1c 
# of CHC Interactions 
Yes 
p = 0.029 
No 
p > 0.05 
1,5-AG 
(µg/mL) 
Initial 1,5-AG 
# of CHC Interactions 
No 
p = 0.229 
No 
p > 0.05 
Insulin 
(μU/mL) 
Initial Insulin 
Initial BMI 
Sex 
# of CHC Interactions 
Yes 
p = 0.010 
No 
p > 0.05 
C-Peptide 
(ng/mL) 
Initial C-peptide 
Initial BMI 
Start Age 
# of CHC Interactions 
No 
p = 0.435 
Yes  
Between Groups 1-2 
P = 0.035 
Proinsulin 
(pmol/L) 
Initial Proinsulin 
# of CHC Interactions 
No 
p = 0.976 
No 
p > 0.05 
BMI 
Initial BMI 
# of CHC Interactions 
Yes 
p < 0.001 
Between Groups 1-4 
p < 0.001 
 
Subject selection and results of analysis of the change in glucose concentration by 
number of CHC interactions.  There were 969 subjects that had at least one CHC 
interaction.  Mahalanobis distances were generated, replacing only CHC Y/N with the number of 
interactions. Thirty-one subjects were identified with a MD > 22.46. These subjects were 
excluded prior to the statistical analyses. To ensure that all CHC interaction groups had at least 
10% of the number of subjects in the largest group, subjects with four or more interactions were 
combined into one group. Table 42 details CHC interaction group demographics and change in 
glucose concentration.  
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Table 42: Demographics and Change in Glucose Concentration for Subjects by Number of CHC 
Interactions 
CHC 
Interactions  
Initial 
Age 
Sex Initial BMI 
Initial 
Glucose 
(mg/dL) 
Change in 
Glucose 
(mg/dL) 
1       
n= 522 Mean 54.6 34% M 29.4 96.9 -0.51 
 SD 13.4 66% F 6.4 16.0 11.70 
2       
n= 219 Mean 56.8 34% M 30.0 98.4 -1.45 
 SD 13.0 66% F 6.4 18.0 13.30 
3       
n= 90 Mean 57.4 26% M 31.0 95.9 0.41 
 SD 13.2 74% F 6.8 14.3 12.46 
4 or more       
n= 107 Mean 59.4 30% M 32.0 99.0 -0.44 
 SD 13.6 70% F 7.2 18.4 13.10 
Total       
n = 938 Mean 55.9 33%M 30.0 97.4 -0.64 
 SD 13.4 67% F 6.6 16.6 12.30 
 
Linear regression revealed no significant relationship between the mean change in 
glucose concentration and the number of CHC interactions. Covariates were entered stepwise 
into the linear regression model, with each subsequent model including the previous CVs and the 
newly entered CV.  The model summary is shown in Table 43. The final model includes all 
significant CVs and the DV. For the change in glucose, the initial glucose accounted for 24.8% 
of the variance. Age, sex and initial BMI explained 1.6%, 0.8 and 0.3% of the variance 
respectively. The number of CHC interactions did not statistically account for any of the 
variance. After adjusting for initial glucose, age, sex, and initial BMI, there was 
no statistically significant relationship between the mean change in glucose and the number of 
CHC interactions (p = 0.971).  
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Table 43: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in Glucose  
Model Model Components R R
2
 
R
2  
Change 
F  
Change 
p value 
1 Initial Glucose .498 .248 .248 308.817 < 0.001 
2 
Initial Glucose 
Start Age 
.514 .264 .016 20.222 < 0.001 
3 
Initial Glucose 
Start Age 
Sex 
.522 .272 .008 10.627 0.001 
4 
Initial Glucose 
Start Age 
Sex 
Initial BMI 
.525 .276 .003 4.471 0.035 
5 
Initial Glucose 
Start Age 
Sex 
Initial BMI 
# of CHC Interactions 
.525 .276 .000 .001 0.971 
 
Graphical representation (Figure 3) suggests a decrease in mean change in glucose 
between CHC interaction groups one and two, but an increase with CHC interaction group three. 
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Figure 3: Mean Change in Glucose by Number of CHC Interactions 
Error bars represent 95% Confidence Intervals 
A Bonferroni multiple comparison table (Table 44) confirms that there was no 
statistically significant difference in the mean change in glucose between CHC interactions 
groups, (p < 0.05).   
Table 44: Bonferroni Multiple Comparison for Glucose and Number of CHC Interactions 
# of CHC 
Interactions 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 .939 0.991 1.000 3.56 -1.68 
3.00 -.925 1.406 1.000 2.79 -4.64 
4.00 -.074 1.307 1.000 3.38 -3.53 
2 1.00 -.939 0.991 1.000 1.68 -3.56 
3.00 -1.863 1.542 1.000 2.21 -5.94 
4.00 -1.013 1.452 1.000 2.83 -4.85 
3 1.00 .925 1.406 1.000 4.64 -2.79 
2.00 1.863 1.542 1.000 5.94 -2.21 
4.00 .850 1.761 1.000 5.51 -3.81 
4 1.00 .074 1.307 1.000 3.53 -3.38 
2.00 1.013 1.452 1.000 4.85 -2.83 
3.00 -.850 1.761 1.000 3.81 -5.51 
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Subject selection and results of analysis of the change in %HbA1c by number of 
CHC interactions.  There were only 1,357 subjects that had at least one CHC 
interactions.  Mahalanobis distance was generated replacing only CHC Y/N with the number of 
CHC Interactions. Fifty-one subjects were identified with a MD > 22.46. These subjects were 
excluded prior to the statistical analysis. To ensure all groups had at least 10% of the largest 
group, subjects with more than four interactions were combined in to one group, four or more. 
Table 45 details CHC interaction group demographics and change in %HbA1c. 
Table 45: Demographics and Change in %HbA1c for Subjects by CHC Number of Interactions 
CHC 
Interactions  
Initial 
Age 
Sex Initial BMI 
Initial 
HbA1c 
(%) 
Change in 
HbA1c (%) 
1       
n= 736 Mean 45.2 42% M 29.4 5.54 0.12 
 SD 14.3 58% F 6.6 0.65 0.37 
2       
n=298 Mean 45.2 48% M 31.3 5.71 0.08 
 SD 14.2 52% F 6.8 0.81 0.42 
3       
n=124 Mean 45.7 44% M 31.0 5.69 0.03 
 SD 14.5 56% F 6.7 0.68 0.43 
4 or more       
n=148 Mean 46.2 55% M 32.9 5.61 0.04 
 SD 15.5 45% F 7.2 0.67 0.46 
Total       
n =1306 Mean 45.3 45%M 30.4 5.61 0.09 
 SD 14.4 55% F 6.8 0.70 0.40 
 
Linear regression revealed there was a significant relationship between the mean change 
in %HbA1c and the number of CHC interactions.  
  Covariates were entered stepwise into the linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary is shown in 
Table 46. The final model includes all significant CVs and the DV. For Change in HbA1c, initial 
HbA1c accounted for 20.1% of the variance explained. The addition of the number of CHC 
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interactions into the model was also significant, explaining 0.3 % of variance. After adjusting for 
initial %HbA1c, analysis confirmed a statistically significant relationship between the mean 
change in %HbA1c and the number of CHC interactions (p = 0.029).  
Table 46: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in %HbA1c 
Model Model Components R R
2
 
R
2  
Change 
F Change p value 
1 Initial HbA1c .448 .201 .201 327.027 < 0.001 
2 
Initial HbA1c 
# of CHC Interactions 
.451 .203 .003 4.752 0.029 
 
Graphical representation (Figure 4) suggests a decrease in the mean change in HbC1a as 
the number of CHC interactions increases until three CHC interactions.  
 
Figure 4: Mean Change in HbA1c by Number of CHC Interactions 
Error bars represent 95% Confidence Intervals 
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A Bonferroni multiple comparison table (Table 47) confirms that there was no 
statistically significant difference in the mean change in HbA1c between CHC interactions 
groups, (p >0.05).   
Table 47: Bonferroni Multiple Comparison for HbA1c and Number of CHC Interactions  
# of CHC 
Interactions 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 .039 .028 0.952 0.111 -0.034 
3.00 .093 .039 0.105 0.196 -0.010 
4.00 .079 .036 0.177 0.175 -0.017 
2 1.00 -.039 .028 0.952 0.034 -0.112 
3.00 .054 .043 1.000 0.167 -0.059 
4.00 .040 .040 1.000 0.147 -0.067 
3 1.00 -.093 .039 0.105 0.010 -0.196 
2.00 -.054 .043 1.000 0.060 -0.167 
4.00 -.014 .049 1.000 0.115 -0.143 
4 1.00 -.079 .036 0.177 0.017 -0.174 
2.00 -.040 .040 1.000 0.067 -0.147 
3.00 .014 .049 1.000 0.143 -0.115 
 
 
Subject selection and results of analysis of the change in 1,5-AG by number of CHC 
interactions.  There were 25 subjects that had at least one CHC interactions.  
Mahalanobis distance was generated replacing only CHC Y/N with the number of CHC 
Interactions. To ensure all groups had at least 10% of the largest group subjects with three or 
more interactions were combined. Table 48 describes the demographics and change in 1,5-AG 
concentration for each CHC interaction group.  
 
 
 
 
  
97 
 
Table 48: Demographics and Change in 1,5-AG Concentration for Subjects by Number of CHC 
Interactions 
CHC 
Interactions  
Initial 
Age 
Sex Initial BMI 
Initial 1,5-
AG 
(µg/mL) 
Change in 
1,5-AG 
(µg/mL) 
1       
n= 12 Mean 45.2 33% M 26.2 16.34 -0.98 
 SD 14.6 67% F 5.9 8.57 2.10 
2       
n=7 Mean 52.9 29% M 30.5 14.63 -0.80 
 SD 14.3 71% F 5.9 7.02 1.01 
3       
n=6 Mean 62.8 50% M 30.3 16.07 1.33 
 SD 10.8 50% F 3.1 12.91 7.01 
Total       
n =25 Mean 51.6 36%M 28.4 15.80 -0.37 
 SD 15.0 64% F 5.6 9.02 3.67 
 
Linear regression revealed no significant relationship between the mean change in 1,5-
AG concentration and the number of CHC interactions.  
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown as Table 49. The final model includes all significant CVs and the DV. For change in 1,5-
AG, initial 1,5-AG accounted for 21.8% of the variance explained. The number of CHC 
interactions did not statistically account for any variance explained. After adjusting for initial 
1,5AG, there was no statistically significant relationship between the mean change in glucose 
and the number of CHC interactions (p = 0.229).  
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Table 49: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in 1,5-AG 
Model Model Components R R
2
 
R
2 
 
Change 
F 
Change 
p value 
1 Initial 1,5-AG .467 .218 .218 6.427 0.018 
2 
Initial 1,5-AG 
# of CHC Interactions 
.519 .269 .051 1.530 0.229 
 
 Graphical representation (Figure 5) suggests a trending increase in the mean change of 
1,5-AG between CHC interaction groups one and three.  
 
Figure 5: Mean Change in 1,5-AG by Number of CHC Interactions 
Error bars represent 95% Confidence Intervals 
 
A Bonferroni multiple comparison table (Table 50) confirms no statistically significant 
difference in the mean change in 1,5-AG between CHC interactions groups, (p >0.05).  
 
 
 
  
99 
 
Table 50: Bonferroni Multiple Comparison for 1,5-AG and Number of CHC Interactions 
# of CHC 
Interaction 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 -.171 1.759 1.000 4.386 -4.728 
3.00 -2.305 1.849 0.677 2.486 -7.096 
2 1.00 0.171 1.759 1.000 4.728 -4.386 
3.00 -2.134 2.057 0.932 3.196 -7.465 
3 1.00 2.305 1.849 0.677 7.096 -2.486 
2.00 2.134 2.057 0.932 7.465 -3.196 
 
  
Subject selection and results of analysis of the change in insulin concentration by 
number of CHC interactions.  For insulin, there were 1,031 subjects that had at least 
one CHC interactions. Mahalanobis distance was generated replacing only CHC Y/N with the 
number of CHC Interactions. Thirty-one subjects were identified with a MD > 22.46. These 
subjects were removed prior to the statistical analysis.  To ensure all groups had at least 10% of 
the largest group, subjects with more than four interactions were combined in to one group, four 
or more. Table 51 describes the demographics and change in insulin concentration for each CHC 
interaction group. 
 
 
 
 
 
 
 
 
  
100 
 
Table 51: Demographics and Change in Insulin Concentration for Subjects by Number of CHC 
Interactions 
CHC 
Interactions  
Initial 
Age 
Sex Initial BMI 
Initial 
Insulin )  
(μU/mL) 
Change in 
Insulin 
(μU/mL) 
1       
N= 577 Mean 54.4 36% M 29.6 11.6 -0.28 
 SD 13.1 64% F 6.38 7.7 5.93 
2       
N =288 Mean 56.4 36% M 29.8 12.1 -1.11 
 SD 13.2 64% F 6.08 6.7 5.92 
3       
N =105 Mean 57.6 27% M 31.0 12.6 -1.49 
 SD 13.0 73% F 6.89 8.7 4.61 
4 or more       
N =110 Mean 57.8 30% M 32.1 12.8 -1.50 
 SD 13.3 70% F 6.55 7.2 5.36 
Total       
N =1000 Mean 55.5 34%M 30.0 11.9 -0.73 
 SD 13.2 66% F 6.43 7.5 5.76 
 
Linear regression revealed a significant relationship between the mean change in insulin 
concentration and the number of CHC interactions. Covariates were entered stepwise into a 
linear regression model, with each subsequent model including the previous CVs and the newly 
entered CV.  The model summary table is shown as Table 52. The final model includes all 
significant CVs and the DV. For insulin, initial insulin, accounted for 17.5% of the variance 
explained. Initial BMI and sex were also explained 2.2%, and 0.4% of the variance respectively. 
After adjusting for initial insulin, initial BMI, and sex, analysis confirmed a 
statistically significant relationship between the mean change in insulin and the number of CHC 
interactions (p = 0.01). 
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Table 52: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in Insulin 
Model 
Model  
Components 
R R
2
 
R
2  
Change 
F  
Change 
p value 
1 Initial Insulin .418 .175 .175 211.510 < 0.001 
2 
Initial Insulin 
Initial BMI 
.444 .197 .022 27.735 < 0.001 
3 
Initial Insulin 
Initial BMI 
Sex 
.448 .201 .004 4.702 0.030 
4 
Initial Insulin 
Initial BMI 
Sex 
# of CHC Interactions 
.454 .206 .005 6.660 0.010 
 
Graphical representation (Figure 6) of the mean change in insulin suggests a downward 
trend with each additional CHC interactions. 
 
Figure 6: Mean Change in Insulin by Number of CHC Interactions 
Error bars represent 95% Confidence Intervals 
A Bonferroni multiple comparison table (Table 53) confirms no statistically significant 
difference in the mean change in proinsulin between CHC interactions groups, (p >0.05).  
  
102 
 
Table 53: Bonferroni Multiple Comparison for Insulin and Number of CHC Interactions 
# of CHC 
Interaction 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 .838 .452 0.384 2.03 -0.36 
3.00 1.209 .611 0.289 2.82 -0.41 
4.00 1.224 .599 0.249 2.81 -0.36 
2 1.00 -.838 .452 0.384 0.36 -2.03 
3.00 .372 .677 1.000 2.16 -1.42 
4.00 .386 .667 1.000 2.15 -1.38 
3 1.00 -1.209 .611 0.289 0.41 -2.82 
2.00 -.372 .677 1.000 1.42 -2.16 
4.00 .014 .784 1.000 2.09 -2.06 
4 1.00 -1.224 .599 0.249 0.36 -2.81 
2.00 -.386 .667 1.000 1.38 -2.15 
3.00 -.014 .784 1.000 2.06 -2.09 
 
Subject selection and results of analysis of the change in C-peptide concentration by 
number of CHC interactions.  For C-peptide, 407 subjects had at least one CHC 
interactions.  Mahalanobis distance was generated replacing only CHC Y/N with the number of 
CHC Interactions. Seven subjects were identified having a MD > 22.46 and removed prior to the 
statistical analysis. To ensure all groups had at least 10% of the largest group , subjects with 
more than four interactions were combined in to one group, four or more. Table 54 describes the 
demographics and change in C-peptide concentration for each CHC interaction group. 
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Table 54: Demographics and Change in C-peptide Concentration for Subjects by Number of 
CHC Interactions 
CHC 
Interactions  
Initial 
Age 
Sex Initial BMI 
Initial  
C-peptide 
Change in 
C-peptide 
(ng/mL) 
1       
n= 229 Mean 55.3 33% M 30.3 2.98 -0.02 
 SD 13.5 67% F 6.6 1.36 0.91 
2       
n=81 Mean 55.3 38% M 29.7 3.13 -0.33 
 SD 14.7 62% F 4.8 1.37 0.76 
3       
n=50 Mean 59.8 28% M 31.4 3.11 -0.10 
 SD 13.4 72% F 7.5 1.33 0.69 
4 or more       
n=40 Mean 59.3 20% M 30.5 3.16 -0.06 
 SD 14.6 80% F 5.8 1.59 0.90 
Total       
n =400 Mean 56.2 32%M 30.3 3.04 -0.10 
 SD 13.9 68% F 6.3 1.38 0.86 
 
Linear regression revealed no significant relationship between the mean change in C-
peptide concentration and the number of CHC interactions  
After adjusting for initial C-peptide, initial BMI, and age, no statistically significant 
effect was detected for the mean change in C-peptide and the number of CHC interactions. 
Covariates were entered stepwise into a linear regression model, with each subsequent 
model including the previous CVs and the newly entered CV.  The model summary table is 
shown as Table 55. The final model includes all significant CVs and the DV. For C-peptide, 
initial C-peptide accounted for 11.7% of the variance explained. Initial BMI and age also 
explained  2.3%, and 1.0% of the variance respectively. The number of CHC interactions did not 
statistically account for any variance explained.  After adjusting for initial C-peptide, initial BMI, 
and age,  there was no statistically significant relationship between the mean change in C-peptide 
and the number of CHC interactions (p = 0.435).    
  
104 
 
Table 55: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in C-peptide 
Model 
Model  
Components 
R R
2
 
R
2 
 
Change 
F  
Change 
p value 
1 Initial C-peptide .342 .117 .117 52.659 < 0.001 
2 
Initial C-peptide 
Initial BMI 
.374 .140 .023 10.595 0.001 
3 
Initial C-peptide 
Initial BMI 
Start Age 
.387 .149 .010 4.514 0.034 
4 
Initial C-peptide 
Initial BMI 
Start Age 
# of CHC Interactions 
.388 .151 .001 .612 0.435 
 
 Graphical representation (Figure 7) suggests a decrease in the mean change in C-peptide 
between CHC interaction groups one and two, with an increase noted with groups three and four. 
 
Figure 7: Mean Change in C-peptide by Number of CHC Interactions 
Error bars represent 95% Confidence Intervals 
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A Bonferroni multiple comparison table (Table 56) confirms a statistically significant 
difference in change in C-peptide between CHC interactions groups. A statistically significant 
difference exist between groups one and two (p=0.035). No other statistically significant 
differences were observed between the number of CHC interaction groups (p > 0.05).  
Table 56: Bonferroni Multiple Comparison for C-peptide and Number of CHC Interactions 
# of CHC 
Interaction 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 0.306 0.111 0.035 0.600 0.013 
3.00 0.080 0.134 1.000 0.434 -0.275 
4.00 0.033 0.147 1.000 0.422 -0.356 
2 1.00 -0.306 0.111 0.035 -0.013 -0.600 
3.00 -0.227 0.154 0.848 0.181 -0.635 
4.00 -0.273 0.165 0.595 0.165 -0.712 
3 1.00 -0.080 0.134 1.000 0.275 -0.434 
2.00 0.227 0.154 0.848 0.635 -0.181 
4.00 -0.047 0.182 1.000 0.435 -0.528 
4 1.00  -0.033 0.147 1.000 0.356 -0.422 
2.00 0.273 0.165 0.595 0.712 -0.165 
3.00 0.047 0.182 1.000 -0.528 0.435 
 
Subject selection and results of analysis of the change in proinsulin concentration by 
number of CHC interactions.  There were 277 subjects that had at least one CHC 
interactions. Mahalanobis distance was generated replacing only CHC Y/N with the number of 
CHC Interactions with difference in health score. Seven subjects were identified with a MD > 
22.46 and excluded prior to the statistical analysis.  To ensure that all visit groups had at least 
10% of the number of subjects in the largest group, subjects with more than four interactions 
were combined in to one group, four or more. Table 57 describes the demographics and change 
in Proinsulin  concentration for each CHC interaction group. 
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 Table 57: Demographics and Change in Proinsulin Concentration for Subjects by Number of 
CHC Interactions 
CHC 
Interactions  
Initial 
Age 
Sex Initial BMI 
Initial 
Proinsulin 
(pmol/L) 
Change in 
Proinsulin 
(pmol/L) 
1       
n= 161 Mean 56.1 35% M 30.065 14.88 -1.07 
 SD 14.2 65% F 6.724 10.89 8.43 
2       
n=56 Mean 53.4 37% M 29.346 13.98 -1.79 
 SD 15.2 63% F 4.289 8.51 5.69 
3       
n=29 Mean 55.4 31% M 30.104 12.59 -.07 
 SD 13.6 69% F 6.8270 8.19 5.65 
4 or more       
n=24 Mean 57.3 17% M 31.535 18.75 -2.25 
 SD 15.0 82% F 5.4504 13.84 11.07 
Total       
n =270 Mean 55.5 33%M 30.051 14.79 -1.21 
 SD 14.4 67% F 6.19270 10.52 7.94 
 
Linear regression revealed no significant relationship between the mean change in 
Proinsulin concentration and the number of CHC interactions. Covariates were entered stepwise 
into a linear regression model, with each subsequent model including the previous CVs and the 
newly entered CV.  The model summary table is shown as Table 58. 
Table 58: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in Proinsulin 
Model Model Components R R
2
 
R
2  
Change 
F  
Change 
p value 
1 Initial Proinsulin .435 .189 .189 62.377 < 0.001 
2 
Initial Proinsulin 
# of CHC Interactions 
.435 .189 .000 .001 0.976 
 
The final model includes all significant CVs and the DV. For proinsulin, initial accounted 
for 18.9% of the variance explained. The number of CHC interactions did not statistically 
account for any variance explained. After adjusting for initial proinsulin, there was 
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no statistically significant relationship between the mean change in proinsulin and the number of 
CHC interactions (p = 0.976). 
 
Graphical representation (Figure 8) suggests a decrease in the mean change in proinsulin 
between CHC interaction groups one and two and between groups three and four.  
 
Figure 8: Mean Change in Proinsulin by Number of CHC Interactions 
Error bars represent 95% confidence interval 
 
A Bonferroni multiple comparison table (Table 59) confirms no statistically significant 
difference in the mean change in proinsulin between CHC interactions groups, (p >0.05). 
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Table 59: Bonferroni Multiple Comparison for Proinsulin and Number of CHC Interactions 
# of CHC 
Interactions 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 717 1.235 1.000 4.00 -2.57 
3.00 -.999 1.606 1.000 3.27 -5.27 
4.00 1.182 1.742 1.000 5.81 -3.45 
2 1.00 -.717 1.235 1.000 2.57 -4.00 
3.00 -1.717 1.821 1.000 3.12 -6.56 
4.00 .464 1.942 1.000 5.63 -4.70 
3 1.00 .999 1.606 1.000 5.27 -3.27 
2.00 1.717 1.821 1.000 6.56 -3.12 
4.00 2.181 2.197 1.000 8.02 -3.66 
4 1.00 -1.182 1.742 1.000 3.45 -5.81 
2.00 -.464 1.942 1.000 4.70 -5.63 
3.00 -2.181 2.197 1.000 -3.66 8.02 
 
Subject selection and results of analysis of the change in BMI by number of CHC 
interactions.  For BMI, 3,920 subjects had at least one CHC interaction.  Mahalanobis 
distance was generated replacing only CHC Y/N with the number of CHC Interactions. Sixty-
four subjects were identified with a MD > 20.52. These subjects were excluded prior to statistical 
analysis. To ensure all groups had at least 10% of the largest group, subjects with more than four 
interactions were combined in to one group, four or more. Table 60 describes the demographics 
and change in BMI concentration for each CHC interaction group. 
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Table 60: Demographics and Change in BMI for Subjects by Number of CHC Interactions 
CHC 
Interactions  
Initial Age Sex Initial BMI 
Change in  
BMI 
1      
n= 2142 Mean 57.9 51% M 29.4 -0.34 
 SD 13.7 49% F 6.38 2.18 
2      
n=919 Mean 57.7 54% M 30.2 -0.57 
 SD 13.4 46% F 6.56 2.27 
3      
n=376 Mean 57.3 53% M 30.8 -0.63 
 SD 13.0 47% F 6.69 2.41 
4 or more      
n=419 Mean 58.1 49% M 31.5 -0.94 
 SD 13.7 51% F 7.00 2.35 
Total      
n =3856 Mean 57.8 52%M 30.0 -0.49 
 SD 13.5 48% F 6.56 2.25 
 
Linear regression revealed no significant relationship between the mean change in BMI 
and the number of CHC interactions. Covariates were entered stepwise into a linear regression 
model, with each subsequent model including the previous CVs and the newly entered CV.  The 
model summary table is shown as Table 61. The final model includes all significant CVs and the 
DV. For BMI, initial BMI accounted for 5.1% of the variance explained. The number of CHC 
interactions did statistically account for some variance explained, 0.4%. After adjusting initial 
BMI, analysis confirmed a statistically significant relationship between the mean change in BMI 
and the number of CHC interactions (p < 0.001). 
Table 61: The Effects of Covariates and the Number of CHC interactions on the Significance of 
Mean Change in BMI 
Model Model Components R R
2
 
R
2  
Change 
F 
 Change 
p value 
1 Initial BMI .226 .051 .051 206.969 0.000 
2 Initial BMI .234 .055 .004 15.104 0.000 
 # of CHC Interactions      
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Graphical representation (Figure 9) of the mean change in BMI suggests a downward 
trend in change in BMI with each additional CHC interaction.  
 
Figure 9: Mean Change in BMI by Number of CHC Interaction 
Error bars represent 95% confidence interval 
The Bonferroni multiple comparison table (Table 62) confirms a statistically significant 
difference in change in BMI between CHC interactions groups.  A statistically significant 
difference in mean change was detected between CHC groups one and four, (p < 0.001) and 
between groups two and four (p = 0.034). Decreases in the mean change in BMI was also seen 
between groups one and two, between two and three, and between three and four, however the 
change was not significant, (p > 0.05).  
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Table 62: Bonferroni Multiple Comparison for BMI and Number of CHC Interactions 
# of CHC 
Interactions 
Additional 
Visit 
Mean 
Difference 
Standard 
Error 
p value 
95% CI of the 
Difference 
Upper Lower 
1 2.00 0.230 0.089 0.056 0.464 -0.003 
3.00 0.295 0.126 0.114 0.626 -0.037 
4.00 0.597 0.120 0.000 0.913 0.280 
2 1.00 -0.230 0.089 0.056 0.003 -0.464 
3.00 0.064 0.137 1.000 0.427 -0.299 
4.00 .366 0.132 0.034 0.716 0.017 
3 1.00 -0.295 0.126 0.114 0.037 -0.626 
2.00 -0.064 0.137 1.000 0.299 -0.427 
4.00 0.302 0.160 0.351 0.723 -0.119 
4 1.00 -0.597 0.120 0.000 -.280 -0.913 
2.00 -0.366 0.132 0.034 -0.017 -0.716 
3.00 -0.302 0.160 0.351 0.119 -0.723 
 
Post-Hoc Analysis of Sample Size Requirements 
Minimum sample size requirements are presented in Table 63. The mean changes and 
SDs of those changes, along with the number of subjects in each group were used in the 
determination of the Cohn’s D for all biomarkers and BMI. Soper’s online sample size calculator 
generates sample size estimates using the estimated effects size, the desired statistical power 
level, number of predictors, and a predetermined probability level. A power of 0.8 and 
probability of 0.05 was used for all sample size calculations. The number of predictors was 
determined by adding the number of CVs used in the ANCOVA to the DV.  Table 63 describes 
the samples size requirements for each biomarker. These requirements were met for each of the 
analyses performed in this study.  
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Table 63: Post-Hoc Sample Size Determination 
Test 
Mean 
Change 
Non-CHC 
Mean (SD) 
Mean 
Change 
CHC 
Mean (SD) 
Non 
CHC 
n 
CHC 
n 
Cohen’s 
D 
Number 
of 
Predictors 
Soper’s 
Sample 
Size 
Glucose 
-0.08 
(13.31) 
0.57 
(12.77) 
964 962 0.049836 4 262 
Hemoglobin 
A1c 
-0.11 
(.39) 
-0.10 
(0.40) 
1295 1315 0.025314 2 378 
1,5-AG 
1.29 
(3.64) 
0.37 
(3.67) 
117 25 0.251708 2 41 
Insulin 
0.11 
(5.31) 
0.78 
(5.65) 
1010 973 0.122204 4 102 
C-Peptide 
0.03 
(0.73) 
0.11 
(0.84) 
422 401 0.101662 4 122 
Proinsulin 
-0.23 
(7.71) 
1.17 
(7.92) 
249 274 0.179127 5 77 
BMI 
0.20 
(2.16) 
0.49 
(2.22) 
3912 3893 0.132408 2 75 
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Chapter 5: Discussion 
 
 
 Chapter 5 provides an overview of the results stated in Chapter Four. This chapter 
discusses the three Specific Aim and markers investigated within each aim. Clinical implications 
and relation to the study hypotheses are presented. Finally, study limitations are discussed as 
well as suggestions for future studies.  
Discussion of the Study 
 This study was conducted to determine if there is a relationship between the changes in 
subjects’ biomarkers of glucose homeostasis and BMI, and their interactions with CHCs. 
Subjects’ laboratory results, demographics, whether or not they engaged in CHC interactions, 
and if so, how many times, were obtained retrospectively from a laboratory in Richmond, VA. 
There are reports that CHCs are effective at improving BMI and %HbA1c; but research on their 
effectiveness at improving other markers of glucose homeostasis, such as insulin, C-peptide, 
proinsulin, and 1,5-AG has not been published. Additionally, research relating the magnitude of 
the change in BMI and biomarkers, and the number of CHC interactions, could not be found. 
This study compared the change in BMI and biomarkers over a one-year period for two groups, 
those who participated in CHC interactions, and those that did not.  
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Specific Aim 1 
The results of this portion of the study confirmed a statistical difference between those 
who had CHC interactions and those who did not, but only for the average decrease in BMI. 
Reductions in the mean BMI were consistent with the findings of Apple et al., in which weight 
reductions were recorded over 24 months of various coaching styles (Apple et al. 2011). 
Clinically significant weight loss is defined as a 5% reduction in body weight (Stevens et al., 
2006). In our study, the subjects’ initial weight was not extracted from the records; but the mean 
change in BMI for the CHC interaction group was only - 0.49, suggesting that the changes were 
not clinically significant.  
For all seven markers, the initial values explained more of the variance in every statistical 
model, than the use of CHCs, or any other CV. This suggests that initial marker value had the 
most influence of the variables used in this study in predicting the change in mean maker values. 
Random error accounted for the most variance. The only marker with a statistically significant 
difference was BMI. The difference in BMI could have been explained by the large sample size. 
BMI had almost three times the number of subjects than another marker. In addition, BMI was 
the only marker directly measured at the time of collection. The phlebotomist or nurse measured 
the patient’s height and weight at the time of visit. The results of BMI were not affected by the 
same analytical sources of error as the other markers. Sources of error found with blood 
collection, sample integrity, or analytical variations on the instrument were not a potential source 
of error for the measurement of BMI. However, BMI could have been affected by variations in 
the scales used for measuring weight or variations with the techniques used to measure height.  
The increase in mean %HbA1c is discordant with the findings of Wayne & Rivito 2014,  
Ko et al. 2007, and Battista et al., 2012. All three studies found that CHCs have a positive impact 
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on glucose homeostasis as evidenced by the improvement in %HbA1c in their patients. Wayne & 
Rivito utilized smartphone technology to accommodate subjects, and concluded that 
communication and support improved %HbA1c. Ko et al. concluded that coaching lowered 
%HbA1c. In addition, Battista et al. reported that dietitian education and guidance led to a 0.6% 
reduction in %HbA1c, a common topic discussed with CHC interactions. The CHCs utilized in 
this study had to be a registered dietician, exercise specialist, or registered nurse. The transition 
from the BioRad Turbo to the Trinity HPLCE methodology could explain the increase. As noted 
in the method comparison, the Trinity HPLC method did have a slightly positive bias compared 
to the BioRad Turbo. The combination of methodology change and variation in calibrator could 
be one factor for the increase. In addition, only a small percentage of variance was explained by 
the CVs and the IV, the majority of variance was unaccounted for as random error.  
The effects of CHC therapies on changes in 1,5-AG, C-peptide, insulin, and proinsulin 
have not been published.  As with the other markers, initial marker values accounted for the most 
variance of the variables used in statistical analysis. This would suggest that initial marker value, 
not the use of CHC interaction were more predictive of improvements in C-peptide, insulin, and 
proinsulin. However, the improvement of insulin, C-peptide, and proinsulin in the both the CHC 
and non-CHC groups could indicate an improvement of beta-cell health and therefore could 
improve overall glycemic control.  
In addition to testing the statistical significance of CHC interactions on the mean change 
in markers, the clinical significance of the changes were also determined. Mean marker changes 
were compared to the range of biological change to determine clinical significance. The initial 
marker minimums and maximums were used to determine the absolute significant change by 
determining the percent change for the minimum and maximum values. The percent biological 
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variation for glucose, %HbA1c, insulin, and C-peptide were transformed to absolute values. The 
mean of the transformed values were compared to the mean change in the observed CHC 
interaction group. Clinically significant changes in biomarkers were not apparent for all subjects. 
The mean changes calculated for glucose, HbA1c, and C-peptide were less than the calculated 
mean absolute within marker changes (see Table 64). The changes in insulin, although not 
statistically significant, may be clinically significant.  
Table 64: Relationship Between Within-Subject Biological Variation and the Observed Mean 
Change in Markers of Glucose Homeostasis for Subjects with CHC Interactions 
Marker 
CVI 
(%) 
Lowest 
Initial 
Result 
Highest 
Initial 
Result 
Absolute 
Mean 
Change 
CHC 
group 
Change 
Required 
for 
Significance 
 
Estimated 
Mean 
Range 
Change for 
Significance 
 
Glucose 
(mg/dL) 
5.6 52 331 0.57 5.8-37 10.7 
Hemoglobin 
A1c (%) 
1.9 4.1 9.9 0.10 0.16-0.38 0.14 
Insulin 
(μU/mL) 
14.6 
1 
 
46 
 
0.78 
 
0.3-13.26 
 
0.50 
 
C-Peptide 
(ng/mL) 
16.6 0.5 8.9 0.11 0.16-7.7 2.0 
CVI = within-subject biologic variation 
(Ricos, 2014) 
 
Furthermore, the reagent lot-to-lot variation could be a source of variation. Table 65 
describes the average bias of the reagent changes during the study timeframe. This could account 
for some of the unexplained variance in the biomarker ANCOVAs.  
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Table 65: Analytical Variation Observed with Reagent Change During the Study Timeframe  
Test 
Number of 
Reagent 
lot-to-lots 
Date Range Average Bias 
(%) 
 
 
Glucose 30 2012-2016 0.7 
Hemoglobin A1c- BioRad 34 2012-2014 -0.3 
Hemoglobin A1c- Trinity N/A N/A N/A 
1,5-Anhydroglucitol 18 2013-2016 1 
Insulin 7 2012-2016 -0.6 
C-Peptide 7 2012-2016 -1.5 
Proinsulin 13 2012-2016 -1 
Specific Aim 2 
The results for blood glucose concentration and %HgbA1c were assigned a health score 
based upon the established ranges for normal, prediabetes, and diabetes. Likewise, results for 
BMI were assigned a health score based upon the established ranges for normal, overweight, and 
obese.  
Initial t-tests indicated that no statistical difference between the change in mean health 
score for those who did and did not participate in CHC interactions exists for glucose or HbA1c 
(p > 0.05). A statistically significant difference was found between the two groups for the 
unadjusted mean change in BMI health score (p < 0.001).  
Statistically significant differences in the changes in mean BMI health scores were found 
between subjects with CHC interactions, and subjects without CHC interactions (p = 0.001). 
However, the differences in the changes in health scores for glucose and %HgbA1c were not 
significantly different between those groups of subjects. As was the case for the actual results for 
these markers, more of the variance in the changes in health scores was explained by the initial 
values for the markers. The low amount of variance accounted for by the CHC interaction group 
and the study CVs suggests that a majority of the difference is explained by random error, as 
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indicated by the analytical imprecision of the glucose and HbA1c  assays and  normal biological 
variation.  
There was a drop in the number of subjects classified as obese in both groups; but there 
were more subjects with CHC interactions who showed an improvement in BMI classification 
than those without CHC interactions. Health coach interactions are known to encourage weight 
loss (Leahey & Wing, 2013, Appel et al., 2011). Therefore, it was expected to observe 
improvements in weight and BMI that would result in a change in BMI health score. For the 
glucose health score, there was a small decrease in the number of subjects classified as diabetic 
in the group with CHC interactions, but no decrease in the group without CHC interactions. On 
the other hand, there was a decrease in the number of subjects classified as normal by their 
HgbA1c health score in both groups.  One explanation could be the tendency of subjects to fast 
before their blood draws, without improving their day-to-day lifestyle. These variations in diet 
and activity can alter glucose results, potentially indicating an improved lifestyle. The HbA1c 
assay is not affected by these variations, producing a more accurate indication of the subject’s 
diet. Furthermore, the decrease in the normal classification could be explained by the change in 
HbA1c assay methodology. The method comparison between the BioRad Turbo and Trinity 
Premier HbA1c assays indicated a slight positive bias with the Trinity assay. Since the subjects 
in the glucose, HbA1c, and BMI groups were different from the each other, comparison of the 
trends between CHC and non-CHC groups was not possible.   
For all of the markers and health scores, the standard deviations in the changes in these 
parameters were much larger than the mean changes. This, along with the small percentage of 
the variances in the changes that was explained by CHC interactions, suggests that there were 
other factors that influenced the behaviors and changes in the markers of the subjects in both 
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groups. These factors could include prescribed medications, dietary habits, or exercise routines. 
All study subjects were provided with the same laboratory report, which included information on 
their overall health. The results of this study suggest that some individuals need CHCs for 
motivation to move through the stages of the TTM towards a healthier lifestyle, while others are 
self-motivated to do so.   
Specific Aim 3 
 There was a statistically significant relationship between the magnitude of change in 
marker results and the number of CHC interactions, but only for insulin and BMI after the effects 
of the covariates were taken into account. The known relationship between increases in BMI and 
insulin resistance (Chung, Cho, Chung, & Chung, 2012) could explain why of the number of 
CHC interactions affected change in Insulin and BMI and not the other markers. However, not 
all subjects in the insulin marker group may have been in the BMI group and vise-versa. As with 
the changes in marker values and changes in health scores, the initial marker values explained 
more of the variance in those changes than any other covariate or CHC interactions.   
In the case of the mean change in %HbA1c, there was an increase in %HbA1c regardless of the 
number CHC interactions, which is not consistent with the changes in insulin concentration and 
BMI. However, there was a transition from the BioRad Turbo Variant to the Trinity Premier 
Boronate affinity HbA1c testing platforms during the study period that could explain this 
observation.  
Glucose and proinsulin are both sensitive to fasting status. If a subject ate or drank 
something during a fasting period, a falsely increased glucose or proinsulin could have been 
present. For not just glucose or proinsulin, if a subject misrepresented their fasting status or the 
duration of fasting, variations in all biomarkers with the exception of HbA1c and 1,5-AG could 
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be present as well. The inability to confirm fasting status in the study poses a limitation for all 
three Aims.  
Conclusions 
 For all three Specific Aims in this study, there was a significant difference in the mean 
changes in BMI between patients who had CHC interactions and those who did not, as well as 
between patients with different numbers of CHC interactions. None of the other markers of 
glucose homeostasis showed consistent, significant differences between subjects in those groups. 
The initial BMI and initial biomarker values also showed consistent and significant effects across 
all three Specific Aims, and appear to be a more powerful motivators for change than CHCs 
alone.   
Limitations 
The first limitation of the study is the uncertainty of additional activities the subjects 
might have engaged in during the study timeframe. Neither the LIS database nor the CHC 
interaction database contains information on other resources/interventions the subjects might 
have utilized. Therefore, differences in training and credentials, coaching style, length of 
interactions, approachability, or recommended strategies specific to each coach may have 
affected the marker results.  
Comorbidities in the study subjects were also not available for the data analysis. 
Diagnosis of diabetes or insulin resistance prior to being seen be the CHC could affect the study 
subjects’ expectations or views of the CHC interactions. Subjects may have had diseases other 
than diabetes such as cardiovascular, liver, or kidney disease that could have affected their ability 
to control their glucose homeostasis.  Liver and kidney diseases can also affect the clearance of 
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the markers and affected the results. In addition, mental and/or physical conditions could limit or 
inhibit the study participants’ ability to adhere to CHC recommendations.  
The inability to confirm that subjects followed the recommendations of the CHCs is also 
a limitation of this study. Whether or not subjects were actually fasting at the time of the blood 
collections could also not be confirmed. In addition, subjects’ motivation to change their own 
behavior and improve glucose homeostasis was not measured. As mentioned earlier, a change in 
the methodology for measuring %HbA1c occurred during the study period, and may have 
introduced a bias in the follow-up results for some subjects.  
  
Recommendations for Future Studies 
 The advantages of a retrospective such as reduced cost, availability of study subjects and 
data, and fewer IRB restrictions, also come with disadvantages. A prospective study could ensure 
that the sample size is the same across all biomarkers, as well as between the control and 
intervention groups. This would allow for multivariate analysis of the biomarkers to investigate 
the overall effect of the CHCs on changes within and across biomarker groups. Future studies 
should identify subjects with comorbidities, medications, or other therapies that could impact the 
measurement of the markers or changes in their results. Future studies should also standardize 
the CHC interactions, themselves. Finally, it would be recommended not include subjects whose 
study timeframe included a methodology change.  
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